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Charcot-Marie-Tooth Disease (CMT) is a clinically and genetically heterogeneous
collection of inherited peripheral neuropathies generally characterized by
progressive muscle atrophy, weakness, and loss of sensation in the distal
extremities. This inherited disorder, for which there is currently no curative
treatment, is the most common inherited disease of the peripheral nervous system,
affecting 1:2,500 individuals worldwide.
Clinically, CMT is broadly divided into demyelinating (type 1) and axonal (type
2) forms. Although the clinical presentation can vary greatly in severity and
progression within individual patients. Genetically, over 1,000 mutations in over
80 loci in the human genome have been linked to specific subtypes of CMT,
suggesting there are many cellular and molecular routes to neurodegeneration in
CMT. Together, these factors conspire against a single effective therapy, for all
subtypes of CMT, suggesting that personalized genetic approaches may represent
a more efficacious therapeutic strategy.

One presumed basis for the phenotypic variability of CMT is the presence of
genetic modifiers. Here, we have used mouse models of CMT to investigate
genetic modifiers of neuropathy. We show that the phenotype of these CMT
mouse models becomes more severe in the presence of either of two other
mutations that cause “subclinical” changes at peripheral nodes. These results have
implications for CMT genetic diagnosis and prognosis and suggest possible
personalized treatment strategies.

Furthermore, the development of gene therapy has provided an effective strategy
for treating Mendelian disorders, such as CMT, where disease is primarily caused
by a single mutation. Personalized gene therapy approaches are being successfully
deployed to treat recessive genetic disorders by restoring the expression of
diseases, where treatment requires a reduction in expression of the mutated allele,
has yet to be established. Here we use virally-delivered allele-specific RNAi to
demonstrate the effectiveness of allele-specific silencing as a long-term treatment
for dominantly-inherited forms of CMT. Importantly, this strategy will also have
broad implications for other dominantly-inherited neuromuscular disorders.

Together, both studies clearly demonstrate how precision genetic approaches,
either by targeting genetic modifiers or the disease allele itself may represent a
more efficacious therapeutic strategy for individuals with CMT and others
inherited neuromuscular disorders.

DEDICATION

Our hard work and progress is dedicated to the Fletcher family & all individuals
affected by Charcot-Marie-Tooth Disease.

iii

ACKNOWLEDGEMENTS

I would like to sincerely thank Dr. Robert Burgess, my advisor, and the rest of my
thesis committee including Drs. Wayne Frankel, Lucy Liaw, Greg Cox, & Dustin
Updike, for unparalleled support, patience, and guidance throughout my doctoral
studies. Dr. Scott Harper, my co-mentor, as well as Dr. Lindsay Wallace, Nettie
Pyne, and Allison Fowler for being outstanding collaborators. It was truly a
pleasure to work with you all. I would also like thank current and past members of
the Burgess lab for all their help especially Dr. Andrew Garrett, future Dr. Emily
Spaulding, and Kate Miers. The Graduate School of Biomedical Science and
Engineering at the University of Maine especially Dr. David Neivandt, and The
Jackson Laboratory, including Dr. Carrie Cowan, for providing an exceptional
training environment. A special thank you goes to my father, Anthony Morelli, and
my husband, Andrew Austin. I could not ask for a more supportive family. Thank
you!

iv

TABLE OF CONTENTS
DEDICATION ....................................................................................................... iii
ACKNOWLEDGEMENTS ................................................................................... iv
LIST OF TABLES ................................................................................................. ix
LIST OF FIGURES .................................................................................................x
LIST OF ABBREVIATIONS ............................................................................... xii
Chapter
1.

CHARCOT-MARIE-TOOTH DISEASE: AN OVERVIEW &
PATHOPHYSIOLY & POTENTIAL THERAPEUTIC
STRATEGIES..................................................................................................1
Introduction..................................................................................................1
Classification of CMT..................................................................................2
Diagnosis & Clinical Management..............................................................3
Emerging Molecular Pathologies & Tested Therapeutic Strategies............6
CMT1: Altered Proteostasis in Myelinating Schwann Cells.......6
CMT2: Impaired Mitochondria Function & Axonal
Transport....................................................................................17
Aminoacyl tRNA Synthetases & Neuronal Homeostasis...........21
Precision Gene Therapy: A Promising Treatment Strategy for
CMT..........................................................................................................25

v

2. SEVERITY OF BOTH DEMYELINATING AND AXONAL
NEUROPATHY MOUSE MODELS IS MODIFIED BY GENE
AFFECTING STRUCTURE AND FUNCTION
OF PERIPHERAL NODES...........................................................................28
Abstract.......................................................................................................28
Introduction.................................................................................................29
Results.........................................................................................................30
The identification of spontaneous Nrcam and Sh3tc2
mutations.........................................................................................30
Demyelinating Sh3tc2 mutations strongly synergize with
Nrcam mutations.............................................................................32
Gars dominant axonal neuropathy is exacerbated by loss
of Nrcam..........................................................................................43
Heterozygosity for Scn8a (NaV1.6) also exacerbates
Gars-associated axonal neuropathy................................................46
Discussion................................................................................................50
Acknowledgements..................................................................................56
3.

ALLELE-SPECIFIC RNA INTERFERENCE: PRECISION GENE
THERAPY FOR DOMINANTLY-INHERITED PERIPHERAL
NEUROPATHIES......................................................................................57
Abstract...................................................................................................57
Introduction.............................................................................................57
Results.....................................................................................................60

vi

Conclusion............................................................................................80
Acknowledgements...............................................................................81
4.

GENE THERAPY GAINS STRENGTH: THE PATH FROM GENETIC
DISCOVERY TO MEDICINE FOR INHERITED
NEUROMUSCULAR DISORDERS.......................................................83
Gene Therapy: An Innovative Treatment Strategy for Inherited
Neuromuscular Disease..........................................................................83
Escalating SMN Expression for Spinal Muscular Atrophy...................84

.

Exon Skipping Methods for Duchenne Muscular Dystrophy................89
Targeting Genetic Modifiers: A Gene Therapy Approach for
Treating Heterogeneous Groups of Neuromuscular Disorders..............94
Treating Neuromuscular Disorders Caused by The Expansion of
Microsatellite Repeats.........................................................................100
Precision Gene Therapy for Charcot-Marie-Tooth Disease................106
Considerations for Clinical Translation...............................................110
Conclusion...........................................................................................114

5. ADDITIONAL CONTRIBUTIONS TO THE FIELD................................116
REFERENCES.................................................................................................119
APPENDIX A: Chapter 2: Supplemental Data...............................................149
APPENDIX B: Chapter 2: Materials & Methods...........................................154
APPENDIX C: Chapter 3: Supplemental Data..............................................163
APPENDIX D: Chapter 3: Materials & Methods..........................................179

vii

BIOGRAPHY OF THE AUTHOR................................................................198

viii

LIST OF TABLES

Table 1. Kinetic analysis of mutant GARS proteins...........................................175
Table 2. Effects of scAAV9.mi.∆ETAQ on in vivo Gars expression in
dorsal root ganglia..............................................................................................176
Table 3. Effects of scAAV9.mi.P278KY on allele-specific Gars
expression in dorsal root ganglia........................................................................177
Table 4. Post onset effects of scAAV9.mi.P278KY on in vivo Gars
expression in dorsal root ganglia........................................................................178

ix

LIST OF FIGURES
Figure 1. Nm4302 mutations in Sh3tc2 and Nrcam.............................................34
Figure 2. Peripheral nerve anatomy and function in Sh3tc2 and
Nrcam mutations...................................................................................38
Figure 3. Neuromuscular junction sprouting and fragmentation in
Nrcam;Sh3tc2 double mutant mice........................................................41
Figure 4. Axonal neuropathy is exacerbated by loss of Nrcam............................45
Figure 5. Axonal neuropathy is exacerbated by partial impairment of
NaV1.6/Scn8a+/-.....................................................................................47
Figure 6. Scn8a heterozygosity enhances a more severe axonal neuropathy
model, GarsP278KY/+...............................................................................49
Figure 7. Compromised axonal length constants synergize with compromise
Na+ conductance....................................................................................51
Figure 8. In vitro and In vivo characterization of the ∆ETAQ GARS variant......66
Figure 9. scAAV9.mi∆ETAQ prevents of the onset of neuropathy in
Gars(∆ETAQ/huEx8) mice............................................................................70
Figure 10. Post-onset therapeutic effects of scAAV9.mi∆ETAQ........................74
Figure 11. Reduction of mutant Gars by RNAi prevents neuropathy in
Gars(P278KY/+) mice...............................................................................78
Figure 12. Effects of Nrcam mutations on nodes of Ranvier..............................149
Figure 13. Myelin structure in peripheral axons................................................ 150
Figure 14. NMJ morphology in double mutant mice..........................................151

x

Figure 15. Two electrode voltage clamp data from NMJs of a double
mutant mouse....................................................................................152
Figure 16. Effects of Nrcam and Sh3tc2 mutations are recessive.....................153
Figure 17. The ∆ETAQ GARS mutation does not affect gene
expression..........................................................................................163
Figure 18. The ∆ETAQ GARS mutation does cause aberrant binding to
NRP1.................................................................................................164
Figure 19. mRNA and protein levels in Gars∆ETAQ/huEx8 mice...........................165
Figure 20. All miRNAs targeting ∆ETAQ disease allele tested in vitro...........166
Figure 21. U6.miP278KY microRNAs can specifically knockdown
P278KY mouse Gars mRNA in vitro................................................168
Figure 22. Reduction in mutant GARS expression also alleviates
neuropathy in post-disease onset Gars(P278KY/+) mice........................169
Figure 23. Escalating doses of scAVV9.miP278KY delivered via ICV delivery
improves peripheral nerve function in gars(P278KY/+) mice................171
Figure 24. Long term therapeutic effects of neonatal
scAAV9.mi.P278KY treatment.........................................................172
Figure 25. Improvements in phenotype negatively correlates with
reductions in mutant Gars expression in dorsal root ganglia............173

xi

LIST OF ABBREVIATIONS

aaRS

Aminoacyl tRNA synthetase

AAV

Adeno-associated virus

AchR

Acetylcholine receptor

ALS

Amyotrophic Lateral Sclerosis

ANOVA

Analysis of variance

ANS

Autonomic nervous system

ASO

Antisense Oligonucleotide

CASPR

Contactin-associated protein

cET

2’-4’-constrained ethyl

CHOP

CAATT enhancer-binding protein homologous
protein

Cm

Membrane capacitance

CMT

Charcot-Marie-Tooth disease

CMTDI

Dominant intermediate CMT

CMT1

CMT type 1

CMT2

CMT type 2

CMT4

CMT type 4

CRISPR

Clustered Regularly Interspaced Short Palindromic
Repeats

Cx32

Connexin 32

xii

dCas9

Nuclease-free dead Cas9

DMD

Dystrophin

DMPK

Dystrophia myotonica protein kinase

DM1

Myotonic Dystrophy type 1
Steinert’s disease

DM2

Myotonic Dystrophy type 2
Proximal myotonic myopathy

DOK-7

Docking Protein 7

DPR

Dipeptide-repeat protein

DRG

Dorsal root ganglia

DSS

Dejerine-Sottas Syndrome

EGR

Early growth response proteins

EGR-2

Early growth response protein 1

EMG

Electromyography

GAN

Giant axonal neuropathy

GARS

Glycyl-tRNA synthetase

GRMD

Golden retriever muscular dystrophy

GWAS

Genome-wide association study

HD

Huntington’s disease

HDAC7

Histone deacetylase 7

HNPP

Hereditary neuropathy with liability to pressure
palsies

xiii

HTT

Huntingtin

iCMAP

Integrated compound muscle action potential

ICV

Intracerebroventricular

IGHMBP2

Immunoglobulin µ-binding protein 2

IT

Intrathecal

kDA

kilodalton

MBP

Myelin Basic Protein

MD

Muscular Dystrophy

mEPCs

Mini excitatory postsynaptic currents

MFN2

Mitofusion 2

MNCV

Motor nerve conduction velocity

NCV

Nerve conduction velocity

NMD

Neuromuscular disorder

nmd

Neuromuscular degeneration

NMJ

Neuromuscular Junction

NRCAM

Neuronal cell adhesion molecule

NRP1

Neuropilin 1

PMP22

Peripheral myelin protein 22

P0

Protein zero

Ra

Axial Resistance
Axonal Resistance

RAN

Repeat-associated non-ATG

Rm

Membrane resistance

xiv

RNAi

RNA interference

scAAV9

Self-Complementary AAV, serotype 9

SCN8A

Sodium voltage-gated channel alpha subunit 8

SERCA

Sarcoplasmic/ER Ca2+ ATPase

SMA

Spinal muscular atrophy

SMARD1

Spinal muscular atrophy with respiratory distress type 1

SMG6

Telomerase-binding protein EST1A

SMN

Survival motor protein

SNCA

Synnuclein alpha

SNP

Single nucleotide polymorphism

snRNP

Small nuclear ribonucleoproteins

SOD1

Cu/Zn superoxide dismutase 1

TBC1D15

TBC1 domain family member 15

TDP-43

TAR DNA-binding protein 43

Tr

Trembler

TrJ

Trembler-J

VEGF

Vascular endothelial growth factor

2’ MOE

2-Methoxyethyl

xv

CHAPTER 1
CHARCOT-MARIE-TOOTH DISEASE: AN OVERVIEW OF
PATHOPHYSIOLOGY & POTENTIAL THERAPEUTIC STRATEGIES
Introduction
Named after the three physicians who initially described it in 1886—J.M
Charcot, P. Marie, and H.H. Tooth—Charcot-Marie-Tooth disease (CMT)
represents a large, heterogeneous group of inherited peripheral neuropathies (Skre
et al.,1974, Charcot et al.,1886 and Tooth, 1886). This inherited disorder, for
which there is currently no curative treatment, is the most common inherited
disease of the peripheral nervous system, affecting 1:2,500 individuals worldwide
or approximately 125,000 people in the United States (Barisic et al., 2008 and
Zuchner et al., 2006). While CMT is used as a term for hereditary motor and
sensory neuropathies, it may also be viewed as a spectrum, ranging from the pure
motor neuropathies to the predominantly pure sensory neuropathies (Brennan et
al., 2015). CMT is generally characterized by progressive and length-dependent
degeneration of peripheral nerves, resulting in gradual distal and symmetrical
muscle weakness and atrophy within the intrinsic foot and peroneal muscles. As
the disease progresses, muscles of the hands and forearms also become affected,
and a reduction in tendon reflexes, skeletal deformities, and sensory loss may
develop.
In many cases, the age of onset is within the first to second decade,
although cases emerging during infancy and up to late-adulthood have been
reported, with clinical severity ranging from mild to severe (Saporta and Shy,
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2013, Dyck and Thomas, 2005). Symptoms are highly debilitating and often limit
mobility, requiring patients to use assistive walking devices such as leg braces or
a wheelchair. Clinically, CMT is broadly divided into demyelinating (type 1) and
axonal (type 2) forms, with intermediate forms that have both axonal and
demyelinating features (Brennan et al., 2015). Genetically, over 1,000 mutations
in over 80 loci in the human genome have been linked to specific subtypes of
CMT (Timmerman et al., 2014).
The identification of disease-associated genes has helped categorize the
pathophysiological bases of CMT, such as structural proteins of myelin (type 1)
and the axonal cytoskeleton, axonal transport, and mitochondrial dysfunction
(type 2), but many forms do not clearly fit these categories, suggesting there are
many cellular and molecular routes to neurodegeneration. Together, these factors
conspire against a single effective therapy for all subtypes of CMT, suggesting
that personalized genetic approaches may represent a more efficacious therapeutic
strategy.
Classification of CMT
CMT is further classified into different subtypes based on the prevalence
of myelin or axonal involvement, electrophysiological examinations, the mode of
inheritance, and the genetic cause. For example, CMT1 causes the demyelination
of peripheral nerves and yields a reduced motor nerve conduction velocity
(MNCV) as slow as 35 m/s with sural nerve biopsies revealing segmental
demyelination and onion bulb formation. On the other hand, CMT2 is a peripheral
neuropathy caused by axon degeneration, and is diagnosed when patients have
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normal MNCVs of about 45 m/s but reduced compound motor action potentials
due to axon loss. Both types are inherited through an autosomal dominant
inheritance pattern and make up 90% of CMT cases. Neurophysiology studies
have also identified another group, CMT intermediate, with nerve conduction
demonstrating intermediate velocities (less than 45 m/s and greater than 38 m/s)
(Hoyle et al., 2016, Saporta et al., 2011 and Reilly and Shy., 2009).
The mode of inheritance further subdivides CMT neuropathies into CMT4
for recessive demyelinating CMT, CMT2R for recessive axonal CMT, CMTDI,
and CMTRI for dominant and recessive intermediate CMT respectively, and
CMT-X for the X-linked CMT. Furthermore, de novo mutations may occur, and
there are many forms of CMT that show incomplete penetrance (Hoyle et al.,
2016 and Blair et al, 1996). Each subtype can be further distinguished by the
specific gene that is altered by the addition of a unique letter of the alphabet. The
letters are in order in which each subtype of CMT was formally defined as a
distinct entity. For example, CMT1B is a demyelinating neuropathy specifically
caused by mutations in the MPZ gene, the second demyelinating form mapped as
denoted by “B”.
Diagnosis & Clinical Management
As alluded to above, electrodiagnostic studies have been valuable clinical
diagnostic tools to differentiate demyelinating and axonal forms of CMT and can
further distinguish a sensorimotor polyneuropathy from a pure motor neuropathy,
or separate a neuropathy from a distal myopathy (Kaku et al., 1993). They can
also distinguish CMT from an acquired neuropathy such as chronic immune
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demyelinating polyneuropathy, which typically causes conduction block or
temporal dispersion, two electrophysiological characteristics that are not usually
observed in CMT (Hoyle et al., 2016). This specific distinction is extremely
important to avoid neurotoxic immunosuppressive treatments that may exacerbate
CMT symptoms. However, electrodiagnostic studies have been confounded as
signs of acquired neuropathy have been occasionally observed in patients with
CMTX, CMT1B, CMT1C, and CMT4J (Cottenie et al., 2013, Murphy et al.,
2011, Michell et al., 2009, and Gerding et al., 2009). Neurologists may also look
for specific phenotypic features to further classify a patient’s subtype of CMT.
Examples of this include white matter lesions with transient focal symptoms or
stroke-like presentations in X-linked CMT, or vocal cord or diaphragm
involvement in CMT2C, an axonal neuropathy caused by mutations in TRPV4
(Sagnelli et al., 2014, McKinney et al., 2014, Echaniz-Laguna et al., 2014,
Landoure et al., 2012, Anand et al., 2010, and Santoro et al., 2002). However, the
clinical presentation of CMT can be extremely similar among patients with
different subtypes. Also, different CMT symptoms can be caused by mutations in
the same gene, and mutations in different genes may result in the same phenotype.
This makes a specific diagnosis based on clinical signs alone impossible, and
prognosis often unreliable.
Clearly genetic testing is the only way to get a clear diagnosis for patients
and our only hope at defining pathological mechanisms underlying CMT required
for proposing treatment strategies (Rossor et al., 2013). CMT-causing loci and
genes were originally identified using tedious genetic linkage studies. Genetic
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testing for CMT first became available in 1991 after the discovery of the PMP22
duplication a molecular lesion underpinning CMT1A (Roa et al., 1991). This
duplication remains the most common genetic cause of the majority of CMT1
cases and about 50% off all CMT cases (Murphy et al., 2012). However, original
DNA sequencing methods, predominantly Sangor sequencing, were expensive
limiting their use in genetic diagnostics (Hoyle et al., 2016). The development of
high-throughput DNA sequencing such as Next-generation sequencing has
allowed whole genomes and exomes to be sequenced in a relatively quick and
inexpensive manner greatly accelerating the identification of CMT loci and genes
(Ankala et al., 2015 and Rossor et al., 2013). In fact, with the use of nextgeneration sequencing, several genome wide association studies have been
completed, showing that over 90% of patients with CMT originating from North
America or Europe have mutations in one of only four genes (PMP22, MPZ,
GJB1 and MFN2) (Ekins et al., 2015, DiVincenzo et al., 2014, Ostern et al., 2013,
and Murphy et al., 2012). Based on these data, a genetic panel that screens
patients for mutations in these four genes should be developed as a quick and
cost-efficient diagnosis for individuals with typical cases of CMT. At the same
time, some CMT-causing mutations are ultra-rare and may require whole-genome
or whole-exome sequencing for identification, as well as further testing to confirm
pathogenicity.
Currently there is no curative, or even disease-modifying, treatment for
any subtype of CMT—only supportive care. Ankle foot orthoses can improve
walking in patients with significant ankle dorsiflexion weakness, and thumb
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opposition splints have been shown to improve hand function in patients with
severe hand muscle weakness (Menotti et al., 2014, Dufek et al., 2014,
Ramdharry et al., 2014, Phillips et al., 2012, Videler et al., 2012, and Guillebastre
et al., 2013). Assistive walking devices, such as full leg braces or wheel chairs,
may also help with mobility. Although data is limited, exercise also appears to be
a safe therapeutic intervention, and may modestly slow down the progression of
several subtypes (Burns et al., 2009 and Chetlin et al., 2004). The genetic defects
and associated pathophysiology of various forms of CMT may increase a patient’s
susceptibility to toxicity from certain chemical exposures (Fonkem et al., 2014,
Beutler et al., 2014, Ursino et al., 2013, Nakamura et al., 2012, and Weimer et al.,
2006). Thus, all neurotoxic medications such as chemotherapy should be avoided.
In summary, although diagnosis remains a complex endeavor and treatment
options are limited, continuing to identify CMT-causing genes will hopefully
soon lead to the identification of cellular pathways underlying pathology, and
provide needed information for targeted therapies.
Emerging Molecular Pathologies & Tested Therapeutic Strategies
CMT1: Altered Proteostasis in Myelinating Schwann Cells
All motor, sensory, and cognitive functions rely on the rapid propagation
of nerve impulses also known as action potentials along central and peripheral
nerves to their effecting target (i.e., muscle, skin, brain, etc.). Much like the
insulation around wires in electrical circuits, glial cells form a fatty, membranous
sheath surrounding axons known as myelin. Myelin is critical for the rapid
propagation of nerve impulses along axons as it reduces the transverse
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capacitance and increases the transverse resistance of the axonal plasma
membrane (axolemma). This provides the structural basis for saltatory conduction
and thereby increases the conduction velocity of action potentials along nerves.
While oligodendrocytes myelinate the axons of the central nervous
system, myelin insulating peripheral axons is composed of glia known as
Schwann cells. To properly insulate peripheral axons, myelinating Schwann cells
contain high concentrations of cholesterol, sphingolipids, and many proteins
including peripheral myelin protein 22 (PMP22), myelin protein zero (P0) and
myelin basic protein (MBP) (Nave et al., 2014 and Scherer et al., 2002). The
regulation of expression and proper folding of all myelin proteins are essential for
the development and homeostasis of peripheral myelin. In fact, mutations in
genes that encode myelin proteins including PMP22, P0, early growth response
gene 2 (EGR-2) and connexin-32 (Cx-32) account for the genetic etiology of most
cases of demyelinating forms of CMT including CMT1A, CMT1B, CMT1D,
CMT2E, and CMTX (Brennan et al., 2016).
CMT1A is the most common form of CMT accounting for ~70% of
CMT1 as well as 50% of all cases of CMT, and is one of the first examples of a
“genomic” disorder (Timmerman et al., 2014). In 1989, the CMT1A locus was
assigned to chromosome 17 through genetic linkage studies in large HMSN
families (Raeymaekers et al., 1989 and Vance et al., 1989). Two years later it was
found that this 1.4 Mb chromosomal region is flanked by two 24 kb homologous
low copy repeats (LCRs) called the proximal and distal CMT1A-REPs
(Raeymaekers et al., 1991 and Lupski et al., 1991). This unique genomic
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architecture creates a non-allelic homologous recombination (NAHR) which can
cause either a tandem-duplication or the deletion of these 1.4 megabases on
chromosome 17 (Timmerman et al., 2014). In 1992, with use of chromosomal
hybrid cell lines, pulsed field gel electrophoresis, and yeast artificial chromosome
maps, it was discovered that the PMP22 gene was in the middle of this 1.4-Mb
region (Matsunami et al., 1992, Patel et al., 1992, Timmerman et al., 1992, and
Valentijn et al., 1992). Subsequently, it was determined by Lupski et al. that an
extra copy (trisomy) of PMP22, resulting in the overproduction of the protein,
was linked to CMT1A (Lupski et al., 1992). In contrast, the heterozygous deletion
of PMP22 that results in the reduction of PMP22 causes a completely different
neuropathy known as hereditary neuropathy with liability to pressure palsy
(HNPP) (Lupski et al., 1992). It remained unclear why the difference in genetic
dosage of this genomic region causes two independent inherited peripheral
neuropathies. To further complicate things, 61 different point mutations in
PMP22 have been linked to both CMT1A as well as HNPP, and missense
mutations in PMP22 that alter the protein’s amino acid sequence cause another
form of CMT1 known as CMT1E (Russo et al., 2011). Taken together, all of these
studies confirmed that any dysregulation of PMP22 can have drastic effects on
myelin homeostasis and, thus, peripheral nerve function.
PMP22 is a 22-kDa membrane glycoprotein which contributes
approximately 2-5% of myelin proteins and is thought to play an integral role in
myelin synthesis and assembly (Garbay et al., 2000). However, its exact function
within the peripheral nervous system remains unclear. It was first identified as a
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growth arrest gene in fibroblasts and may be involved in the cell cycle of
Schwann cells (Jetten et al., 2000). Additional studies in injured nerves suggest a
role critical in Schwann cell growth and differentiation (D’Urso et al., 1997, De
Leon et al., 1994, Snipes et al., 1993, Kuhn et al., 1993, Spreyer et al., 1991 and
Welcher et al., 1991). A novel role for PMP22 has been found in the linkage of
the actin cytoskeleton with the plasma membrane, possibly through regulating the
cholesterol content of lipid rafts (Lee et al., 2014). Yet, the mechanisms
underlying these hypotheses have yet to be established and how its dysregulation
causes neuropathy remains elusive. Several established rodent models of PMP22associated CMT1, including the Trembler (Tr) and Trembler J (Tr J) mice which
are spontaneous Pmp22 mutants harboring two missense mutations, Gly150Asp
and Leu16Pro, respectively, and the transgenic rats and mice carrying extra copies
of the Pmp22 gene, are being used to gain significant insights into the
pathophysiology underpinning these neuropathies (Jetten et al., 2000, Sereda et
al., 1996, Maycox et al., and Suter et al., 1992). For example, several studies
using both Trembler (Tr) and Trembler-J (Tr J) mice have reported that both
missense mutations within PMP22 disrupt its trafficking to the plasma membrane
of Schwann cells from endoplasmic reticulum or Golgi apparatus (Schlebach et
al., 2015, Fontanini et al., 2005, Tobler et al., 2002, Ryan et al., 2002, Dickson et
al., 2002, Colby et al., 2000, Naef et al., 1999, and Naef et al., 1997). This
increases the propensity of PMP22 to misfold and become degraded by the
endoplasmic reticulum associated degradation system. These data suggest that a
loss-of-function mechanism may contribute to pathogenesis of CMT1E. However,
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both Trembler models have significantly less peripheral myelin and a more severe
neuropathy phenotype compared to mice that are hemizygous for PMP22,
suggesting that dominant-negative or toxic gain-of-function mechanisms may also
contribute to disease (Mittendorf et al., 2017).
Considering much more needs to be understood about the mechanism
through which different mutations in PMP22 cause demyelination, current
treatment strategies aimed to regulate PMP22 gene dosage are being developed.
Two compounds that have been shown to alter PMP22 mRNA levels in rodents
are ascorbic acid and progesterone. Ascorbic acid (Vitamin C) is necessary for
myelination and Schwann cell basal lamina formation (Passage et al., 2004).
Interestingly, ascorbic acid supplementation was found to reduce PMP22 mRNA
expression as well as improve myelination in a transgenic mouse model of
CMT1A with several copies (7) of Pmp22 (Passage et al., 2004). However, it was
not found to be effective in mitigating neuropathy in adults nor children with
CMT1A in several international clinical trials (Lewis et al., 2013, Micallef et al.,
2009, Burns et al., 2009, Verhamme et al., 2009, Pareyson et al., 2008, Pareyson
et al., 2006). Animal studies also have shown some promise with the progesterone
antagonist, onapristone, to decrease PMP22 expression and improve myelination
(Sereda et al., 2003). Unfortunately, onapristone was found to be toxic in humans,
although further research is ongoing to develop less toxic progesterone
antagonists suitable for future clinical trials (Brennan et al., 2015). Ongoing
efforts to identify additional compounds that reduce Pmp22 expression that are
safe and effective at treating individuals with CMT1A are currently being funded

10

by the Charcot-Marie-Tooth Association (Brennan et al., 2015).
CMT1B is the second most frequent autosomal dominant inherited
neuropathy, accounting for 10% of CMT1 cases, and is caused by mutations in
MPZ, the gene encoding P0 (Shy et al., 2004). P0 is a transmembrane
glycoprotein with a large amino-terminal extracellular domain and a short
carboxy-terminal intracellular tail. It is the most abundant protein expressed in
myelinating Schwann cells, accounting for about 50% of myelin proteins, and is
critical for stabilizing myelin around peripheral nerves (Nave et al., 2014 and
Scherer et al., 2002). This is supported by the fact that transgenic mice that lack
Mpz show uncompaction of myelin early in development, whereas mice with a
heterozygous disruption of MpZ display late-onset demyelination of peripheral
nerves (Martini et al., 1995 and Giese et al., 1992).
More than 120 mutations in MPZ, mostly affecting its extracellular
domain, have been identified and are known to cause not only CMT1B but also
two severe neuropathies including childhood-onset Dejerine-Sottas neuropathy
(DSS) and congenital hypomyelinating neuropathy (Shy et al., 2004). However,
why certain mutations cause different peripheral neuropathies remains to be fully
understood. Dominant inheritance and widely varying phenotypes suggest that
many P0 mutations cause neuropathy through toxic gain-of-function or dominantnegative mechanisms.
For example, deletion of serine 63 (S63del) in MPZ results in CMT1B
while the missense mutation S63C leads to DSS in humans (Hayasaka et al., 1993
and Kulkens et al., 1993). Furthermore, demyelination within transgenic mice
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expressing mutant forms of MPZ cannot be rescued by the overexpression of
wildtype P0 (Wrabetz et al., 2006). One proposed neomorphic mechanism
suggests that mutant forms of MPZ are retained in the ER, causing high levels of
ER stress. The latter, in turn, activates the unfolded protein response (UPR) in
myelinating Schwann cells, ultimately causing apoptosis and demyelination to
occur. This hypothesis is supported by the fact that mutant MPZ accumulates in
the ER of Schwann cells and triggers the UPR in two independent mouse models
of CMT1B that harbor two different MPZ mutations, S63del and R98C (Pennuto
et al., 2008 and Ikegami et al 1996). Also, the deletion of a transcription factor
critical for the UPR, CHOP (CAATT enhancer-binding protein homologous
protein) recuses motor deficits and mitigates demyelination within a mouse model
of CMT1B that harbors the S63del mutation (Pennuto et al., 2008).
In response, therapeutic strategies for CMTB and other MPZ-associated
neuropathies have been centered on relieving ER stress in Schwann cells. For
example, curcumin, a component of turmeric, is a natural, low affinity,
sarcoplasmic/ER Ca2+ ATPase (SERCA) inhibitor that can mitigate ER retention.
Oral administration of curcumin improved Schwann cell differentiation and
alleviated ER stress, reducing the UPR in the MPZS63del/+ model, although it was
not successful in alleviating neuropathy in clinical trials (Khajavi et al., 2007 and
Brennan et al., 2015). Although recent work has shown that pharmacological
activation of the integrated stress pathway initiated by the phosphorylation of the
alpha-subunit of eukaryotic translation initiation factor 2 (eIF2) can both prevent
and mitigate neuropathy in mouse models of this disease. Indeed, Das et al has
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shown that the small molecule Sephin1, a selective inhibitor of a
holophosphatase, can prolong the phosphorylation of eIF2 preventing the
expression of anti-apoptotic genes and prevent the onset of demyelination in
mouse models of CM1B (Das et al., 2015). As for post-disease onset therapeutic
effects, pharmacological inhibition of Gadd34 via Salubrinal, an activator of
CHOP, also increases the phosphorylation of eIF2 as well as improves
myelination and reduces accumulation of mutant P0 in the ER also within an
established mouse model of CMT1B (D’Antonio et al., 2013). However,
treatment salubrinal at concentration higher than 40µM have been identified as
toxic limited its therapeutic effects and complicating its translation into a
treatment for the clinic (D’Antonio et al., 2013).
Mutations in EGR2, a gene that encodes early growth response 2 (EGR2,
also known as Krox2), cause CMT1D (Brennan et al., 2015). EGR2 is a zincfinger transcription factor of the early growth response (EGR) family, which
regulates gene expression by binding to cis-acting elements of target genes. It is
highly expressed early in development within migrating neural crest cells and is
required for both hindbrain development and the myelination of the peripheral
nervous system directly activating the expression of myelin genes, such as
PMP22, Cx32, and PRX (Mirsky et al., 2008, Le et al., 2005 and Topilko et al.,
1994). Egr2(-/-) mice display disrupted hindbrain development and
hypomyelination of the peripheral nervous system with Schwann cells blocked at
an early stage of development, with the expression of late myelin genes (P0,
MPZ) either decreased or not expressed at all (Schneider et al., 1993 and Swiatek
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et al., 1993). Although, mice that are heterozygous for Egr2 are phenotypically
normal, making it unclear why dominant mutations in EGR2 cause a
demyelinating neuropathy (Nagarajan et al., 2001).
Interestingly, most mutations identified in patients with CMT1D are
located the zinc-finger DNA binding domain (DBD) of EGR2, and subsequent
studies have shown that zinc-finger mutations affect DNA binding, with the
amount of residual binding directly correlating with the severity of neuropathy
(Warner et al., 1999). Like other forms of CMT1, both suggest that mutant forms
of EGR2 cause neuropathy through a dominant negative mechanism. Indeed,
Nagarajan et al determined that neuropathy-associated mutant forms of EGR2
dominantly-negatively inhibit wildtype EGR from initiating the expression of
essential myelin genes (including MPZ, PMP22, and P0), required for
myelination. Interestingly, they also determined that the reintroduction of
wildtype ERG2 into postnatal, Egr2-deficient Schwann cells results in the
expression of genes critical for myelination, suggesting that EGR2 gene
replacement therapy may be an efficacious therapeutic approach for CMT1D
(Nagarajan et al., 2001).
CMT1X represents the second most frequent form of CMT and results
from mutations in the gap junction protein beta 1 (GJB1), the gene the encodes
connexin 32 (Cx32), a gap junction protein that is expressed in Schwann cells
(Bergoffen et al., 1993). Gap junction proteins are integral membrane proteins
that form functional gap junctions, or channels that allow the rapid transport of
ions and small nutrients between contiguous cells in tissues (Kyriakoudi et al.,
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2017 and Goodenough et al., 1996). Gap junctions are formed by two
hemichannels (or connexons), each made up of six connexin molecules; a
complete channel is formed when one hemichannel docks with another
hemichannel in an adjacent cell membrane (Kyriakoudi et al., 2017, Goodenough
et al., 1996, and Bruzzone et al., 1996). In Schwann cells, Cx32 forms
intracellular gap junctions between paranodal loops and Schmidt-Lanterman
incisures in non-compact regions of myelin, that allow the diffusion of ions and
small molecules through the myelin sheath (Kyriakoudi et al., 2017 and Scherer et
al., 1995). Over 400 mutations in Cx32 have been identified in patients with
CMTX1 that include missense, nonsense, frameshift, and large deletions, all of
which are evenly dispersed throughout all functional domains of the protein
(Pareyson et al., 2009 and Kleopa et al., 2006). Mutant forms of Cx32 are thought
to cause demyelination and neuropathy through a loss-of-function mechanism, as
mice deficient in Cx32 display reduced nerve conduction velocities and
hypomyelination that is similar to what is observed in individuals with CMTX1
(SArgiannidou et al., 2009, Shy et al., 2007, Scherer et al., 1998, Anzini et al.,
1997 and Bruzzone et al., 1994).
Many Cx32 missense mutants have been studied in vitro and have shown
abnormal trafficking and intracellular retention in the endoplasmic reticulum (ER)
and/or Golgi followed by proteasomal or lysosomal degradation (Kleopa et al.,
2002, Yum et al., 2002, VanSlyke et al., 2000, Martin et al., 2000, Deschenes et
al., 1997 and Omori et al., 1996). Other mutants, both missense and nonsense, can
traffic to the membrane, but form non-functional channels or channels with
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altered biophysical properties (Castro et al., 1999, Ressot et al., 1998, and Castro
et al., 1999). Additional studies in HeLa cells show that some missense mutants
form nonfunctional chimeric connexons with wildtype connexons that are not
properly inserted into the cytoplasmic membrane (Omori et al., 1996). Taken
together, these data suggest, as in other subtypes of CMT1, that protein
misfolding and/or mislocalization may be involved in pathology along with
possible dominant-negative activity.
Overall, all the aforementioned mutations lead to the accumulation of
mislocalized and/or misfolded proteins within myelinating Schwann cells causing
deficits in their differentiation and homeostasis, causing subsequent
demyelination. Thus, much effort has been expended to develop a therapy that can
promote myelin differentiation and stabilization for patients with a demyelinating
form of CMT. Along these lines, Fledrich et al identified reduced expression of
genes required for Schwann cell differentiation within several, preonset Pmp22transgenic rodent models of CMT1A. Markers of immature and dedifferentiated
Schwann cells were also found to be upregulated in sciatic nerves from postdisease onset rodent models of CMT1A caused by reduced activity of the PI3KAkt signaling pathway within myelinating Schwann cells. Based on these
findings, they determined that treatment with neuregulin-1, a growth factor
known to enhance PI3K-Akt signaling, can drive undifferentiated Schwann
cells to mature in early-onset rodent models of CMT1A, and preserves
myelination throughout adulthood (Fledrich et al., 2014). Although the
therapeutic window of this therapy is short, neuregulin-1 supplementation
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might be able to treat childhood onset CMT1A, or, if one of the mentioned
CMT1-causing mutations is known to affect a family, before the onset of
disease.
CMT2: Impaired Mitochondria Function & Axonal Transport
Mitochondria are unique organelles that provide every cell with energy, in
the form of ATP, by oxidative phosphorylation. Due to high-energy requirements
and low intrinsic energy reserves, neurons require continual delivery of ATP to
maintain excitability and protein phosphorylation reactions that mediate
neurotransmission and synaptic integrity. Thus, not surprisingly, the dysregulation
of mitochondrial function has been implicated in a number of neurodegenerative
disorders, such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease, in
addition to CMT (Johri et al., 2012). In fact, over 50 different mutations in
mitofusion 2 (MFN2), an outer mitochondrial membrane protein, together are the
most common cause of axonal CMT (CMT2A), identified in ~20% of patients
with CMT2 and accounting for 4% of all CMT cases (Patzko and Shy, 2011).
MFN2 is a dynamin family GTPase involved in mitochondrial fusion, although it
has also been implicated in regulation of mitochondrial oxidative function (Harel
et al., 2014, de Brito el al., 2008 and Chen et al., 2005). Why mutations in this
ubiquitously-expressed gene specifically cause axon degeneration is unclear.
However, most reported MFN2 mutations are classified as missense, have a
dominant inheritance pattern, are fully expressed, and are localized to
mitochondria, suggesting that dominant-negative or toxic effects of the mutant
protein may contribute to disease (Misko et al., 2012, Baloh et al., 2007 and Chen
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et al 2005). Recent research has shown that mutant forms of MFN2 disrupt axonal
mitochondrial transport. Considering mitochondria need to be transported to distal
axon terminals to help maintain synaptic connections, this loss is predicted to
cause length-dependent axonal degeneration as seen with CMT2 (Jerath et al.,
2015). The accumulation of mitochondria within distal portions of axons within a
mouse model of CMT2A further supports impairment in mitochondrial transport
along axons (Misko et al., 2010).
Indeed, axonal transport (axoplasmic flow), the intraneuronal transport of
organelles along microtubules within axons, is an essential cellular process for the
proper function and survival of neurons. Human lower motor neurons have axons
more than 1 meter in length, making axonal transport critical for anterograde
delivery of proteins, lipids, and mitochondria, required for proper synaptic
transmission to distant axon terminals (Millecamp et al., 2013). Axonal transport
also removes recycled or misfolded proteins, clearing potential neurotoxic protein
aggregates (Perlson et al., 2010). Several axonal forms of CMT are caused by
mutations in genes critical for axonal transport (Pareyson et al., 2015). For
example, similar to CMT2A, CMT2E is caused by dominant mutations in NEFL
(neurofilament light) that disrupt neurofilament assembly and transport, thereby
interrupting axonal mitochondrial transport with mitochondria being sequestered
in the axon initial segment (Prior et al., 2017).
CMT2B results from mutations in TBC1D15 (TBC1 domain family
member 15), the gene that encodes RAB7, a GTPase-activating protein critical for
retrograde axon transport (McCray et al. 2010). RAB7 is part of a large family of
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ubiquitously-expressed Rab GTPases that regulate the formation, transport and
fusion of cellular vesicles and are involved in the recruitment of molecular motors
for vesicular transport and trafficking of ion channels (Amaya et al., 2016, Saraste
et al., 2016, and Bucci et al., 2014). Rab7 itself regulates vesicular transport to
late endosomal and lysosomes in the endocytic pathway (Zhang et al., 2013). This
includes the lysosome-mediated degradation of epidermal growth factor (EGF)
and its cognate receptor (EGFR) along with nerve growth factor and tropomyosin
receptor kinase A. This, axon degeneration in CMT2B may result from disrupted
neurotrophin trafficking by mutant forms of Rab7 (Liu et al., 2017 and Zhang et
al., 2013). Indeed, loss of GTPase activity is thought to be the pathological
mechanism underlying CMT2B as the loss of rab7, but not overexpression of
CMT-linked mutant forms of rab7 caused adult-onset neurodegeneration in
Drosophila (Cherry et al., 2013). Although in contrast additional research
discovered that CMT-causing mutations in Rab7 leave it in a constitutively active,
GTP-bound conformation (Spinosa et al., 2008). Furthermore, mutant forms of
Rab7 have been recently identified to abnormally bind to the intermediate
neurofilament protein, peripherin, in vitro (Cogli et al., 2013). Together, these
data suggest that these mutations may have multiple neurotoxic effects possibly
through both loss- and gain- of function mechanisms, including interfering with
retrograde axonal transport by possibly altering neurofilament assembly and
depleting neurotrophins needed for neuronal homeostasis.
Interestingly, axonal transport is also altered in CMT2F, an axonal
neuropathy caused by HSPB1, encoding heat shock protein ß1 (Evgrafov et al.,
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2004 and Ismailov et al., 2001). Heat shock proteins normally remove misfolded
protein from cells, among other diverse roles in modulating intracellular redox
states, cell differentiation, and the assembly of cytoskeleton (Arrigo et al., 2007,
Dierick et al., 2005, and Xanthoudakis et al., 2000). However, in vitro, in addition
to the accumulation of intracellular protein aggregates, mutant forms of HSPB1
disrupt neurofilament networks and axonal transport (Zhai et al., 2007, Ackerley
et al., 2006 and Evgrafov et al., 2004). This finding was confirmed in vivo with a
severe loss of axonal transport within peripheral nerves of two conditional mouse
models of CMT2F, that harbor missense mutations in HSPB1 within neurons and
exhibit symptoms of CMT symptoms starting at 6 months-of-age (d’Ydewalle et
al., 2011). This reduction in axonal transport was found to be initiated by a
reduction in acetylation of alpha-tubulin, a process that is important for the
association of molecular motor proteins, including kinesin and dynein, to
microtubules (d’Ydewalle et al., 2011). Both behavioral and electrophysiological
symptoms were reversed with pharmacological inhibition of HDAC6 (histone
deacetylase 6), a microtubule-associated deacetylase that deacetylates acetylated
alpha-tubulin (d’Ydewalle et al., 2011). In response, there has been much effort
expended in translating the treatment of HDAC inhibitors for CMT2F into clinical
practice. Translation has been difficult, as many current HDAC inhibitors exhibit
transient pharmacokinetics with short half-lives in vivo, and poor selectivity
causing several adverse off-target related toxicities (Benoy et al., 2017).
However, more stable and selective HDAC inhibitors are currently being
developed (Benoy et al., 2017). Improvements in HDAC inhibitors are critical as
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reductions in acetylated alpha-tubulin and axonal transport have also recently
been found within the peripheral neurons of several mouse models of CMT2D, an
axonal neuropathy caused by dominant mutations in GARS (Mo et al., 2018 &
Benoy et al., 2018). Interestingly, these effects were found to be caused by the
direct aberrant interaction of mutant GARS to HDAC6, enhancing its
deacetylation activity on α-tubulin (Mo et al., 2018). Importantly, treatment
with HDAC inhibitors were effective at reversing deficits in axonal transport as
well as improving motor function in multiple mouse models of this disease (Mo
et al., 2018). Considering deficits in axonal transport are implicated in several
other forms of CMT2, levels of acetylated alpha-tubulin within peripheral nerves
of other models of CMT2 (i.e., CMT2B, CMT2A, and CMT2E) should be
evaluated. Improvement in axonal transport by HDAC inhibitors may be an
effective treatment strategy for several forms of CMT.
Aminoacyl tRNA Synthetases & Neuronal Homeostasis
Aminoacyl tRNA synthetases (aaRSs) are ubiquitously-expressed
enzymes that catalyze the aminoacylation of tRNAs with their cognate amino
acids, playing an essential, non-redundant role in protein translation (Pang et al.,
2014, Guo et al., 2011 and Ibba et al., 2000). These enzymes are critical for
fidelity of the genetic code as each tRNA harbors a specific anticodon triplet, and
mischarging an amino acid to its non-cognate tRNA could cause large,
detrimental changes to the proteome. Therefore, about half of the aaRSs have
evolved pre- and/or post-transfer amino acid editing mechanisms to ensure the
highest level of fidelity during protein synthesis (Mascarenhas et al., 2008).

21

Evolution has also obliged several aaRSs to have additional, idiosyncratic, noncanonical roles in an array of other biological functions, including glucose and
amino acid metabolism, angiogenesis, inflammation, cellular stress responses,
apoptosis, the regulation of transcription and translation, rRNA transcription,
autoimmunity, tRNA maturation, and mitochondrial RNA splicing (Pang et al.,
2014 and Guo et al., 2010).
Mutations in as many as five genes encoding aaRSs (GARS, MARS, YARS,
AARS, & KARS) have been implicated in axonal and intermediate forms of CMT
(Hyun et al., 2014, McLaughlin et al., 2010, Latour et al., 2010, Jordanova et al.,
2006 and Antonellis et al., 2003). However, why mutations in these ubiquitouslyexpressed housekeeping genes specifically cause peripheral neuropathy remains
unclear. It is proposed that reductions in aminoacylation either by
haploinsufficiency or dominant-negative activity may contribute to pathology.
Indeed, loss of canonical activity may deplete aminoacylated cognate tRNAs,
leading to ribosome stalling at codons for these cognate amino acids, and thereby
reducing translation of critical proteins. This hypothesis is supported by the fact
that the majority of the amino acid residues that are mutated in all five CMTassociated aaRSs are highly conserved during evolution, suggesting that
disruption of their ancient, essential function, aminoacylation, may contribute to
the onset of neuropathy (Storkebaum et al., 2016). However, none of the
mutations in aaRSs identified in patients with CMT result in protein-null
mutations such as stop codons, frame shifts, splicing defects, or large deletions.
All reported CMT-linked mutations in aaRSs result in either single amino acid
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changes or small in-frame deletions that are dispersed throughout all the
functional domains of the enzyme (Meyer-Schuman et al., 2017). Several in vitro
aminoacylation assays have also confirmed that not all CMT-associated mutant
forms of aaRSs have reduced aminoacylation activity, including GARS E71G,
YARS E196K, and AARS E778A, all of which segregate with disease in family
pedigrees (Niehus et al., 2015, Mclaughlin et al., 2012, Froelich et al., 2011,
Storkebaum et al., 2009, Nangle et al., 2007, and Antonellis et al., 2006).
Furthermore, a reduction in tRNAGly aminoacylation activity is not observed
within mouse models of CMT2D (GarsC201R/+ and GarsP278KY/+) which harbor
amino acid substitutions, C201R and P278KY, within Gars (Seburn et al., 2006).
Similarly, while homozygous Gars knockout mice are embryonic lethal,
haploinsufficiency is not observed in the heterozygous Gars-null strain,
GarsXm256/+ (Seburn et al., 2006). Furthermore, mischarging of any CMTassociated aaRSs has yet to be demonstrated, and only 2 out of the 5 of the aaRS
loci have editing abilities (Pang et al., 2014 and Stum et al., 2011). Taken
together, these data suggest that neither the loss nor misregulation of
aminoacylation contributes to pathology underlying CMT pathogenesis. A loss of
a newly-evolved idiosyncratic function is possible, although neither a noncanonical role of aaRS in neuronal homeostasis nor a common non-canonical
function among all 5 CMT-linked aaRS loci has been identified. However, one
non-canonical function of YARS has recently been discovered and involves its
translocation into the nucleus upon oxidative stress where in plays a role in
preventing DNA damage. However, it remains unclear if this function occurs in
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peripheral neurons nor if this non-canonical function is disrupted by CMTcausing mutations in YARS play any role to the onset of neuropathy (Wei et al.,
2014).
As for other potential pathological mechanisms, an emerging body of
research largely supports mutant forms of aaRSs causing neuropathy through a
toxic gain-of-function (neomorphic) mechanism that specifically affects
peripheral nerves. For example, both established mouse models of Garsassociated CMT (GarsC201R/+ and GarsP278KY/+) display a distal axonal neuropathy
that could not be rescued by overexpression of wildtype Gars; whereas increasing
the genetic dosage of mutant Gars increased the severity of the neuropathy in
mouse models expressing either mutant allele (Motley et al., 2011). Furthermore,
over-expression of several mutant forms of human GARS (E71G, G240R, and
G526R) and YARS (G41R, 153-156delVKQV, and E196K) within motor and
sensory neurons results in a cell-autonomous reduction in global protein
translation within neurons, that, in turn, causes a neuropathy in fully developed
Drosophila, which cannot be rescued by the overexpression of wildtype aaRS
(Niehues et al., 2015). These data suggest that mutant forms of aaRS may
interfere with translational machinery that, though it may occur in all cells, may
be particularly toxic in neurons, which are high-energy cells that require constant
production of proteins needed for neurotransmission.
In contrast, He et al. predicts that mutant forms of GARS cause CMT by a
non-cell autonomous, possibly systemic, mechanism, involving the abnormal
binding of mutant GlyRS to neuropilin 1 receptor (nrp1). This aberrant interaction
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interferes with the binding of vascular endothelial growth factor (VEGF), a
cognate ligand of nrp1, whose neurotrophic effects are critical for neuronal
protection and survival (Neufeld et al., 2002). These data are further supported by
the fact that the motor nucleus of the facial nerve does not migrate caudally in
GarsP278KY/+ embryos, resembling Nrp1 or Vegf knockout phenotypes (He et al,
2015). However, deletion of Nrp1 at P10 does not cause neuropathy and does not
enhance symptoms of neuropathy in adult mouse models of CMT2D (Morelli et
al., unpublished).
Interestingly, as previously mentioned, mutant forms of GARS also
aberrantly bind to HDAC6 causing reductions in axonal transport and subsequent
neuropathy (Mo et al., 2018). However, both mechanisms may only be
idiosyncratic to mutant forms of GARS and may not apply to all CMT-associated
aaRS loci. Nonetheless, taken together, these data strongly suggest that treatment
strategies aimed at reducing mutant aaRS expression may be of therapeutic
benefit for patients with aaRS-related forms of CMT.
Precision Gene Therapy: A Promising Treatment Strategy for CMT
Advancement in diagnostic DNA sequencing, primarily Next Generation
Sequencing, has significantly enhanced our understanding of CMT by isolating
the primary genetic cause of many different subtypes of this disorder. Thus,
identification and thorough study of such disease-associated genes has helped
categorize the pathophysiological bases of CMT, such as structural proteins of
myelin (type 1) and axonal cytoskeleton, axonal transport, and mitochondrial
dysfunction (type 2), but many forms do not clearly fit these categories,
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suggesting there are many cellular and molecular routes that lead to
neurodegeneration. For example, it remains unclear why mutations in so many
ubiquitously-expressed, often housekeeping genes, specifically cause peripheral
neuropathy, leaving patients that harbor these mutations without an effective
treatment.
Furthermore, many CMT-associated genes have pleiotropic effects, often
leading distinct mutations within the same gene to have variable effects on
peripheral nerve function. For example, dominant mutations in NEFL can cause
either a demyelinating CMT (CMT1F) or an axonal form of the disease
(CMT2E), as neurofilaments play critical roles in axon-Schwann cell interactions,
maintenance of the axonal cytoskeleton, and axonal transport. Together, these
factors conspire against a single effective therapy for all subtypes of CMT, such
as ascorbic acid or HDAC inhibitors, suggesting that personalized genetic
approaches may represent a more efficacious therapeutic strategy.
Gene therapy is a promising treatment strategy for CMT as well as many other
inherited neuromuscular disorders. This experimental therapy encompasses
several therapeutic approaches, including gene replacement therapies for
recessive disorders caused by haploinsufficiency, and anti-sense oligonucleotides,
that can either inactivate or edit genes contributing to disease. Thus, different
gene therapies can be designed to target the direct molecular cause underlying
each specific form of CMT, tailoring treatment to each patient’s specific
pathology. Here we report several advancements in gene therapy for CMT. For
example, gene therapy approaches are being successfully deployed to treat rare,
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recessive genetic disorders by restoring the expression of mutated genes.
However, the feasibility of these approaches for dominantly-inherited diseases—
where treatment may require reduction in the expression of a dominantly toxic
mutant protein—is unclear. Here, we use viral vector-delivered, allele-specific
RNAi in combination with precision mouse models of an autosomal dominant
form of CMT to demonstrate the effectiveness of allele-specific silencing as a
long-term treatment for dominantly-inherited forms of CMT. We have designed
our therapy for a single patient, but this sets an important precedent, as 90% of
CMT subtypes are inherited in an autosomal dominant inheritance pattern.
In addition to genetic heterogeneity, patients with CMT also exhibit
clinical heterogeneity, even within individuals with the same CMT-causing
mutation. This indicates that in addition to potential environmental factors, genes
that modify the effects of primary mutations may contribute to the phenotypic
heterogeneity among patients with CMT. With such epistatic control over primary
genes, genetic modifiers may contribute to the variation of the age of onset,
severity, and the progression of CMT. Thus, genetic factors underlying this
variability may represent targets for therapeutic intervention for multiple
subtypes of the same NMD or multiple independent disorders. Here we describe
several potential genetic modifiers of CMT that may one day lead to therapies that
can mitigate several forms of CMT.
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CHAPTER 2
SEVERITY OF BOTH DEMYELINATING AND AXONAL
NEUROPATHY MOUSE MODELS IS MODIFIED BY GENES
AFFECTING STRUCTURE AND FUNCTION OF PERIPHERAL NODES
Abstract
Charcot-Marie-Tooth disease (CMT) is a clinically and genetically
heterogeneous group of inherited polyneuropathies. Mutations in 80 genetic loci
can cause forms of CMT, resulting in demyelination and axonal dysfunction. The
clinical presentation, including sensory deficits, distal muscle weakness and
atrophy, can vary greatly in severity and progression. Here we used mouse models
of CMT to demonstrate genetic interactions that result in a more severe
neuropathy phenotype. The cell adhesion molecule Nrcam and the Na+ channel
Scn8a (NaV1.6) are important components of nodes. Homozygous Nrcam and
heterozygous Scn8a mutations synergized with both an Sh3tc2 mutation,
modeling recessive demyelinating Charcot-Marie-Tooth type 4C, and mutations
in Gars, modeling dominant axonal Charcot-Marie-Tooth type 2D. We conclude
that genetic variants perturbing the structure and function of nodes interact with
mutations affecting the cable properties of axons by thinning myelin or reducing
axon diameter. Therefore, genes important for peripheral nodes are candidate
modifiers of peripheral neuropathy.
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Introduction
CMT is considered a Mendelian disorder, with over 80 associated loci in
humans (Timmerman et al., 2014). However, the severity of neuropathy can vary
even within alleles (Pareyson and Marchesi, 2009). Therefore, it is likely that
many pathways can influence the severity of peripheral neuropathy, and one
presumed basis for the variability is the presence of genetic modifiers (GonzagaJauregui et al., 2015). Here we have used mouse models of two forms of CMT to
investigate genetic modifiers of neuropathy. First, we identified a spontaneous
mutation in Sh3tc2 that creates a model of recessive CMT-4C, a demyelinating
neuropathy (Arnaud et al., 2009, Senderek et al., 2003). We also use two different
point mutations in glycyl tRNA synthetase (Gars) (Seburn et al., 2006, Achilli et
al., 2009) that are models of CMT2D, a dominant axonal neuropathy (Antonellis
et al., 2003). In the present study, we demonstrate that the phenotype of these
CMT mouse models becomes more severe in the presence of either of two other
mutations that cause "subclinical" changes at peripheral nodes.
The Nav1.6 (Scn8a) sodium channel is the primary voltage-gated sodium
channel at peripheral nodes of Ranvier and axon initial segments (Caldwell et al.,
2000). The Ig superfamily-member cell adhesion molecule Nrcam (Neuro-glialrelated cell adhesion molecule) is part of a transmembrane complex at nodes.
During development, NRCAM and gliomedin in the Schwann cell establish a
heminode in the axon at the boundary of the maturing Schwann cell, which then
fuses into a mature node (Eshed-Eisenbach and Peles, 2013, Rasband and Peles,
2015, Feinberg et al., 2010). The loss of Nrcam results in delayed formation of
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nodes, and occasional "split nodes" in adult peripheral nerves, but no obvious
signs of neuromuscular dysfunction (Amor et al., 2014, Custer et al., 2003).
NRCAM’s role is somewhat redundant, as Nrcam and Gliomedin double-mutant
mice fail to maintain nodes (Amor et al., 2014). Similarly, mutations in the
paranodal protein CASPR are more severe in combination with Nrcam mutations
(Feinberg et al., 2010). In the axon, NRCAM binds to ankyrins intracellularly,
and ankyrins bind sodium channels (Davis and Bennett, 1994, Jenkins and
Bennett, 2001). Similarly, Scn8a homozygous mice have extensive neurological
problems, but heterozygotes are behaviorally and histologically normal (Burgess
et al., 1995). However, we found that introducing either Nrcam homozygous or
Scn8a heterozygous mutations into our CMT models results in a more severe
neuropathy. Our results demonstrate that mutations that reduce myelin thickness
or axon diameter act synergistically with mutations that alter nodes and/or reduce
sodium currents in peripheral axons. These results have implications for CMT
genetic diagnosis and prognosis, and suggest possible treatments.
Results
The identification of spontaneous Nrcam and Sh3tc2 mutations.
The synergy of demyelinating peripheral neuropathy and impairments in
peripheral node organization was made evident in a spontaneous mouse mutation
identified and characterized at The Jackson Laboratory. This strain –nm4302 –
arose in the background of a knockout of the cannabinoid receptor 2. Some mice
displayed impaired hind limb function soon after weaning, which progressed to
near complete hind limb paralysis and death by five months of age. This was
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inconsistent with the Cnr2 knockout phenotype (Tschop et al., 2009), and was not
linked to the knockout allele, indicating a spontaneous mutation had arisen. This
mutation was recessive, since unaffected parents produced litters with a subset of
affected offspring. Hind limb muscles in affected mice showed severe atrophy.
Angular fibers and foci of atrophy without signs of degeneration/regeneration,
fibrosis, or fatty infiltration were consistent with neurogenic etiology (Figure 1A,
B).
Using genetic mapping and exome sequencing, we identified two
mutations in these mice. Genetic mapping revealed regions on Chrs. 12 and 18 as
associated with the paralysis phenotype (Figure 1C and methods). Affected mice
were recovered not at 1:4, but at closer to 1:16 in the mapping cross, consistent to
two recessive loci, and mildly affected mice were also observed, presumably
carrying only one of the mutations. We also performed exome sequencing on an
affected mouse, which revealed a single base pair C to T conversion in exon 3 of
Sh3tc2 on Chromosome 18, creating a premature stop codon at amino acid 71
(G71X, Figure 1D). Mutations in Sh3tc2 cause a recessive demyelinating
neuropathy (CMT 4C), and knockout mice have reduced myelin thickness and
progressive retraction of Schwann cells from nodes of Ranvier (Arnaud et al.,
2009, Senderek et al., 2003). The Sh3tc2 gene is within the mapping interval on
Chromosome 18, making Sh3tc2 a strong candidate. On chromosome 12, we
identified a B2 element insertion in exon 26 of Nrcam (see Methods). The Nrcam
gene is within our mapping interval, and is a candidate gene for its role in Na+
channel localization at nodes of Ranvier and axon initial segments, and for its

31

previously reported genetic interactions with Lpin1, causing transient hind limb
paralysis (Douglas et al., 2009). The B2 element disrupts coding sequence and
splicing of Nrcam, resulting in premature stop codons (Figure 1 E).
NRCAM is 1256 amino acids, with a single transmembrane domain at
amino acids 1120-1142. Both of the B2-element associated stop codons terminate
translation before the transmembrane domain, resembling a previously reported
allele, Q1033X, which is a protein null (Douglas et al., 2009). Consistent with
this, anti-NRCAM immunolabeling with an antibody raised against the entire
extracellular domain was eliminated at nodes of Ranvier in the sciatic nerve in
Nrcam mutant samples (Figure 1F,G), and no NRCAM protein was detected by
Western blotting from brain homogenates (Figure 1H).
Demyelinating Sh3tc2 mutations strongly synergize with Nrcam mutations
The phenotype of the Sh3tc2 mutation on its own is consistent with
previous reports (Arnaud et al., 2009), and the mice develop a tremor and
demyelinating neuropathy. The Nrcam mutation on its own is also consistent with
previous reports, with occasional split nodes, having two distinct bands of NaV1.6
and AnkyrinG (Figure 1 I, J and supplemental figure 1) (Amor et al., 2014). This
occurred at 6.6±2.8% percent of the Nrcam-/- nodes, versus zero at control nodes
(n=4, average of 99 nodes per nerve scored). Levels of NaV1.6 in the sciatic
nerve were reduced on western blots (Figure 1 K, L). Normalizing to beta-Actin
as a loading control, NaV1.6 levels in Nrcam-/- mice were reduced to 49% of wild
type levels (n=3 mutant and 3 C57BL/6J control mice). Since Na+ channels may
localize to internodal axon membranes (Shrager, 1989), we performed semi
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quantitative immunofluorescence with NaV1.6 and neurofilament light chain as
an internal control, but did not detect a decrease in NaV1.6 labeling at nodes of
Nrcam-/- nerves (supplemental figure 1). Localization of paranodal proteins such
as CASPR were unaffected (Feinberg et al., 2010, Amor et al., 2014).
Despite the changes in NaV1.6 localization and abundance, the Nrcam-/mice do not have an overt neuromuscular phenotype or obvious deficits in motor
behavior. Other axonal parameters, such as the internodal distance were
unchanged (Figure 1M). The average internodal distance divided by fiber
diameter was 70.3±12.4 for Nrcam-/- axons and 64.9±10.0 for C57BL/6J control
mice
The mild neuromuscular dysfunction of the Nrcam or Sh3tc2 mutant mice
is further substantiated by phenotyping performed by the knockout mouse
program, with Nrcam-/- mice having poor performance on a rotarod test and
Sh3tc2-/- mice having reduced grip strength, but otherwise no significant (p<0.05)
neuromuscular phenotypes (KOMP2; https://www.mousephenotype.org).
However, in combination, these two mutations cause paralysis in the spontaneous
double mutant strain nm4302.
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Figure 1 Nm4302 mutations in Sh3tc2 and Nrcam A, B) Muscle histology from
the gastrocnemius of control (A) and an affected Nm4302 mouse (B) demonstrate
signs of neurogenic atrophy in the mutant, including clusters of angular fibers and
signs of reinnervation/regeneration. C) Genetic mapping revealed significant
associations with both Chromosome 12 and 18. The logarithm of the odds score
(LOD, Y-axis) of single nucleotide polymorphisms (SNPs) is plotted versus their
chromosomal location (X-axis). D) Chromatograms of sequencing PCR products
from genomic DNA of a wild type (top), Sh3tc2 heterozygote (middle) and
Sh3tc2 homozygote (bottom) show the C to T conversion in exon three creating a
stop codon at residue 71. E) The B2 element insertion in exon 26 of Nrcam results
in a 259 bp insertion with a duplication of the flanking 15 bp of the exon. Splicing
from exon 25 to 26 results in a premature stop codon in the B2 element sequence.
Aberrant splicing into the B2 element itself results in a premature stop codon 23
bp downstream of the new splice junction. F, G) Immunolabeling of NRCAM
(red) at nodes of Ranvier in teased sciatic nerve axons from wild type mice (F) or
Nrcam mutant mice (G) reveals an absence of signal in the mutant, confirmed in
teased nerves from three mice per genotype. Nodes were double labeled with
antibodies against KV1.2 potassium channels (green). H) Western blotting protein
from brain extracts also revealed an absence of signal in Nrcam mutant mice
(Nrcam-/-). Mice from the KOMP2 program carrying an Nrcam mutation
(Nrcamk/k) and a strain matched littermate control (NrcamWTB6/N) were used as a
control. Wild type littermates from each Nrcam mutant strain contain protein at
the predicted size, and anti-GAPDH was used as a loading control (below). Three
independent blots were probed, and three mice per genotype were examined. The
Nrcam mutant phenotype resembles previous reports. I) Wild type nodes of
Ranvier have a single, colocalized site of NaV1.6 and ankyrinG
immunoreactivity. J) In Nrcam mutant mice, “split” nodes with two sites of
NaV1.6 and ankyrinG labeling were observed, although these proteins still
colocalized. Four mice of each genotype were examined. K) Western blot of
sciatic nerve lysates probed with antibodies against NaV1.6 revealed reduced
signal relative to beta actin loading control. Proteins migrated at their anticipated
molecular weights of ~225 kDa and ~42 kDa for NaV1.6 and beta actin
respectively. L) Quantification of the NaV1.6:beta actin signal revealed a 51%
decrease in NaV1.6 intensity (3 Nrcam-/- and 3 C57BL/6J control analyzed,
p=0.03). M) The relationship between internodal distance and fiber diameter was
not changed in Nrcam-/- mice compared to C57BL/6 controls (n=3 mice per
genotype,37 Nrcam-/- and 34 Nrcam+/+ axons measured). Scale bar in J is 7 µm for
F, G and 14 µm for I, J.
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The basis for this progressive paralysis was explored by examining
peripheral nerve anatomy and function in control, Nrcam-/-, Sh3tc2-/-, and double
mutant mice. Cross-sections of the motor branch of the femoral nerve were
examined (Figure 2 A-D). No changes in axon diameter, myelin thickness or axon
number were observed for Nrcam mutant samples (Figure 2B, E-G). As expected,
Sh3tc2-/- samples had reduced myelin thickness (p<0.0001) and supernumerary
Schwann cell processes, but no decrease in myelinated axon number, and no
change in axon diameter (Figure 2C, E-G). Axons in double mutant mice
essentially mirrored the Sh3tc2-/- reduction myelin thickness (p<0.0001 vs. control
and p=0.27 vs. Sh3tc2-/-), but no change in axon number or size (Figure 2 D, EG). Thus, the Nrcam mutation does not exacerbate the demyelinating effects of
Sh3tc3-/-. In functional assays, nerve conduction velocity (NCV) was slightly
decreased in Nrcam-/- mice (p=0.04). A previous study of Nrcam mutant mice
reported normal NCV, but at P2, early the process of myelination, whereas we
studied adult mice (Custer et al., 2003). NCV was more decreased in Sh3tc2-/mice (p<0.001), and even more severely reduced in double mutant animals
(p<0.001) (Figure 2 H). Myelin packing was examined by transmission electron
microscopy (Supplemental figure 2). Myelin wraps on Nrcam-/- axons were
slightly closer (12.9±1.4 nm between wraps) than control and Sh3tc2-/- axons
(14.7±1.6 and 14.1±0.7 respectively, P<0.05), but this was not additionally
reduced in the double mutant mice (12.3±2.0). The reduced overall myelin
thickness in Sh3tc2-/- and double mutant mice was therefore due primarily to a
reduced number of myelin wraps, not changes in myelin packing. The relationship
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between axon diameter and myelin thickness (the “g ratio”) is comparably
reduced compared to control in both Sh3tc2-/- and double mutant mice, but
unchanged in Nrcam mutant nerves (Supplemental figure 2).
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Figure 2. Peripheral nerve anatomy and function in Sh3tc2 and Nrcam
mutations (A-D) Cross sections of the motor branch of the femoral nerve from
wild type (A), Nrcam-/- (B), Sh3tc2-/- (C), and double mutant (D) mice are shown.
E) A cumulative histogram of axon diameters indicates no change in the single or
double mutants. F) Cumulative histograms of myelin thickness reveal no change
in Nrcam-/- nerves, a significant decrease in Sh3tc2-/- nerves, but no additional
decrease in double mutant nerves. G) Axon number was not changed in any
genotype. H) Nerve conduction velocity was reduced in Nrcam-/- mice, was
reduced to a greater degree in Sh3tc2-/- mice, and was further reduced in double
mutant mice. Data from eight mice per genotype are presented in E-G, H includes
10 control, 14 Nrcam-/-, 10 Sh3tc2-/-, and 14 double mutant mice. Values in G, H
are mean ± S.D. Mice were from 73-145 days old (average 104 days) in E-G, and
57-125 days old (average 103 days) in H. * = p<0.05, **=P<0.01 Scale bar in D
is 50 µm for A-D.
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Nrcam mutant nerves have no changes in myelination, axon diameter, or
internodal distance, so their reduced NCV may result from Na+ channel
dysfunction at nodes. However, NRCAM also interacts with paranodal proteins
such as CASPR, and Sh3tc2 mutations also cause the Schwann cells to retract
from the node, so changes in other nodal properties and channel types could also
contribute to the phenotype of both mutants.
Changes such as axon loss do not explain the muscle atrophy and paralysis
in double mutant mice. Examining neuromuscular junctions (NMJs) did not show
evidence of denervation or die-back neuropathy (Seburn et al., 2006, Spaulding et
al., 2016), but NMJs did show a phenotype. The NMJ morphology of the plantaris
muscle in Nrcam-/- and Sh3tc2-/- single mutant animals was normal (Figure 3 AC). However, in double mutant mice by 3.5 months of age (~100 days), NMJs
showed extensive fragmentation, sprouting of nerve terminals, and extrasynaptic
acetylcholine receptor expression (Figure 3 D,E). These changes were not evident
at 2.5 months of age (Supplemental figure 3).
Nerve terminal sprouting and extrasynaptic AChR expression are also
seen when peripheral nerves are silenced by chronic application of tetrodotoxin to
the axon or botulinum toxin to the nerve terminal (Duchen and Strich, 1968,
Pestronk and Drachman, 1978, Brown and Ironton, 1977). Consistent with motor
neuron action potentials not reaching presynaptic terminals in the double mutant
mice, we saw evidence of conduction block (Mallik and Weir, 2005) in our NCV
studies (Figures 2H, 3F). Normally, the integrated compound muscle action
potential (iCMAP) amplitudes of the distally (ankle) and proximally (hip) evoked
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EMG are equal, but with conduction block, the proximally evoked EMG is
reduced. Clinically, decrements of at least 20% are classified as conduction block
(Mallik and Weir, 2005). Conduction block was present in the double mutant
mice, with the proximal iCMAP reduced compared to distal (-35%) (Fig. 3F).
Interestingly, Nrcam and Sh3tc2 mutant mice had intermediate effects (~ -25%)
and conduction block was not present in control nerves (-12%).
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Figure 3. Neuromuscular junction sprouting and fragmentation in
Nrcam;Sh3tc2 double mutant mice A) Normally, the motor nerve terminal
(green) completely overlays the postsynaptic acetylcholine receptors (red). B, C)
Mice with mutations in Nrcam (B) or Sh3tc2 (C) did not show abnormal NMJ
morphology or nerve occupancy. D) Double mutant mice showed profound NMJ
defects after 3.5 months of age, with sprouting nerve terminals, sites of partial and
complete denervation, aneural puncta of AChRs, and fragmentation of NMJs.
Few if any normal NMJs persist, as shown at a lower magnification (E).
Sprouting and NMJ dysmorphology (D, E) were observed in all double mutant
mice >3 months of age (n=5) and were never observed in control or single mutant
mice. F) The integrated compound muscle action potential evoked from distal
stimulation was larger than when evoked by proximal stimulation in double
mutant mice. The mice in F are the same as those analyzed in Figure 2H. Scale
bar in E represents 14µm in A-D and 84 µm in E.
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Statistically, the variability inherent in CMAP amplitude with
transcutaneous stimulation resulted in no significant changes by ANOVA
(p=0.07), but double mutant mice had significant conduction block when
compared to control in pairwise comparisons (ttest p=0.01 double mutant vs.
control). The duration of the proximal iCMAPs was increased by less than 10%
compared to the distal in all genotypes. Thus, temporal dispersion is not
pronounced. Taken together, the immunofluorescence and conduction block data
are consistent with failures in action potential propagation with distance in the
double mutants.
To further investigate this, one double mutant mouse was examined for
synaptic transmission at the NMJ by two-electrode voltage clamp. In this muscle,
five of the ten fibers recorded produced normal postsynaptic responses following
nerve stimulation (EPC) (Supplemental figure 4). However, no evoked response
was produced by nerve stimulation in the other five fibers despite the presence of
spontaneous mini excitatory postsynaptic currents (mEPCs). Recently, we
examined 184 NMJs in wild-type mice, only 4 (2%) had mEPCs without a
corresponding EPC, and within single experiments where 6-11 NMJs were
examined, an mEPC without an EPC never occurred more than once (Spaulding
et al., 2016). Thus, the finding that 50% of double mutant terminals showed
spontaneous release without an evoked response is consistent with neuromuscular
transmission being relatively normal at active synapses (supplemental figure 4),
but that action potentials fail to reach some nerve terminals.
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These effects are completely recessive. The progressive paralysis
phenotype was only observed in double homozygous mice. Mice heterozygous for
either or both the Nrcam and Sh3tc2 mutations were normal (supplemental figure
5). Furthermore, if mice were homozygous for one mutation, being heterozygous
for the second did not make the phenotype worse (supplemental figure 5).
Therefore, many of the control values reported are pooled data from heterozygous
and homozygous wild-type mice.
Together, these results led us to hypothesize that mutations that
compromise the axonal length constant will synergize with mutations that
compromise depolarization, and specifically Na+ currents at nodes. However,
since Nrcam mutations potentially affect more than Na+ currents, and since
Sh3tc2 mutations also impact nodes as well as myelination, we performed
additional experiments compromising the length constant by reducing axon
diameter, and directly compromising NaV1.6.
Gars dominant axonal neuropathy is exacerbated by loss of Nrcam
We used a dominant mutation in glycyl tRNA synthetase (Gars) to specifically
decrease axon diameter (Achilli et al., 2009). The GarsC201R/+ mice have smaller
diameter axons than wild type mice, but no axon loss. Thus, in GarsC201R/+ mice,
the axonal length constant is compromised, and we would predict that diminished
function at nodes would worsen the phenotype. We bred GarsC201R/+ mice into an
Nrcam-/- background and repeated our analysis of nerve and muscle histology and
function. Cross-sections of the motor branch of the femoral nerve confirmed the
reduced axon size in the GarsC201R/+ mice (p<0.0001), which was not exacerbated
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by the additional loss of Nrcam (Figure 4 A-D). Axon number was unchanged in
any genotype (Figure 4E). Nrcam-/- muscles were of normal size, but GarsC201R/+
muscles were smaller, and muscles from Nrcam-/-;GarsC201R/+ mice were smaller
still (p<0.001), as assessed by the ratio of the muscle weights to total body weight
(Figure 4F). NCV was further reduced in double mutant mice compared to either
single mutant (p<0.001) (Figure 4 G). In examining NMJs, no partial innervation
or denervation was observed in Nrcam-/- mice alone (p=0.56), but significant
innervation defects were seen in GarsC201R/+ (p<0.05) and were worsened by the
loss of Nrcam (Figure 4H). The double mutant mice were also overtly more
affected based on size, tremor, and poor motor performance. However, the mice
did not progress to paralysis and premature death. These studies support the
hypothesis that the introduction of defects at nodes caused by the Nrcam mutation
synergize with the GarsC201R/+ mutation to cause a more severe phenotype.
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Figure 4. Axonal neuropathy is exacerbated by loss of Nrcam (A-C) Cross
sections of the motor branch of the femoral nerve were examined for three month
old wild type (A), GarsC201R/+ (B), and GarsC201R/+;Nrcam-/- mice. D) Axon
diameters were reduced in GarsC201R/+ compared to wild type and Nrcam-/- mice,
with no further reduction in double mutants. E) Axon number was not reduced in
any genotype. F) Muscle size was assessed by the ratio of muscle weight (g) to
total body weight (g) (MW/BW*100) for the triceps surae. No change was
observed in Nrcam-/- mice, but GarsC201R/+ mice showed reduced MW:BW.
Double mutant mice showed the largest reduction in MW:BW ratio. G) NCV was
more severely reduced in double mutant mice than in either single mutant. H) The
GarsC201R/+ mice have reduced NMJ occupancy, with more partial innervation of
NMJs, and some instances of complete denervation. NMJ occupancy was more
severely reduced in double mutant mice, whereas Nrcam-/- mice had no change in
NMJ occupancy compared to controls. D, E are based on 8 mice per genotype, F
on 7 control, 7 Nrcam-/-, 9 GarsC201R/+, and 8 double mutant mice, G on 8 control,
7 Nrcam-/-, 9 GarsC201R/+, and 9 double mutant mice, and H on 8 control, 6 Nrcam/, 7 GarsC201R/+, and 4 double mutant mice. Values for E-H are mean ± S.D.
Animals were 3 months of age, and an approximately equal mix of male and
females were used. *=p<0.05, **=p<0.01, ***=p<0.001. Scale bar in C is 50µm
for A-C.
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Heterozygosity for Scn8a (NaV1.6) also exacerbates Gars-associated axonal
neuropathy
Next we directly compromised NaV1.6 to assess their possible
contribution. Since homozygous mutations in Scn8a cause a variety of
neurological phenotypes in mice and humans (O'Brien and Meisler, 2013), we
used mice heterozygous for a spontaneous point mutation in Scn8a, R914S, which
produces a pronounced med-like phenotype as a homozygote (Duchen, 1970) but
no overt symptoms as a heterozygote. GarsC201R/+ mice were bred to Scn8a+/mice, and offspring of all subsequent genotypes were analyzed. The Scn8a+/- mice
did not show a reduction in axon size or axon diameter, and the reduced axon size
observed in GarsC201R/+ was not exacerbated by heterozygosity for Scn8a (Figure
5 A-F). NCV was reduced in the Scn8a+/- mice, and the NCV in Gars;Scn8a
double heterozygous mice was lower than in either single mutant alone (Figure
5G). Although additional muscle atrophy was not seen in the heterozygous mice,
NMJ innervation status was worse than GarsC201R/+ alone, whereas Scn8a+/- mice
did not have NMJ defects (Figure 5 H,I). Thus, Scn8a heterozygosity produced no
phenotype on its own beyond a modest reduction in NCV, but made the
GarsC201R/+ phenotype more severe both for NCV and for NMJ innervation. The
GarsC201R/+;Scn8a+/- double heterozygous mice were also overtly more severe.
These data support our conclusion that the Nrcam effects are largely through
NaV1.6 mislocalization or decreased NaV1.6 channel function.
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Figure 5. Axonal neuropathy is exacerbated by partial impairment of
NaV1.6/Scn8a+/- (A-D) Cross sections from the motor branch of the femoral
nerve for control (A), Scn8a+/- (B), GarsC201R/+ (C), and double heterozygous mice
(D). (E) Axon diameters were not changed in Scn8a+/-, and double heterozygous
mice did not show a greater reduction in axon diameters than GarsC201R/+ alone. F)
Axon number in the motor branch of the femoral nerve was unchanged in any
genotype. G) Nerve conduction velocity was mildly reduced in Scn8a+/- mice, and
double heterozygotes had conduction velocities reduced below either single
mutant. H) No muscle atrophy was observed in Scn8a+/- mice, and no additional
muscle atrophy beyond the effects of GarsC201R/+ was observed in double
heterozygotes. I) Scn8a+/- mice did not show changes in innervation at the NMJ,
but double heterozygous mice had more partial innervation and denervation at
NMJs than GarsC201R/+ mice. Values are mean ± S.D. Analyses were performed
on eight mice per genotype at three months of age with an approximately equal
mix of males and females. *=p<0.05, **=p<0.01. Scale bar in D is 50µm for A-D.
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The GarsC201R/+;Scn8a+/- double heterozygous mice also did not progress
to paralysis and death, consistent with the slow progression of the GarsC201R/+
phenotype. However, we also mated Scn8a+/- mice to mice with a more severe
allele of Gars, P278KY/+. These mice develop a similar, but more severe, motor
and sensory neuropathy, and also lose 20 to 30% of their peripheral axons by a
few months of age (Seburn et al., 2006, Motley et al., 2011). We saw a similar
increase in the severity of the double heterozygous phenotype over GarsP278KY/+
alone by 2.5-3.5 months of age (Figure 6). The GarsP278KY/+ mice did not have
more severe axon atrophy or axon loss when heterozygous for Scn8a (Figure 6
A,B), but did have more severe reductions in nerve conduction velocity (p<0.01),
muscle atrophy p<0.01), and NMJ occupancy (p<0.0001) (Figure 6 C-E).
Eventually, these mice did become severely impaired in motor ability by six
months of age and were not maintained longer.
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Figure 6. Scn8a heterozygosity enhances a more severe axonal neuropathy
model, GarsP278KY/+ (A) There was no additional reduction in axon diameter in
the motor branch of the femoral nerve over GarsP278KY/+ in mice also
heterozygous for Scn8a. (B) The GarsP278KY/+ mice have fewer myelinated axons,
but this reduction was not exacerbated by Scn8a heterozygosity. (C) Nerve
conduction velocity was further reduced in double heterozygotes, beyond the
effects of GarsP278KY/+ alone. (D) Additional muscle atrophy was present in
double heterozygous mice. (E) Additional defects were present at NMJs, with
increased denervation and partial innervation, and virtually no fully innervated
junctions. Analyses were performed on eight mice of each genotype between 2.5
and 3.5 months of age, except C, in which 8 control, and 9 Scn8a+/- mice were
used and results from 1 GarsP278KY/+ and 2 double heterozygous mice were not
included because a reliable EMG signal and conduction velocity could not be
ascertained. Values in B-E are mean ± S.D. *=p<0.05, **=p<0.01 ***=p<0.001,
****=p<0.0001.
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Discussion
Our results indicate that mutations that subtly compromise nodes of
Ranvier and sodium channel function in peripheral axons can be relatively
innocuous on their own, but synergize with mutations that cause thinner myelin or
smaller diameter axons in the peripheral nervous system to cause a much more
severe phenotype. Homozygous mutations in Nrcam or heterozygous mutations in
Scn8a result in a minor reduction in NCV, and occasional mis-localization and
reduced numbers of sodium channels in peripheral nerves (Nrcam homozygotes).
These mutations do not cause overt neuromuscular phenotypes. Furthermore,
Nrcam-/- or Scn8a+/- mutations do not result in muscle atrophy or histological
changes in nerve, muscle, or neuromuscular junctions. However, in combination
with either demyelinating (Sh3tc2 homozygous) or axonal (Gars heterozygous)
models of CMT, the Nrcam homozygous and Scn8a heterozygous mutations
exacerbate the phenotype. With Gars mutations, this results in an additional
reduction in NCV, additional muscle atrophy (in GarsP278KY/+), and additional
denervation at the NMJ. With Sh3tc2, the effect is particularly severe, resulting in
progressive paralysis and muscle wasting, leading to death by five months-of-age.
These results are consistent with peripheral nerve biophysics. Saltatory
conduction results from depolarizing action potentials opening voltage-gated
sodium channels localized to nodes. This local depolarization is propagated very
rapidly from node to node by the passive “cable properties” of the axon. The
depolarization decays over distance, but as long as it is suprathreshold and opens
sodium channels at the next node, saltatory conduction continues. The “length
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constant” of the axon describes the passive decay in potential with distance, and
depends on the resistance of the membrane (Rm), the axial resistance along the
axon (Ra), and the capacitance of the membrane (Cm), largely determined by
myelin thickness (Figure 7).

Figure 7. Compromised axonal length constants synergize with compromised
Na+ conductance Action potentials occur only at nodes of Ranvier in myelinated
peripheral axons. Depolarization spreads to the next node by passive cable
properties of the axon, determined by the membrane capacitance (Cm), the
membrane resistance (Rm), and the axial resistance (Ra). The decay in the passive
propagation of depolarization with distance is the axonal length constant (l).
Increasing Cm through thinner myelin or increasing Ra through smaller axons
both decrease l (dashed line), resulting in less depolarization at the next node.
Due to the safety factor, this is usually still sufficient to cause suprathreshold
depolarization at the next node. However, if the amplitude of the action potential
is also decreased, the same change in the length constant could result in a failure
to reach the action potential threshold at the next node.
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The peripheral nerve normally has a "safety factor," such that the length
constant is ~5 times longer than necessary to sustain saltatory conduction (Li,
2015). Thus, as predicted, our Nrcam homozygous or Scn8a heterozygous
mutations that only slightly compromise sodium currents, produce a very mild
phenotype. The modest reduction in nerve conduction velocity observed in both
Nrcam homozygous and Scn8a heterozygous nerves is also consistent with a
reduction in sodium currents at the nodes. The rapid passive propagation of
depolarization has to overcome the capacitance current. If Cm is increased, or if
current is decreased, the rate of change in potential will decrease (following the
equation: ∂V /∂T = i/C). The reduced sodium influx may also slow the time to
reach threshold depolarization and initiate an action potential.
To explore the feasibility of our hypothesized interaction, we used a
simple mathematical model of myelinated axons (Moore JW, Stuart AE. Neurons
in Action 2: Tutorials and Simulations in NEURON.
(2007) file:///Applications/NIA2.app/Contents/X_NIA2/splash.htm), with default
settings for Cm and Na+ current density based on Hodgkin and Huxley parameters
for a standard myelinated axon. We used 8 µm for a large diameter axon (see
Figures 2E, 4D, and 5E, as well as (Seburn et al., 2006, Motley et al., 2011)), and
obtained a nerve conduction velocity of 40 m/s, closely matching our
experimental results. The 17% decrease in NCV in the Nrcam-/- mice requires
only a 33% decrease in Na+ current density, less than our estimated loss measured
by western blotting (Figure 1K, L); although we did not detect a sodium channel
decrease specifically at nodes by immunofluorescence. The 60% reduction in
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myelin thickness in Sh3tc2-/- axons produces an NCV of 28.6 m/s in this model,
closely matching our experimental value. The combined effect of the Sh3tc2 and
Nrcam mutations using the model is an NCV of 22 m/s, which underestimates the
effects we see in vivo. A number of additional factors not considered by this
model may also be involved. First, the axon initial segment may also be affected
by the loss of NRCAM (Xu and Shrager, 2005). Our distal sciatic nerve
stimulation circumvents this, but for normal physiological function, it is clearly a
consideration. Second, in addition to thin myelin, the retraction of the Schwann
cells from nodes in Sh3tc2 mutant mice may also be increasing K+ conductances
and shunt current (Arnaud et al., 2009). Nrcam mutant axons do not have
disrupted paranodes ((Custer et al., 2003, Amor et al., 2014) and not shown), but
loss of Nrcam interacts with loss of paranodal CASPR to create a more severe
phenotype (Feinberg et al., 2010). Therefore, we cannot rule out that
Nrcam;Sh3tc2 double mutant mice have even more severely disrupted paranodes.
However, whether the effect is decreased Na+ currents or increased K+ currents,
our hypothesis and the effect on saltatory conduction is fundamentally unchanged.
Third, peripheral axons typically conduct action potential trains, and propagation
failures may become more widespread at higher frequency. Finally,
demyelination or aberrant channel function may alter the resting potential of the
axon (Kuwabara and Misawa, 2004).
Nonetheless, the schematic in Figure 7 illustrates the point that a change in
the length constant that is still within the safety factor, and a change in the
amplitude of depolarization that is still within the safety factor, could additively
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result in subthreshold depolarization and action potential failure, as seen in double
mutant mice. This reflects the functional interdependence of these processes and
does not require physical interaction between the proteins.
These results can also be considered in the context of CMT genetics. Since
virtually all CMTs compromise the axonal length constant, through demyelination
or axon atrophy, we would anticipate any mutations that compromise nodes to be
synergistic. Both Gars/CMT2D and Sh3tc2/CMT4C are reported to be influenced
by genetic modifiers (Sivakumar et al., 2005, Colomer et al., 2006), but
identifying modifiers is difficult in rare diseases. The SCN8A gene in humans is
associated with cognitive impairment with and without cerebellar ataxia, and
early infantile epileptic encephalopathy, and in mice it causes the motor endplate
degeneration (med) phenotype (Burgess et al., 1995, Trudeau et al., 2006,
Veeramah et al., 2012, O'Brien and Meisler, 2013). Nrcam mutations are
associated with neurodevelopmental disorders and addictive behaviors in humans
(Bonora et al., 2005, Sakurai et al., 2006, Ishiguro et al., 2006, Kim et al., 2009,
Marui et al., 2009, Yoo et al., 2012). However, our point is not to make a direct
case for NRCAM or SCN8A as human disease modifiers for CMT, indeed, their
clinical associations are more severe than the “subclinical” mouse mutations we
are describing, but instead to use them as a demonstration of the principle that
variants that impact nodes will lead to more severe CMT phenotypes. Such
variants may include any of the key components of the node of Ranvier (see
(Rasband and Peles, 2015) for review). Although the frequency of such modifiers
is currently unknown, as genetic diagnostic sequencing improves variants in such
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genes in patients diagnosed with CMT can be tested for correlation with the
disease severity, which could improve the prognostic accuracy for disease
severity and progression.
Finally, these results may also suggest a treatment strategy. Sodium
channels are generally antagonized by more slowly gated potassium channels,
which attenuate and truncate the sodium-mediated depolarization. Thus, if
decreased sodium currents are detrimental, then perhaps reduced potassium
currents would be beneficial. This is readily testable in these mouse models.
In summary, genetic analyses in mice have led to the general hypothesis
that mutations compromising the axonal length constant will synergize with
mutations that alter nodes and/or reduce Na+-channel mediated depolarization in
peripheral axons. These findings are consistent with our understanding of axonal
action potential propagation, and have implications for the diagnosis and
treatment of diseases resulting in neuropathy, such as CMT.
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CHAPTER 3
ALLELE-SPECIFIC RNA INTERFERENCE: PRECISION GENE
THERAPY FOR DOMINANTLY-INHERITED PERIPHERAL
NEUROPATHIES
Abstract
Recent advances in personalized medicine have given rise to effective,
targeted therapeutic interventions for diseases ranging from cancers to human
airway disease. Furthermore, personalized gene therapy approaches are being
successfully deployed to treat rare, recessive genetic disorders by restoring the
expression of mutated genes. However, the feasibility of these approaches for
dominantly-inherited diseases—where treatment may require reduction in the
expression of a dominantly toxic mutant protein—is unclear. Here, we use viral
vector-delivered, allele-specific RNAi in combination with precision mouse
models of an autosomal dominant neurodegenerative disease to demonstrate the
effectiveness of allele-specific silencing as a long-term treatment for dominantlyinherited neuromuscular disorders.
Introduction
Personalized medicine seeks to provide the optimized treatment for an
individual based on the molecular characteristics of their specific disease. For
example, cancer treatments are customized to the genetics of the patient and the
tumor (Reck et al., 2016 and Capdeville et al., 2002). However, in rare Mendelian
diseases, the genetic basis or DNA variant effects may be uncertain or, even when
defined, chronic, effective treatments may be unavailable (Chong et al., 2015).
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Animal models recapitulating molecular lesions offer a means for validating the
causality of new human mutations and can serve as surrogates in preclinical
therapeutic development studies (Robinson et al., 2014). Furthermore, gene
therapy approaches can address the primary cause of genetic conditions without a
detailed understanding of the genetic model, systems biology or pathophysiology
of the disease (Naldini et al., 2015). Gene therapy approaches are being
successfully deployed to treat recessive conditions often resulting from loss-offunction (LoF) alleles, by restoring the expression of the mutated genes (Mendell
et al., 2017 and Bainbridge et al., 2015). However, the feasibility of these
approaches for dominantly-inherited, monoallelic mutations—where treatment
may require reduction in the expression of a toxic mutant protein resulting from a
gain-of-function (GoF) allele—is unclear. Here, we combine precision models of
a dominant inherited neuropathy [Charcot-Marie-Tooth Disease Type 2D
(CMT2D), MIM#601472, caused by mutations in glycyl-tRNA synthetase, GARS
MIM#600287] with allele-specific knockdown by viral-vector delivered gene
therapy to demonstrate the effectiveness of this strategy. We designed our therapy
for a single patient, but this sets an important precedent as 90% of inherited
peripheral neuropathies-and the majority of familial amyotrophic lateral sclerosis
cases- are inherited in an autosomal dominant manner (Boylan et al., 2015 and
Saprta et al., 2013).
Charcot-Marie-Tooth Disease Type 2D (CMT2D), also known as distal
spinal muscular atrophy V (dSMAV), is a rare, progressive, inherited axonal
neuropathy caused by dominant mutations in GARS, an essential, housekeeping
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gene encoding glycl-tRNA synthetase (Antonellis et al., 2003). There is no
treatment for CMT2D or any of the over 80 genetic forms of inherited peripheral
neuropathy. To date, at least thirteen individual mutations in GARS have been
identified in patients with CMT2D, all of which result in single amino acid
changes in different functional domains of glycl-tRNA synthetase (Lee et al.,
2012, Abe et al., 2009, Rohkamm et al., 2007, James et al., 2006). However, the
mechanisms through which mutant forms of GARS cause axon degeneration
remain unclear, limiting the development of a targeted therapy.
All disease-associated GARS variants studied to date cause impaired
enzymatic activity in charging glycine onto tRNAGly in vitro and/or decreased
cellular viability in yeast complementation assays, consistent with a LoF effect
(Griffin et al., 2014 and Antonellis et al., 2006). However, protein null alleles in
mice and humans do not cause dominant neuropathy, ruling out
haploinsufficiency and suggesting a dominant- negative GoF (antimorph)
mechanism (Lek et al., 2016, Motley et al., 2011, and Seburn et al., 2006).
Furthermore, transgenic overexpression of wild-type GARS does not rescue the
neuropathy in mouse models, suggesting that mutant forms of GARS gain toxic
GoF (neomorph) activity that the wild-type protein cannot out compete (Motley et
al., 2011). One proposed toxic gain-of-function mechanism involves the abnormal
binding of mutant GARS to the developmental receptor neuropilin 1 (NRP1).
This interaction interferes with the normal binding of vascular endothelial growth
factor (VEGF), an endogenous ligand of NRP1, whose neurotrophic effects are
critical for neuronal development and survival (He et al., 2015).
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The aggregate data support the contention that suppression of the mutant
allele of GARS should be beneficial, whereas enhancing normal GARS function is
of questionable benefit in the continued presence of the mutant protein. We
hypothesized that for a GoF mutant allele, suppression would have a
therapeutically beneficial effect. To achieve this suppression, we developed a
gene therapy strategy for CMT2D that reduces the levels of mutant Gars
transcripts through allele-specific RNAi, triggered through the delivery of mutant
Gars-targeted artificial microRNA expression cassettes packaged within selfcomplementary adeno-associated viral vectors, serotype 9 (scAAV9).
Results
To determine whether our approach could be translational, we sought to
demonstrate the therapeutic efficacy of a patient-specific RNAi based gene
therapy in a “humanized” mouse model expressing a patient-specific GARS
mutation introduced into the mouse Gars gene. We chose a GARS variant that we
recently identified in a now six-year-old female who presented clinically by
displaying decreases in muscle tone, head lag, axillary slippage, mild tongue
atrophy, ligamentous laxity in the hands and feet, and excessive retraction of the
chest wall starting at 13 months of age. Muscle biopsy at 15 months was
indicative of neurogenic changes consistent with neuropathy. This included
marked atrophy of type I and II fibers, and no evidence of myofiber necrosis,
degeneration, or regeneration, nor of dystrophic or inflammatory myopathy. EMG
and nerve conduction studies were also consistent with motor neuron disease.
After negative tests for spinal muscular atrophy, whole-exome sequencing
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analysis revealed that the patient is heterozygous for an in-frame deletion of 12
nucleotides in exon 8 of the glycyl-tRNA synthetase (GARS) gene (c.894_905del;
NM_002047.2), resulting in the deletion of four highly conserved amino acids in
the GARS protein (p.Glu299_Gln302del; NP_002038.2) hereafter, referred to as
∆ETAQ. No other potentially pathogenic variant was identified at another locus
that could potentially explain the severity of the neuropathy by a dual molecular
diagnosis. Neither parent carries the identified GARS mutation, nor does the
patient’s twin brother, indicating a de novo mutation. GARS functions as a dimer
to ligate glycine onto cognate tRNA molecules. The substrate glycine is bound
within a pocket of each monomer, and one tRNA molecule associates with each
half of the dimer. Importantly, the ∆ETAQ GARS mutation results in the deletion
of four amino-acid residues that are conserved from human to bacteria and that
reside within the glycine-binding pocket (Figure 8 A) (Qin et al., 2014).
To determine if the ∆ETAQ GARS mutation affected mRNA expression or
stability, we performed RNA-seq to assess the expression of wild-type and mutant
alleles in patient primary dermal fibroblasts. These analyses revealed an even
distribution of wild-type (53.7%) and ∆ETAQ (46.3%) RNA-seq reads indicating
that ∆ETAQ GARS does not dramatically affect transcript levels (Supplemental
figure 6 A). To determine if ∆ETAQ GARS impacted GARS protein levels, we
performed western blot analysis on whole-cell lysates from these cells compared
to a control primary dermal fibroblast cell line (i.e., bearing no GARS mutations).
These experiments did not reveal an observable difference in total GARS protein
levels in the affected fibroblasts compared to the control cell line, consistent with
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the mutant protein being expressed and stable (Supplemental figure 6 B). We next
performed two experiments to assess if ∆ETAQ GARS affects the primary
function of the enzyme: aminoacylation assays and yeast complementation tests.
Analysis of the initial rate of aminoacylation as a function of the tRNA substrate
concentration showed that ∆ETAQ GARS retained less than 0.01%
aminoacylation activity (Figure 8 B, Supplemental table 1) compared to wild-type
GARS indicating that it is a functional null allele. Although the P234KY allele
showed activity in assays with saturating tRNA and glycine substrate
concentrations, a re-evaluation of kinetic properties under Michaelis-Menton
conditions also showed a marked decrease in enzyme activity, making ETAQ
GARS analogous to P234KY GARS (equivalent to the mouse P278KY mutation,
numbered without the mitochondrial targeting sequence included) (Figure 8 B).
The reduced function of the ∆ETAQ allele was further supported by the failure of
this mutant protein to complement ablated cellular growth associated with
deletion of the yeast ortholog GRS1 (Figure 8 C). Data from this latter assay also
support the LoF effect associated with P278KY Gars (Figure 8 C) and was
consistent with the failure of the mouse P278KY allele to complement an RNAnull allele of Gars (Seburn et al., 2006).
Previous studies showed that neuropathy-associated GARS mutations
cause inappropriate binding to neuropilin-1 (NRP1), which leads to impaired
NRP1/VEGF signaling in motor neurons (He et al., 2015). To directly test for
binding between ∆ETAQ GARS and NRP1, we expressed V5-tagged wild-type,
P234KY, and ∆ETAQ GARS in the mouse motor neuron cell line NSC-34. After
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immunoprecipitation with an anti-NRP1 antibody, proteins were subjected to
western blot analysis using an anti-V5 antibody. These studies revealed strong V5
signal associated with P234KY GARS, very weak V5 signal associated with
∆ETAQ GARS, and no V5 signal associated wild-type GARS (Figure 8 D). The
lack of an interaction between ∆ETAQ GARS and NRP1 was also demonstrated
in unbiased mass spectrometry analyses of proteins immuno-precipitated from
mouse neuroblastoma (MN1) cells expressing FLAG-tagged wild-type or V5tagged ∆ETAQ GARS (Supplemental figure 7). In sum, ∆ETAQ showed changes
in activity characteristic of other neuropathy-associated GARS mutations,
supporting the pathogenicity in the phenotype described above. However, the
particularly severe phenotype of the and the lack of an interaction between
∆ETAQ GARS and NRP1 warrant further studies on the link between this
mutation and peripheral nerve dysfunction.
To validate the pathogenicity of ∆ETAQ GARS in vivo, we engineered a
mouse model in which the mutation was introduced into exon 8 of the mouse
Gars gene (Gars∆ETAQ/+) using CRISPR/Cas9 genome-editing technology (see
Methods for details). For subsequent preclinical studies, Gars∆ETAQ/+ mice were
crossed to GarshuEx8/huEx8, a second mouse model we engineered that harbors a
“humanized” wild-type Gars exon 8. The Gars gene is highly conserved,
including intron/exon structure, and the fifty amino acids encoded by exon 8 are
100% identical between mouse and human, although there are some silent singlenucleotide differences that could affect allele-specificity of gene silencing,
thereby necessitating humanizing the wild-type exon.
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This breeding produced a cohort of Gars∆ETAQ /huEx8 mice with GarshuEx8/+
littermate controls. Reverse transcriptase-PCR using cDNA isolated from sciatic
nerve of heterozygous mice revealed co-expression of ∆ETAQ and wild type
Gars (Supplemental figure 8 A). At the protein level, a western blot analysis of
brain homogenates using a polyclonal anti-GARS antibody confirmed that
∆ETAQ Gars did not alter GARS protein levels, suggesting that a stable
transcript and protein products are produced from the ∆ETAQ allele similar to our
results with patient fibroblasts (Supplemental figure 8 B).
At 12 weeks-of-age, Gars∆ETAQ/huEx8 and GarshuEx8/+ littermates were
evaluated for features of primary neuropathy, as observed in other mouse models
of CMT2D (Achilli et al., 2009 and Seburn et al., 2006). Like these previous
models, Gars∆ETAQ/huEx8 mice displayed overt neuromuscular dysfunction and a
significant reduction in body weight (p = 0.0006) and grip strength (p = 0.0002)
compared to huEx8/+ controls (Figure 8 E-F). Histological changes in
Gars∆ETAQ/huEx8 mice were observed in cross sections of the motor branch of the
femoral nerve, including an overall decrease in axon number (p = 0.0293) and
axon diameter (p = <0.0001) (Figure 8 G-I). Nerve conduction velocities (NCV)
were also reduced by 62%, falling from 35 ± 6.29 m/s in control animals to 13.5 ±
4.1m/s (p =0.0002) in the sciatic nerve in mutant mice (Figure 8 J). This decrease
was consistent with NCVs observed in other mouse Gars neuropathy models and
in some patients with GARS-mediated peripheral neuropathy (CMT2). The loss of
motor axons resulted in a concomitant disruption of neuromuscular junctions
(NMJs) in distal muscles. While postsynaptic receptor fields of NMJs in the
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plantaris muscle were fully occupied by motor nerve terminals in control
littermates, 60% ± 14.2% of NMJs were partially occupied and 8.5% ± 9.9% were
completely denervated in mice that expressed the ∆ETAQ mutation (Figure 8 KM). Thus, Gars∆ETAQ/huEx8 mice display primary features of peripheral neuropathy
similar to those observed in established mouse models of CMT2D, confirming
that the ∆ETAQ GARS mutation was indeed pathogenic and causative of the
neuropathy (Morelli et al., 2017, Bais et al., 2016, Achilli et al., 2009 and Seburn
et al., 2006).
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Figure 8. In vitro and in vivo characterization of the ∆ETAQ GARS variant
(A) The position and evolutionary conservation of the ∆ETAQ (red) and P234KY
(green) GARS mutations are shown, along with flanking amino acid residues. (B)
Initial aminoacylation rates (pmole/min) of wild-type, P234KY, and ∆ETAQ
(blue) GARS were plotted against tRNA concentrations and fit to the MichaelisMenten equation. Error bars indicate standard deviations. (C) Representative
cultures of yeast strains lacking GRS1, the yeast ortholog of glycyl tRNA
synthetase, were plated on solid growth medium containing 5-FOA to induce
expression of transfected vectors containing no insert (Empty pYY1), or
containing either a wild-type or mutant (∆ETAQ or P234KY) human GARS openreading frame. Before inoculating on medium containing 5-FOA, each strain was
either undiluted, or diluted 1:10 or 1:100 in water. Two independently generated
expression constructs were employed for each mutation. (D) Wild-type (WT),
P234KY, or ∆ETAQ GARS were expressed in mouse motor neuron cells.
Subsequently, immunoprecipitation with an anti-NRP1 antibody was performed
to detect aberrant interactions. Western blots were performed with anti-NRP1 and
anti-V5 antibodies. (E) The body weight of Gars∆ETAQ/huEx8 mice and littermate
controls was measured at 12 weeks. Gars(∆ETAQ/huEx8) mice were significantly
lighter, weighing 19 ±1.9 grams (p=0.0006, n=8) compared to GarshuEx8/+
controls, which weighed 27.4 ±4.84 grams (n=7). (F) Gross motor performance in
Gars∆ETAQ/huEx8 mice was quantified using a wire hang test. While GarshuEx8/+
mice averaged 55 ±9.57 seconds before letting go, Gars∆ETAQ/huEx8 mice (n=8) fell
after only 17.3 ±11.3 seconds. (G) Axon number in the motor branch of the
femoral nerve was reduced by 21% from 551 ±45 axons in littermate controls to
438 ±92 axons in Gars∆ETAQ/huEx8 (n=6 mice per genotype). (H) Axons were also
smaller in diameter, as shown in a cumulative histogram of axon diameters
(p<0.0001), with a complete absence of large diameter axons in Gars(∆ETAQ/huEx8)
mice (average diameter =1.6 ±0.8 µm, n= 6) compared to Gars(+/huEx8) littermates
(3.3 ±2.198 µm n=6). (I) These changes are evident in images of nerve cross
sections. (J) Nerve conduction velocity (NCV) was significantly reduced from 35
±6.29 m/s in littermate controls to 13.5 ±4.1m/s in Gars∆ETAQ/huEx8 mice
(p=0.0002, n=6 Gars∆ETAQ/huEx8, n=7 GarshuEx8/+). (K) In addition, neuromuscular
junctions (NMJs) from the plantaris muscle showed partial innervation and
denervation, scored based on the overlap between pre- and post-synaptic staining.
While 98.0% of control NMJs were fully innervated, only 32.6% were fully
innervated in Gars∆ETAQ/huEx8 mice, with 60% being partially innervated and 8.5%
completely denervated. Representative images of NMJs morphology and
innervation are shown (L, M) after labeling with antibodies against neurofilament
and synaptic vesicles and alpha-bungarotoxin. Differences between body weight,
grip strength, conduction, axon number between genotypes were statistically
evaluated using a two-way student’s t test, while axon diameter was evaluated by
a KS test. Significant difference in overall % NMJ innervation was determined by
two-way ANOVA with Tukey’s HSD posthoc comparisons. For all analyses
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 represents posthoc
significance between genotypes. Values are mean ± S.D. All scale bars = 100 µm.
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To test whether the allele-specific knockdown of mutant GARS using
RNAi would be efficacious in the context of a pathogenic human GARS mutation,
we first engineered a miRNA shuttle designed to specifically target ∆ETAQ
transcripts for degradation (Figure 9 A-B, Supplemental figure 9) in the
Gars∆ETAQ/huEx8 mice. Specifically, we designed six different mir-30 based
artificial microRNAs shuttles (mi.∆ETAQ1-6) with a mature guide strand
designed to specifically target both human and mouse mutant Gars ∆ETAQ
mRNA for degradation (Figure 9 B, Supplemental figure 9). To identify our lead
microRNA shuttle, we cloned each mi.∆ETAQ sequence into an U6-promoterdriven expression cassette. These were used in an initial in vitro dual-luciferase
screening assay (Boudreau et al., 2011) in which we cloned the ∆ETAQ or
wildtype Gars target sequences into the 3’ UTR of sea pansy (Renilla reniformis)
luciferase and used firefly luciferase as a standard. Knockdown efficiency and
disease-allele specificity were tested following co-transfection of the reporter
plasmid and each U6.mi.∆ETAQ shuttle (or a control vector) into HEK293 cells.
The most effective construct (mi∆.ETAQ-5, now referred to as mi.∆ETAQ)
(Figure 9 B) was cloned into a self-complementary adeno-associated viral vector
(serotype 9, scAAV9) for in vivo delivery (Figure 9 B, Supplemental figure 9).
To first establish the proof-of-principle of this approach in vivo, we tested
whether the reduction of mutant Gars expression before disease onset could
prevent the onset of neuropathy in Gars∆ETAQ/huEx8 mice. A total dose of ~2.6x1011
vg of scAAV9.mi.∆ETAQ or scAAV9.mi.LacZ (expressing a control microRNA
targeting the E. coli LacZ gene) were delivered with an intracerebroventricular
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(ICV) injection at postnatal day 0-1 (P0-1) to Gars∆ETAQ/huEx8 and littermate
control (GarshuEx8/huEx8) pups. All mice were evaluated for established signs of
neuropathy at 4-weeks-of-age, ~1.5 weeks after the initial onset of overt signs of
neuropathy. Gars∆ETAQ/huEx8 mice treated with scAAV9.mi.∆ETAQ showed
significant improvement in a wire hang test of grip strength, increased muscle to
body weight ratios (MW:BW), and improved sciatic nerve conduction velocity
(NCV) compared to control-treated ∆ETAQ mice (Figure 9 C-E). Examination of
cross-sections of the motor branch of the femoral nerve revealed that
scAAV9.mi.∆ETAQ treatment prevented the axon loss and lessened the decrease
in axon diameters observed in untreated and vehicle control-treated ∆ETAQ mice
(Figure 9 F-H). Importantly, injection with scAAV9.mi.∆ETAQ (or
scAAV9.LacZ) did not cause adverse effects in control mice by any of these
outcome measures or by observation for overt reactions. Collectively, these data
show that allele-specific knockdown of mutant ∆ETAQ Gars expression prior to
disease onset has a significant therapeutic effect and almost completely prevents
behavioral, physiological, and histological signs of neuropathy, providing proofof-concept data that allele-specific knockdown using virally delivered RNAi may
be an effective approach for treating CMT2D.
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Figure 9. scAAV9.mi∆ETAQ prevents of the onset of neuropathy in Gars(∆ETAQ/huEx8)
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and gene silencing pathways in target cells. Each miGARS or control sequence was
cloned as a DNA template downstream of a U6 promoter and then delivered to cells via
plasmid transfection (in vitro) or within scAAV9 particles in vivo (depicted here). Once
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processed by the RNAses Drosha and Dicer and the nuclear export factor Exportin-5
(Exp5). The mature antisense strand (red line) incorporates into the RNA-Induced
Silencing Complex (RISC) to elicit sequence-specific degradation of the mutant Gars
mRNA. (B) MiRNAs were efficacy tested in vitro by co-transfecting HEK293 cells with
individual U6-miGARS, or control, plasmids miRNA and a dual-luciferase reporter
plasmid containing one of four target genes cloned into the 3’ UTR of Renilla luciferase:
wild type Human GARS, human ∆ETAQ GARS, wild type mouse Gars, or the mouse
Gars gene containing the same ETAQ deletion. Target gene silencing was then
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as mean ratios ±SEM, and the significance of knockdown efficiency was analyzed using
a two-way ANOVA. Also shown is the sequence of the guide strand of the lead
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four amino acid deletion is shown in red. Base pairing between the miRNA and target
genes is shown with vertical lines, with red lines indicating wobble G-U bonds present in
RNA duplexes. (C-F) scAAV9.mi∆ETAQ treatment in vivo deliver ICV to

neonatal mice significantly prevented deficits at four weeks of age in gross motor
performance quantified by the wire hang test (p= 0.0001) as well as reductions in
MW:BW ratios (p = 0.0315) and NCVs (<0.0001), compared to vehicle-treated
Gars(∆ETAQ/huex8) mice. (F-H) Furthermore, quantification of axon number and
axon size indicated that scAAV9.mi∆ETAQ could partially prevent axon loss (p=
0.0272) and reductions in axon diameter (p = <0.0001) compared to
scAAV9.miLacZ-treated ∆ETAQ mice as displayed in cross sections of the motor
branch of the femoral nerve. Axon diameter was analyzed using a KS normality
test while all other outcomes measures were analyzed using a two-way ANOVA
with Tukey’s HSD posthoc comparisons. *=p<0.05, **=p<0.01, ***=p<0.001,
****=p<0.0001 represents posthoc significance between scAAV9.mi∆ETAQand scAAV9.miLacZ- treated ∆ETAQ mice. Values are mean ± S.D. All scale
bars = 100 µm. Untreated Gars(huEx8/huEx8) n=4, miLacZ-treated Gars(huEx8/huEx8)
n=3, scAAV9.mi∆ETAQ-treated Gars(huEx8/HuEx8) n=5, mi.LacZ-treated
Gars(∆ETAQ/huEx8) n=5, and scAAV9.mi∆ETAQ-treated Gars(∆ETAQ/huEx8) n=5.
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To practically establish the translational potential of our strategy, we next
delivered scAAV9.mi.∆ETAQ to cohorts of both early- (5-week-old) and late- (9week-old) symptomatic Gars∆ETAQ/huEx8 mice and littermate controls via a single
intrathecal (IT) injection into the lumbar spinal cord. When left untreated, 5-week
old early symptomatic Gars∆ETAQ/huEx8 mice are undergo active axon loss, while
axon loss has slowed and muscle atrophy accelerates in 9-week old late
symptomatic ∆ETAQ mice. These time point were chosen to determine if
scAAV9.mi.∆ETAQ could halt the progression of axons loss during early stages
of neuropathy as well as have therapeutic effects in late stages of neuropathy after
axon loss has ceased.
The scAAV9.mi.∆ETAQ-treated early-symptomatic Gars∆ETAQ/huEx8 mice
displayed enhanced grip strength and significant increases in body weight starting
at ~5 weeks post treatment compared to untreated controls (Figure 10 A). When
analyzed for primary signs of neuropathy at 7 weeks post treatment, earlysymptomatic Gars∆ETAQ/huEx8 mice also exhibited significant increases in MW:BW
ratios, nerve conduction velocity, NMJ innervation and a reduction in axon loss,
but no improvement in axon size compared to untreated Gars∆ETAQ/huEx8 mice
(Figure 10 B-D, F). When treated with scAAV9-mi.∆ETAQ at 9 weeks of age,
Gars∆ETAQ/huEx8 mice gained weight and displayed enhanced grip strength starting
at 5-7 weeks post treatment (Figure 10 A). While MW:BW ratios were not
improved and axon loss and atrophy were not prevented, scAAV9.mi.∆ETAQ did
improve nerve conduction velocity and NMJ innervation (Figure 10 B, E-F).
Analysis of mRNA from sensory dorsal root ganglia (DRGs) via pyrosequencing,
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which were also transduced by scAAV9, indicated that mutant Gars mRNA levels
were significantly reduced in scAAV9.mi.∆ETAQ treated mice compared to
vehicle-treated controls (Supplemental table 2).
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Figure 10. Post-Onset therapeutic effects of scAAV9.mi∆ETAQ
(A-B) Reduction in mutant Gars expression improves grip strength and increases
body weight in early- and late- symptomatic Gars∆ETAQ/huEx8 mice. (A)
Mi.∆ETAQ-treated early-and late-symptomatic Gars∆ETAQ/huEx8 mice exhibit
enhanced grip strength and significant increases in body weight starting at ~5
weeks post treatment. (B) When evaluated at 7 weeks post treatment for primary
signs of neuropathy, these data correlate with trending increases in MW:BW
ratios and significant improvements in nerve conduction velocity in mi.∆ETAQtreated late-symptomatic Gars∆ETAQ/huEx8 mice. (B) In addition, early-symptomatic
Gars∆ETAQ/huEx8 mice treated with mi.∆ETAQ displayed significantly higher
MW:BW ratios and faster nerve conduction velocity most likely resulting from
the greater number of motor axons observed in cross-sections of the motor branch
of the femoral nerve although significant in axon diameter was not observed
displayed in C-D. In contrast, reversal of axon atrophy was not observed in
mi.∆ETAQ-treated late-symptomatic Gars∆ETAQ/huEx8 mice (E). Although both
early- and late- symptomatic overall displayed significant increases in NMJ
innervation (F). Data was analyzed using a one-way ANOVA followed by
Tukey’s HSD posthoc comparisons. Significant changes within axon diameter (E)
were determined with a Kolmogorov-Smirnov test. *=p<0.05, **=p<0.01,
***=p<0.001, ****=p<0.0001 represents posthoc significance between miLacZtreated and scAAV9.mi∆ETAQ-treated Gars∆ETAQ/huEx8 mice. A = significant
difference in fully innervated NMJs, B = significant difference in partially
innervated NMJs, & C = significant difference in denervated NMJs. Latesymptomatic Cohort: MiLacZ-treated Gars(huEx8/huEx8) n=5-7, scAAV9.mi∆ETAQtreated Gars(huEx8/HuEx8) n=3-5, mi.LacZ-treated Gars(∆ETAQ/huEx8) n=6, and
scAAV9.mi∆ETAQ-treated Gars(∆ETAQ/huEx8) n=7. Early-symptomatic Cohort:
Gars(huEx8/huEx8) n=6-7, scAAV9.mi∆ETAQ-treated Gars(huEx8/HuEx8) n=3-5,
mi.LacZ-treated Gars(∆ETAQ/huEx8) n=7, and scAAV9.mi∆ETAQ-treated
Gars(∆ETAQ/huEx8) n=9-11. Values are mean ± S.D. All scale bars = 100 µm.
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Given that ∆ETAQ GARS is a de novo mutation and may function through
a different mechanism than other GARS mutants (i.e. independent of NRP1
binding), we sought to confirm the generality of our approach in a second mouse
model of CMT2D, GarsP278KY/+ (Seburn et al., 2006). A miRNA shuttle targeting
the mouse P278KY allele was optimized in our luciferase assay and packaged into
scAAV9, as before (Supplemental figure 10). Similar improvements were also
observed in neonatal, early- and late- symptomatic GarsP278KY/+ mice that were
treated with 1x1011 viral genomes of scAAV9.mi.P278KY delivered by ICV
(neonates) or IT (adults) injection (Figure 11, Supplemental figure 11).
Furthermore, the therapeutic effects of scAAV9.mi.P278KY were dose-dependent,
and were greater with ICV delivery compared to a systemic, intravenous injection
delivering the same total dose (Supplemental figure 12). The beneficial effects of
ICV delivery of the high dose (1x1011 v.g.) of scAAV9.mi.P278KY at P0 lasted at
least one year (Supplemental figure 13).
The outcomes in post-onset studies in both genotypes were variable, likely
because of the challenges in intrathecal delivery in mice. However, the
knockdown efficacy of mutant Gars transcripts within dorsal root ganglion
strongly correlated with therapeutic outcomes within both post-onset studies
(Supplemental figure 14 A-B, E-F). This correlation was stronger with DRGs than
when outcomes were compared to mutant Gars mRNA levels in liver, another
peripheral tissue transduced by scAAV9 (Supplemental figure 14 C-D, G-H). This
is consistent with mutant forms of GARS causing neuropathy through a cellautonomous mechanism. These data indicate that allele-specific knockdown may
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be a general therapeutic strategy for patients with CMT2D, and suggest that
delivery needs to effectively target peripheral neurons. Taken together, these data
confirm that allele-specific RNAi-based gene therapy can improve symptoms of
neuropathy in two mouse models of CMT2D—including a “humanized” model—
and even at post-onset phases of the disease.
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Figure 11. Reduction of mutant Gars by RNAi prevents neuropathy in
Gars(P278KY/+) mice (A) scAAV9.miP278KY treatment by ICV delivery neonatally
significantly prevented deficits in gross motor performance quantified at four weeks-ofage by the wire hang test (p= 0.0001) and (B) reductions in MW:BW ratios (p= 0.0463)
compared to untreated and vehicle-treated P278KY mice. (C) Nerve conductions
velocities were also significantly improved (p= <0.0001) in treated P278KY mice. (D)
Quantification of axon number within cross sections of the motor branch of the femoral
nerve showed that while axon number was reduced by 17% in control-treated P278KY
mice, axon counts in scAAV9.miP278KY-treated P278KY mice (589±15 axons) were
similar to untreated control littermates (600±11 axons). (E) As shown in a cumulative
histogram of axon diameters, scAAV9.miP278KY treatment also restored the presence of
large diameter axons, with average axon diameter within control-treated P278KY mice
being 1.98±4.47 µm, 2.71±3.71 µm for scAAV9.miP278KY-treated P278KY mice, and
3.84±3.74 in untreated Gars(+/+) . The prevention of axon atrophy is evident in
representative images of cross sections of the motor branch of the femoral nerve isolated
from untreated Gars(+/+) and Gars(P278KY/+) mice as well as scAAV9.miP278KY-treated
P278KY mice (F). Representative images of neuromuscular junction (NMJ) morphology
isolated from plantaris muscle are shown (G) after labeling with antibodies against
neurofilament and synaptic vesicles (green) and alpha-bungarotoxin (red). While over
70% of the NMJs are partially or completely denervated in control-treated Gars(P278KY/+)
mice by 4 weeks of age (H) less than 30% of NMJs show any degree of denervation
scAAV9.miP278KY-treated Gars(P278KY/+) mice. Ns for the all outcome measures include;
untreated Gars(+/+) n=5, control-treated Gars(+/+) n=4, scAAV9.miP278KY-treated
Gars(+/+) n=8, untreated Gars(P278KY/+) n=6, control-treated Gars(P278KY/+) n=5,
scAAV9.miP278KY-treated Gars(P278KY/+) n=7. Significance in (A-D, H) was determined
by two-way ANOVA with Tukey’s HSD posthoc comparisons. Significant changes
within axon diameter (E) were determined with a Kolmogorov-Smirnov test.
*=p<0.05,**=p<0.01, ***=p<0.001, ****=p<0.0001 represents posthoc significance
between miLacZ-treated and scAAV9.miP278KY-treated GarsP278KY/+ mice. Values are
mean ± S.D. All scale bars = 100 µm.
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Conclusion
To date, all data from patients with CMT2D and mouse models of
CMT2D are consistent with the selective silencing of mutant GARS expression
being the best strategy for treating this disease. The gene therapy strategy we
developed reduces the expression of mutant Gars transcripts through allelespecific RNAi. The efficacy of this treatment was demonstrated in vivo in a
“humanized” mouse model of CMT2D that expresses a patient-specific GARS
mutation, including benefit with post-onset treatment, and results were confirmed
by showing similar benefits with a different vector targeting an independent
Gars/CMT2D mouse mutation. These studies demonstrate how precision animal
modeling can be used to engineer improved “humanized” preclinical models for
testing personalized therapies for rare and orphan diseases, and set an important
precedent for the use of a RNAi-based gene therapy for this dominant
neuromuscular disease. This approach could conceivably be applied to other,
related disorders including other dominantly inherited peripheral neuropathies or
motor neuron diseases.
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CHAPTER 4
GENE THERAPY GAINS STRENGTH: THE PATH FROM GENETIC
DISCOVERY TO MEDICINE FOR INHERITED NEUROMUSCULAR
DISORDERS
Gene Therapy: An Innovative Treatment Strategy for Inherited
Neuromuscular Disease
Although each individual form may be rare, in aggregate, over 400
clinically- and genetically-diverse inherited neuromuscular disorders (NMDs) that
lead to muscle weakness and immobility affect an estimated 1:3500 individuals
worldwide (Emery, 1991). To date, not one NMD is currently curable, likely due
to their genetic and clinical heterogeneity, making treatment development for
NMDs an extremely difficult endeavor. Although, with the amazing
advancements in Next Generation sequencing, genome-editing technologies, and
other innovative genetic tools, the direct genetic cause of, or genes that contribute
to the severity of a neuromuscular disorder, have been identified. In response, the
research community has put much effort into developing cutting-edge, innovative
gene-targeting therapies for these devastating diseases. Here we review both the
success of current FDA-approved treatments as well as promising preclinical
support for prospective gene therapy approaches for a number of NMDs. We also
highlight several considerations that must be taken when engineering future gene
therapies for the clinic. All told, gene therapies have the potential to provide a
powerful and effective treatment strategy for many deserving individuals affected
by a NMD.
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Escalating SMN Expression for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) represents a group of autosomal-recessive
neurodegenerative disorders generally characterized by progressive muscle
weakness and paralysis within proximal limb muscle resulting from the
degeneration of lower motor neurons (Mendell et al., 2017). Its estimated
incidence is 1 in 10,000 to 1 in 6,000 live births, with a high carrier frequency of
~1 in 54 (Sugarman et al., 2012). The clinical presentation of this disorder can
vary, and is further classified, based on the age of onset and clinical progression,
into SMA Type I-IV (D’Amico et al., 2011 and Wang et al., 2007). About 60% of
patients are diagnosed with SMA I, also known as Werdnig-Hoffmann disease,
the most severe form of SMA and the leading genetic cause of infant death
(D’Amico et al., 2011, Dubowitz., 1999 and MacLeod et al., 1999). It presents
very early in life, with most patients diagnosed at 6 months of age with an average
survival of 3 years (Hoyert et al., 2011). Type II SMA is intermediate in severity,
with onset before 18 months of age and patients never gaining the ability to walk.
Types III & IV SMA are relatively mild, with onsets after 18 months and in late
adulthood, respectively (D’Amico et al., 2011and Wang et al., 2007). Patients
with either Type III or IV only experience mild muscle weakness and often retain
the ability to walk (Wang et al., 2007).
All cases of SMA are caused by mutations within the survival motor
neuron (SMN) gene (Lefebvre et al., 1995). In humans, SMN is located within an
inverted duplication on chromosome 5q13 that contains four genes present in both
telomeric and centromeric copies that can vary from 0-4 copies per chromosome,
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making it prone to rearrangements and deletions (Tisdale et al., 2015). Indeed,
variants within this region are often caused by unequal crossing over between the
repeated units during paternal meiosis, increasing carrier frequency of this disease
(Tisdale et al., 2015). Both telomeric (SMN1) and centromeric (SMN2) copies of
SMN share 99.8% sequence homology and encode the same protein. SMN1 can
be distinguished from SMN2 by only five nucleotide differences: one within
intron 6, exon 7, and exon 8, and two within intron 7 (Kashima et al., 2000). The
nucleotide exchange within exon 8 lies within the 3’ untranslated region, while
the C to T transition is in an exon splice enhancer site in exon 7 that, while
translationally silent, alters splicing, and often results in the exclusion of exon 7
within SMN2 transcripts (Kashima et al., 2000 and Lorson et al., 1999). As a
result, while SMN1 always yields full-length transcripts, SMN2 primarily
produces a truncated transcript lacking exon 7 (~60%) and a relatively small
number of full-length transcripts (~40%) (Cho and Dreyfuss, 2010 and Lorson
and Androphy, 2000). Considering exon 7 of the SMN genes encodes a functional
domain that is responsible for self-oligomerization, SMNΔ7 protein oligomerizes
less efficiently, is unstable, and rapidly degrades (Vitte et al., 2007). Not
surprisingly, homozygous deletion or mutations in exon 7 of SMN1 have been
identified in 94% of patients with SMA yielding a significant reduction in SMN
protein (Wirth, 2000). There is a slightly higher frequency of homozygous
absence of SMN1 in types I and II (96% and 94%, respectively) as compared to
type III SMA (86%) (Wirth, 2000). Also, copy number of SMN2 correlates with
disease severity, with patients with a higher copy number often displaying milder
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symptoms, indicating the loss of SMN protein largely accounts for disease onset
(Gavrilov et al., 1998 and Lefebvre et al., 1997).
SMN is a ubiquitous 38 kDa polypeptide that is highly expressed in spinal
motor neurons (Tisdale et al., 2015). Recent research has shown that plays an
essential role in spliceosomal snRNP biogenesis and pre-mRNA splicing (Li et
al., 2014 and Fischer et al., 2011). It is expressed in both the cytoplasm and in
compartments within the nucleus called gems (Tisdale et al., 2015). However,
why the absence of this housekeeping protein results in specific lower motor
neuron loss remains unclear. Nevertheless, therapeutic strategies have been
centered on increasing total levels of SMN in motor neurons of the spinal cord.
The first FDA-approved treatment for SMA, Nusinersen, a modified 2’-Omethoxyethyl phosphorothioate antisense oligonucleotide (ASO), is designed to
increase the inclusion of exon 7 into SMN2 transcripts, and thus increase
production of a functional, stable SMN protein, which can compensate for the
disease-causing null and loss-of-function mutations in the SMN1 gene (Finkel et
al., 2016). This is accomplished by 10 arginine-serine dipeptide repeats within
the ASO that drive the artificial recruitment of splicing enhancer factors to exon 7
of SMN2 (Finkel et al., 2016 and Singh et al., 2006). Interim analysis of a phase
III, double-blind, sham-procedure controlled clinical trial showed the post-onset
benefit of Nusinersen for infantile-onset SMA patients who had two or more
copies of the SMN2 gene (Finkel et al., 2016). Indeed, 40% of treated patients
achieved critical developmental motor milestones compared to sham-procedure
controls (Finkel et al., 2016). This treatment was found to be so beneficial that all
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subjects within the placebo group were switched to Nusinersen (Finkel et al.,
2016). Similar effects of this SMN2-targeting ASO were identified when given to
later-onset SMA patients with 2-4 copies of SMN2 (Parente et al., 2018). This
study was stopped prematurely, based on a highly significant treatment effect
based on the Hammersmith Functional Motor Scale – Expanded (Parente et al.,
2018). Both studies imply that this treatment strategy may be therapeutically
beneficial for all SMA patients across its phenotypic scale; however, both studies
had non-responders, indicating possible variable effects.
Although highly efficacious, the effects of Nusinersen are transient,
requiring patients to receive four intrathecal injections of the ASO within the first
few weeks of treatment, and every 6 months thereafter (Parente et al., 2018,
Mendell et al., 2017, Finkel et al., 2016). This type of injection is invasive and
could cause adverse effects in patients. In response, an alternative gene therapy
has been developed that involves a one-time intravenous delivery of SMN1
complementary DNA under the control of a hybrid cytomegalovirus enhancerchicken beta-actin promoter with the use of a recombinant viral delivery vehicle:
self-complementary adeno-associated viral vector (scAAV9) (Dominguez et al.,
2011, Foust et al., 2010, Valori et al., 2010, and Foust et al., 2009). This therapy
is designed for rapid and sustained expression of SMN, not only in motor
neurons, but other peripheral tissues that contribute to SMA symptoms, including
the autonomic and enteric nervous systems, the heart, and the pancreas. In a phase
1 clinical trial, 15 treated SMA patients exhibited longer survival, greater
achievement of motor milestones, and significant improvements in motor function
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compared to historical cohorts. Although additional studies will be required to
confirm both safety and efficacy of this gene therapy approach, preliminary data
show that phenotypic improvement can be achieved with a single, noninvasive,
intravenous injection regardless of SMN2 copy number within each patient
(Mendell et al., 2017).
Due to the success of SMN gene replacement therapy, an analogous
therapeutic approach has been developed for patients with a similar infantile-onset
motor neuron disease known as spinal muscular atrophy with respiratory distress
type 1 (SMARD1) (Eckart et al., 2012 and Grohmann et al., 2001). This
autosomal recessive neuromuscular disorder is caused by the haploinsufficiency
of another housekeeping gene encoding the immunoglobulin µ-binding protein 2
(IGHMBP2) (Jankowsky et al., 2011 and Guenther et al., 2009). IGHMBP2 is an
adenosine triphosphatase/helicase motif-containing DNA-binding protein that
regulates several nuclear, RNA, and translation processes (Nizzardo et al., 2015).
However, as in SMN1, it is unclear why the loss of this ubquitous housekeeping
gene leads to selective loss of motor neurons. Recent studies have shown that a
single, systemic delivery of IGHMBP2 transgene via scAAV9 can largely prevent
motor neuron loss, increase survival, and improve motor function in the nmd
mouse model of SMARD1 when delivered at the preonset age of postnatal day 1
(Nizzardo et al., 2015). This model harbors a splice site mutation in Ighmbp2 and
exhibits a neuromuscular phenotype similar to patients (Cox et al., 1998).
Furthermore, the delivery of wild-type IGHMBP2 rescued the disease phenotype
in human SMARD1 motor neurons in vitro (Nizzardo et al., 2015). Both
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experiments yield the premise for future clinical trials testing gene replacement
therapy for SMARD1, although its postonset effects in vivo remain unclear.
Exon Skipping Methods for Duchenne Muscular Dystrophy
Muscular dystrophy (MD) represents an entire heterogeneous group of
inherited myogenic disorders characterized by progressive muscle wasting and
weakness that affects limb, axial, and facial muscle, although severity, age of
onset, and the overall progression can vary greatly among different forms.
Additionally, in some cases, the diaphragm, cardiac smooth muscle, and
swallowing muscles can also be affected (Mah et al., 2016).
Duchenne and Becker MDs are both X-linked, recessive forms of MD,
together affecting 1 in 3,500 to 5,000 newborn males worldwide. Both disorders
are caused by mutations in the dystrophin gene (DMD), the longest human gene,
consisting of 2.4 megabases, or 1% of DNA within chromosome X (Koenig et al.,
1987 and Kenwrick et al., 1987). It contains at least seven independent, tissuespecific promoters and two polyA-addition sites, producing 17 different isoforms
that are named based their lengths and splicing patterns (Rumeur., et al 2015).
The full-length isoform is expressed in all striated skeletal muscle and consists of
an N-terminal domain that binds to actin filaments (encoded by exons 1-8), a
central rod domain (exons 9-61), and a C-terminal cysteine-rich domain (exon 6280) that help anchor dystrophin to the plasma membrane, where it interacts with
many integral muscle proteins, including cytoskeletal actin, microtubules, and
intermediate filaments to the extracellular matrix (Ervasti et al., 2007). Thus,
dystrophin acts as scaffolding protein that is critical for sarcolemmal integrity.
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Any disruption of dystrophin’s scaffolding network can lead to either Duchenne
or Becker MD.
Over 2/3 of patient of patients with either Duchenne or Becker MD harbor
mutations that delete one or more exons in DMD (Rumeur., et al 2015).
Duchenne, the more severe of the two disorders, is caused by frameshift
mutations that disrupt the open reading frame of DMD, resulting in the complete
loss of dystrophin (Rumeur et al., 2015 and Monaco et al., 1988). Patients with
this form of MD exhibit severe, progressive muscle wasting causing the loss of
ambulation within the first decade of life, and suffer from cardiomyopathy often
leading to premature death (Kohler et al., 2005). Becker MD, meanwhile, is
caused by in-frame deletions that result in a truncated but partially-functional
dystrophin that often retains its N-terminal and C-terminal domains (Rahimov et
al., 2013 and Davies et al., 2006). Patients with this disorder have a milder
clinical pathology and normal lifespan (Bushby et al., 1993). Even individuals
lacking more than 60% of the central rod domain are diagnosed with mild Becker
muscular dystrophy (Rahimov et al., 2013 and Davies et al., 2006). This implies
that even a DMD gene with large in-frame deletions can yield partially functional
dystrophin and ameliorate the severity of the disease. Thus, treatment
development has been centered on altering splicing in an effort to restore the open
reading frame within DMD genes affected by nonsense mutations. The goal is to
turn a frameshift mutation into an in-frame deletion, in the hopes of converting
severe forms of Duchenne MD to a milder Becker phenotype.
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For example, a series of ASOs designed to skip 20 different exons have
been developed (exons 2, 8, 17, 19, 29, 40-46, 48-53, 55 and 59) and found to
restore the reading frame of DMD, subsequently producing truncated dystrophin
in various in vivo and in vitro models of Duchenne MD (McClorey et al., 2006,
Goyenvalle et al., 2004, Aartsma-Rus et al., 2004, Surono et al., 2004, AartsmaRus et al., 2003, vanDeutekom et al., 2001, and Takeshima et al., 2001). Exondys
51 (eteplirsen), an ASO designed to skip exon 51 within DMD, is currently being
tested for safety and efficacy in clinical trials (Mendell et al., 2013). Specifically,
this ASO binds to exon 51 in DMD and masks the exon inclusion signals that are
used for splicing. Removal of exon 51 from an exon 45 to 50, 47 to 50, 48 to 50,
49 to 50, 50, 52 or 52 to 63 deleted transcript allows restoration of the open
reading frame and synthesis of an internally-truncated, semi-functional dystrophin
protein. By targeting exon 51, approximately 13% of patients with Duchenne
could potentially be treated, the largest proportion of patients that could benefit
from targeting a single dystrophin exon (Mendell et al., 2013). In 2016, the Food
and Drug administration accelerated approval for the use of Exondys 51, based on
its ability to increase the expression of dystrophin in skeletal muscle within
patients affected by Duchenne, although the extent of its efficacy and long-term
effects on motor function are still being determined (Aartsma-Rus et al., 2017).
Considering ASOs exhibit variable tissue transduction efficacies and
transient effects, several exon-skipping approaches based on clustered regularly
interspaced short palindromic repeats (CRISPR)-Cas9 genome editing are
currently being developed (Long et al., 2018, Juliano et al., 2016, Tabebordbar et
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al., 2016, Ousterout et al., 2015). This direct genome editing approach would only
require a one-time treatment that would result in an irreversible genomic
modification and production of exon-deleted mRNA, which would, in turn,
produce a semi-functional dystrophin protein. In addition, this method could
potentially eliminate the disease from being inherited by future generations, if the
germline were also allowed to be modified. In a proof-of-concept study, AAV9delivered CRISPR/Cas9 endonucleases and paired guide RNAs were shown to
excise a nonsense mutation in exon 23 of the dmd gene within adult mdx mice, an
established model of DMD (Tabebordbar et al., 2016). This restoration of the
gene’s reading frame initiated the expression of dystrophin and partially
recovered muscle function (Tabebordbar et al., 2016). However, the diseasecausing mutation in the mdx mouse is a point mutation that leads to a premature
stop codon and subsequent disruption of dystrophin expression. Point mutations
have only accounted for 5-9% cases of DMD, while over 3000 different
frameshift mutations in DMD have been reported to cause Duchenne muscular
dystrophy (Rumeur et al., 2015). Thus, there is a great need to develop an exonskipping or alternative gene therapy that can treat wider populations of patients.
In response, an alternative gene therapy approach that consist of a virallydelivered truncated dystrophin transgene with non-essential regions of the gene
deleted known as ∆R4-R23/∆CT and is often referred to as micro-dystrophin (µdys). Remarkably, both intramuscular and intravenous administration of AAV
vectors containing µ-dys expression cassettes significantly improves muscle
membrane integrity and function in the mdx mouse and greatly extended the
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lifespan of dystrophin/utrophin double knockout mice (Gregorevic et al., 2006,
Yue et al., 2006, Liu et al., 2005, Gregorevic et al., 2004, Yue et al., 2003, Harper
et al., 2002). This therapy, now fornally being tested in clinical trials for efficacy
and safety (https://clinicaltrials.gov/ct2/show/NCT03375164) has a major
advantage over exon-skipping methods as this treatment can treat any individual
with Duchenne’s MD regardless of their distinct mutation in DMD. Furthermore,
recent studies have shown that 60% of DMD mutations are clustered in two
“hotspots” within the human DMD gene: one within exons 45 to 55 and another
between exons 2 and 10 (Aartsma-Rus et al., 2009). In response, several research
groups have developed a CRISPR/Cas9-based therapy that eliminates a 336-kb
genomic region flanking exons 45 to 55 in the human DMD gene with the use of
multiplexed single-guide RNAs (Ousterout et al., 2015). This technique could
restore dystrophin expression in human DMD myoblasts, yet it did exhibit offtarget effects, including chromosomal rearrangements (Ousterout et al., 2015). To
avoid the elimination of large genomic regions and in order to treat patients with
mutations within exon 2-10, Long et al have recently developed a series of single
guide RNAs designed to excise the 12 most common affected exons in DMD and
induce the expression of dystrophin in both patient-derived iPSCs and derivative
cardiomyocytes (Long et al., 2018). Remarkably, these single guides could even
restore muscle force and contraction within a three-dimensional engineered heart
muscle derived from treated DMD patient-derived induced cardiomyocytes (Long
et al., 2018). However, long-term efficacy and safety have yet to be determined in
a formal preclinical study.
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In future, personalized CRISPR/Cas9 based gene therapies should be
developed not just to convert a DMD mutation to a BMD mutation but to engineer
a complete DMD transcript. This way, a fully-functional dystrophin protein will
be expressed, treating both Becker and Duchenne muscular dystrophies. This
could potentially be accomplished by delivering a specific DNA donor template
with an RNA guide designed to excise the specific DMD mutations alongside
Cas9 mRNA. Consequently, the mutation would be replaced with the
corresponding wildtype DMD sequence provided by the DNA template via
homology-directed repair, and the entire transcript would be fixed, eliminating
disease.
Targeting Genetic Modifiers: A Gene Therapy Approach for Treating
Heterogeneous Groups of Neuromuscular Disorders
Although the symptoms of all NMDs are quite similar, most have a range
of clinical presentation, with variance even between siblings with the same
disease-causing mutation (Lamar et al., 2014). This indicates that in addition to
potential environmental factors, genes that modify the effects of primary diseasecausing mutations may contribute to the phenotypic heterogeneity among NMDs.
With such epistatic control over primary genes, genetic modifiers may contribute
to the variation of the age of onset, severity, and the progression of one or more
NMDs. Thus, genetic factors underlying this variability may represent targets
for therapeutic intervention for multiple subtypes of the same NMD or multiple
independent disorders.
Amyotrophic lateral sclerosis (ALS) is a prime candidate for a modifier-
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based gene therapy. Age of onset is typically around 50 years, and most patients
die within 2–5 years of diagnosis (Lamar et al., 2014). However, the clinical
presentation of ALS is quite variable, both in age of onset and disease duration
(Lamar et al., 2014). Similar to SMA, ALS is a progressive motor neuron disease,
although the genetic cause of ALS is far more diverse than that of SMA, with a
primary disease-causing mutation identified in only 10% of cases (Chen et al.,
2013). Thus, there is a great need for identifying possible genetic modifiers of
ALS in hopes of uncovering a therapeutic target for this heterogeneous disease.
Mutations in Cu/Zn superoxide dismutase 1 (SOD1) is one identified
genetic cause of ALS, accounting for 20% of familial forms and several
spontaneous cases (Czaplinski et al., 2006). Interestingly, mouse models of ALS
that harbor mutations in SOD1 not only develop motor neuron disease, but, like
humans, exhibit variation in both disease onset and progression, depending on the
genetic background of the model (Riboldi et al., 2011). This indicates that genetic
modifiers may contribute to phenotypic severity of ALS. In response, several
genome-wide association studies (GWAS) have been conducted in an effort to
identify potential genetic loci that may contribute to the difference in disease
onset in multiple mouse models of ALS (Sher et al., 2014, Nardo et al., 2013,
Mancuso et al., 2012, and Kunst et al., 2000). Interestingly, a strong linkage was
identified on chromosome 13 within a locus containing Smn, the known genetic
cause of SMA (Kunst et al., 2000). Further studies have shown lower levels of
SMN protein within spinal cords in both mice and human ALS patients that
harbor mutations in SOD1 (Turner et al., 2014 and Turner et al., 2009). In
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addition, Turner et al showed that SMN deficiency enhances phenotypic severity
while its overexpression improves both neuromuscular function and motor neuron
survival in SOD1 mouse models of ALS (Turner et al., 2014). These data do not
only show that SMN may be a genetic modifier of both ALS and SMA but
existing gene therapies for SMA designed to increase SMN expression may also
help reduce the severity of ALS caused by mutations in SOD1.
Furthermore, other studies have identified EPHA4, the gene that encodes
Ephrin type A receptor 4 (EPHA4) as a genetic modifier of ALS and SMA (Van
Hoecke et al., 2012). EPHA4 is a tyrosine kinase receptor that modulates axonal
repulsion and synapse formation in the developing nervous system through ephrin
signaling (Klein et al., 2009). Reductions in Epha4 expression by genetic or
pharmacological inhibition increase motor performance and lengthen survival in
SOD1 zebrafish and mouse models of ALS, as well as zebrafish models of SMA
(Van Hoecke et al., 2012). Interestingly, knockdown of Epha4 also rescues the
axonopathy within zebrafish induced by expression of mutant TAR DNAbinding protein 43 (TDP-43), another gene linked to both familial and sporadic
forms of ALS (Van Hoecke et al., 2012 and Sreedharan et al., 2008).
Importantly, human GWAS studies have determined that EPHA4 expression
inversely correlates with disease onset and survival, and loss-of-function
mutations in EPHA4 are associated with long term survival in patients with ALS
(Van Hoecke et al., 2012). Taken together, these data highlight a possible
molecular connection between different forms of ALS and SMA, as well as the
importance of ephrin signaling for the general homeostasis of motor neurons; and
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it suggests that gene therapies designed to reduce EPHA4 expression may be
effective at slowing the progression of multiple forms of ALS and SMA.
In addition to motor neuron disorders, several genetic modifiers that may
contribute to the phenotypic variability in patients with muscular dystrophy have
been identified. For example, when overexpressed, several genes that are integral
for the extracellular matrix and the structural integrity of skeletal muscle—
including alpha-7 integrin, laminin-alpha7, biglycan, sarcospan, galectin-1, and
osteopontin—have been found to improve dystrophic phenotypes in several
animal models of Duchenne muscular dystrophy (Marshall et al., 2015, Van et al.,
2015, Wuebbles et al., 2013, Pegoraro et al., 2011, Guo et al., 2006, and Rooney
et al., 2006). Considering the loss of dystrophin disrupts the link between the
cytoskeleton and extracellular matrix within muscle, a therapy designed to
increase the expression of one or more of the aforementioned genes may help
prevent the loss of or help rebuild muscle integrity in patients suffering from a
dystrophy. A successful modifier-based gene therapy would substantially improve
treatment options for individuals with Duchenne muscular dystrophy: as
previously mentioned, the current gene therapy approved for the treatment of this
disease is therapeutically efficacious for only 13% of patients (Mendell et al.,
2013).
One of the first genetic modifiers of Duchenne muscular dystrophy was
identified in two distinct Brazilian Golden Retriever muscular dystrophy (GRMD)
dogs, who, though dystrophin-deficient, displayed a mild dystrophy phenotype
and normal lifespan, a phenotype never reported in typical GRMD dogs whose
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survival is only around two years of age (Zatz et al., 2015 and Ambrosio et al.,
2008). Whole-genome sequencing and transcriptome analysis of muscles from
both traditional GRMD canine models and the two Brazilian “escaper” GRMD
dogs showed that this mild phenotype was correlated with higher levels of
Jagged-1 (Jagged-1) (Vieira et al., 2015). Subsequent studies showed that the
overexpression of Jagg-1 can alleviate muscle atrophy in both canine and
zebrafish models of DMD, confirming its modifying capability and therapeutic
potential (Vieira et al., 2015).
Jagged-1 is a critical ligand for several Notch receptors (Lindsell et al.,
1995). In addition to its role in regulating gene expression patterns required for
proper embryonic muscle development, the notch signaling pathway is critical for
muscle regeneration in adults (Wen et al., 2012 and Conboy and Rando et al.,
2003). Although Notch signaling was found to be dysregulated in both muscle
satellite cells and dystrophin-deficient muscles within the mdx mouse model, the
exact role of Jagg-1 in the maintenance of adult skeletal muscle has yet to be fully
elucidated (Jiang et al., 2014). Interestingly, mutations that lead to
haploinsufficiency of Jagged-1 cause Alagille syndrome, a multi-organ disorder
negatively affecting liver, heart, and kidney function, but which leaves skeletal
muscle intact, further complicating the role of Jagg-1 in muscle physiology
(McCright et al., 2002). Nonetheless, considering the function of Jagg-1 does not
seem to have a direct link to dystrophin and/or the extracellular matrix of muscle,
understanding the impact of Jagg-1 in muscle regeneration may help discern
further therapeutic targets for other forms of muscular dystrophy. Future studies
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aimed at determining if the overexpression Jagged-1 mitigates multiple forms of
muscular dystrophy should be completed.
Dok7 is another potential gene therapy target that may treat multiple forms
of NMD. Dok7 is a gene that encodes the cytoplasmic protein, downstream of
tyrosine kinase 7 (DOK-7). DOK-7 is an activator of MuSK, a receptor tyrosine
kinase required for the formation and maintenance of the neuromuscular junction
(Okada et al., 2006). NMJs do not form in mouse models that lack Dok-7, and
partial loss-of-function mutations in Dok-7 have been determined to cause
familial, autosomal recessive limb-girdle myasthenia (DOK-7 myasthenia), a
NMD characterized by muscle weakness and small NMJs (Inoue et al., 2009 and
Selcen et al., 2008). The overall size of NMJs can impact synapse function by
limiting synaptic transmission of acetylcholine, a neurotransmitter required for the
initiation of muscle contraction, leading to subsequent muscle weakness (Beeson
et al., 2006). Such structural defects have been identified in multiple NMDs,
including muscular dystrophy, ALS, SMA, and age-related sarcopenia (Beeson et
al., 2006). Indeed, Arimura et al report that the administration of an AAV vector
that expresses human DOK-7 results in an enlargement of NMJs and improved
muscle strength within mouse models of both DOK-7 myasthenia and autosomal
dominant Emery-Dreifuss muscular dystrophy, a completely different NMD
characterized by small NMJs Arimura et al., 2014). These results suggest that
DOK-7 gene therapy could help ameliorate multiple forms of NMDs that result
from compact NMJS.
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Treating Neuromuscular Disorders Caused by The Expansion of
Microsatellite Repeats
Instability of repetitive DNA sequences within the human genome is
associated with numerous disorders. The expansion of unstable, microsatellite
repeats, often consisting of 2-9 base pairs, is a major cause of many NMDs with
the type of repeat and its location within the gene defining each disorder. In
addition to disrupting the canonical function of the gene, tandem nucleotide
repeats in non-coding regions typically cause the formation of toxic, nuclear RNA
foci and/or aberrant dipeptide-repeat (DPR) proteins through repeat-associated
non-AUG dependent (RAN) translation, having noxious effects on motor neurons
and skeletal muscle. Examples include the most common familial form of ALS,
Friedreich ataxia, myotonic dystrophy (types 1 and 2) and Huntington’s diseaselike 2 (Todd et al., 2010 and Gatchel et al., 2005).
In response, an array of ASOs have been designed to eliminate nucleotide
repeat-containing RNA foci and protein aggregates by base pairing with target
mRNAs, subsequently catalyzing degradation mediated by RNase-H, an
endogenous enzyme within mammalian cells. For example, Wheeler et al
developed several ASOs designed to target and degrade CTG repeats within the 3’
UTR of human DMPK (dystrophia myotonica protein kinase) a mutation that
causes myotonic dystrophy type 1 (DM1). In addition to DMPK
haploinsufficiency, this triplet repeat expansion initiates RNA toxicity with
CTGexp-containing transcripts folding into dsRNA hairpins that remain in the
nucleus, forming ribonuclear foci. Muscle degeneration results when these RNA
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foci bind to and sequester Muscleblind-like (MBNL) proteins, a family of tissuespecific RNA splicing regulators, leading to their accumulation within nuclei of
skeletal myocytes and causing a misregulation in alternative splicing, and
subsequent detrimental changes in the muscle transcriptome. The ASOs
developed were phosphorothioate–modified chimeric ASOs synthesized with a
2’-O-methoxyethyl (2’ MOE) modification in order to enhance nuclease
resistance, and a central region of unmodified nucleotides to improve RNase-Hmediated degradation of transcripts—collectively referred to as a “MOE gapmer”.
Subcutaneous administration of the MOE gapmer ASO significantly reduced the
expression of disease-causing triplet repeat-containing mRNA within several
hindlimb muscles in an established mouse model of DM1 (HSALR transgenic
mice). In addition, alternative splicing of several MBNL1-dependent exons was
normalized, and symptoms of mytonia were partially reversed, with therapeutic
effects lasting for one year post-treatment. However, the reduction in mutant
transcripts was not uniform within all hindlimb muscles, and the ASO did
gradually degrade over time (by ~50%), limiting its therapeutic potential
(Wheeler et al., 2012).
Jauvin et al recently developed a similar ASO that contains a different
phosphodiester backbone modification consisting of 2’-4’-constrained ethyl (cET)
gapmer and that targets the 3’ UTR of the human DMPK. Upon subcutaneous
injection, this ASO (ISIS 486178) displayed enhanced bioavailability, reducing
triplet repeat-containing mRNA and foci by 70% in multiple skeletal muscles and
by 40% in the heart muscle of DMSXL mice, a transgenic mouse model of MD1
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that expresses the human DMPK gene. Systemic treatment also improved body
weight and muscle strength and reduced skeletal muscle maturation in post-onset
DMSXL mice, although the long-term effects and pharmacokinetics still need to
be established (Jauvin et al., 2017).
In addition to DM1, an ASO with a similar chemistry was recently
developed as a potential treatment for a familial form of ALS caused by a
hexanucleotide GGGGCC repeat expansion within intron 1 of the C9ORF72 gene
(Jiang et al., 2016). This allele-specific ASO was designed to target sequences 5’
to the microsatellite expansion only within mutant transcripts. This treatment
yielded significant reductions in RNA foci and several DPRs in the cortex and
spinal cord of C9 transgenic mice expressing 450 GGGGCC repeats in the
C9ORF72 gene, while preserving wildtype C9ORF72 expression. However,
considering C9 transgenic mice do not exhibit motor deficits, the therapeutic
efficacy of this treatment has yet to be determined (Jiang et al., 2016).
Compared to non-coding repeats, nucleotide repeat expansion within exons often
results in expanded polyglutamine or polyalanine tracts in translated proteins,
causing them to form toxic protein aggregates. Examples of this type of NMD
include Huntington’s disease, as well as spinal bulbar and muscular atrophy.
Although expanded nucleotide repeats within the coding region drive a different
outcome, similar therapeutic strategies to those developed for NMDs caused by
intronic tandem repeats are currently being developed (Todd et al., 2010 and
Gatchel et al., 2005). For example, another ASO was developed as a prospective
gene therapy for Huntington’s disease (HD), a neurodegenerative disease
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characterized by progressive chorea, dystonia, incoordination, and cognitive
decline with selective neuronal loss in the striatum (Kordasiewicz et al., 2012).
This autosomal dominant NMD is caused by the expansion of a CAG triplet
within the first exon of the huntingtin gene (HTT), that leads to an elongated
glutamine tract in the N-terminus of the huntingtin protein. Normally, this CAG
segment is repeated 10 to 35 times within exon 1 of HTT, while individuals with
Huntington’s disease have approximately 40 or more (Todd et al., 2010 and
Gatchel et al., 2005).
In an effort to reduce the accumulation of toxic huntingtin protein,
Kordasiewicz et al developed a MOE gapmer-containing ASO complementary to
human huntingtin mRNA. Therapeutic efficacy was assessed in several
established mouse models of HD (BACHD, YAC128, & R6/2) all of which
express a fragmented or full-length human HTT gene with 97-125 CAG repeats
within exon 1. Each line also develops motor deficits, hypoactivity, cognitive
dysfunction, and brain atrophy at various time points, recapitulating both the
genetics and phenotypes implicated in the human form of the disease. Direct
administration of the ASO into the central nervous system led to a significant—
though transient—reduction in human huntingtin mRNA within neurons of the
striatum and many other brain regions, as well as a partial reversal of the HDassociated phenotype or extended survival within each symptomatic HD mouse
model. Since the ASO used was designed to target both wildtype and mutant HTT
transcripts, and since reducing huntingtin by 75% throughout the central nervous
system did not exacerbate the HD phenotype in any model, it is evinced that
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normal huntingtin may not be required for normal adult brain function
(Kordasiewicz et al., 2012). This is an important insight into the pathogenesis of
HD, as it remains unclear why this ubiquitously-expressed gene leads to selective
neurodegeneration. Hence, this study further demonstrates the use of gene
therapies as tools that can help us learn more about the pathology underlying
complex NMDs. Excitingly, ASOs designed to reduce human HTT are currently
in clinical trials and in early stages of possible FDA approval for the treatment of
HD (https://clinicaltrials.gov/ct2/show/NCT02519036). Taken together, these
studies highlight innovative modifications in ASO chemistry and examples of
some of the first translatable gene therapies designed to treat expansion repeat
disorders.
ASO-based gene therapies do not represent the only therapeutic strategy
currently being developed for tandem nucleotide repeat disorders. In an effort to
obviate the required continuous administration and limited bioavailability of
ASOs, an RNA-targeting CRISPR/Cas9 system has been designed to eliminate
several NMD-associated RNA foci containing microsatellite expansions. A study
completed by Batra et al determined that a nuclease-dead Cas9 (dCas9) fused to a
non-specific RNA endonuclease domain (PIN-deCas) from SMG6 (nonsensemediated mRNA decay factor), or a dCas9 alone along with a cognate gRNA, can
destabilize microsatellite repeat-containing toxic RNA foci within COS-M6 cells
transfected with different plasmids encoding either CTGexp (DM1), CCTGexp
(DM2), CAGexp (HD), or GGGGCCexp (C9ORF72-ALS) expansions. This PINCas9 system also eliminated CTGexp- and CCTGexp- containing RNA foci in
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myoblasts and fibroblasts derived from DM1 patient biopsies, restoring the
splicing abilities and localization of MBNL1. Furthermore, for potential
translation, a truncated, AAV compactible version of PIN-Cas9, capable of
reducing toxic RNA foci in vitro, was developed. Taken together, these data
support the proof-of-concept of a new gene therapy aimed at eliminating toxic
tandem nucleotide repeats, although their potential therapeutic effects in vivo need
to be established before further therapeutic development (Batra et al., 2017).
Human disorders caused by tandem nucleotide repeats often demonstrate genetic
anticipation, meaning the number of nucleotide repeats in the disease-causing
gene continues to expand with each subsequent generation. Considering that the
number of repeats positively correlates with earlier disease onset and increased
phenotypic severity—although technically difficult—gene therapies designed to
eliminate toxic nucleotide repeats within DNA and, hence, the germline would
significantly advance treatment for these disorders. Preliminary support for this
potential gene therapy strategy was recently described. Van Agtmaal et al
designed a CRISPR/Cas9 gene editing system with the ability to precisely excise
tracts of triple repeats within the 3’ UTR of the DMPK gene and remove toxic
RNA foci within DM1-affected human myoblasts (van Agtmaal et al., 2017).
However, its potential to revere disease in vivo without adverse, off-target effects
has yet to be established. Nonetheless, taken together, all studies here mentioned
have significantly contributed to the extraordinary advancements in therapeutic
development for the number of currently incurable NMDs caused by tandem
nucleotide repeat disorders.
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Precision Gene Therapy for Charcot-Marie-Tooth Disease
Many different NMDs display high degrees of genetic and phenotypic
heterogeneity among individual patients. For example, Charcot-Marie-Tooth
disease (CMT) is a NMD that encompasses a collection of 80 different inherited
peripheral neuropathies Gonzaga-Jauregui et al., 2015, Sivakumar et al., 2005,
and Shy et al., 2004). Remarkably, over 1000 distinct genetic mutations in 80
different loci within the human genome can cause individual forms of CMT, with
only a small percentage of loci having a direct link to peripheral nerve function
(Timmerman et al., 2014). Together, these factors conspire against a single
effective therapy for all subtypes of CMT, suggesting that personalized genetic
approaches may represent a more efficacious therapeutic strategy.
The first potential gene therapy for this kind of inherited neuropathy was
developed for giant axonal neuropathy (GAN), a very rare form of CMT. GAN is
an autosomal recessive NMD characterized by progressive muscle weakness and
premature death caused by enlarged axons with densely packed and disordered
microtubules and intermediate filaments (Nalini et al., 2008 and Demir et al.,
2005). It is caused by loss-of-function mutations in GAN1, the gene that encodes
gigaxonin, an E3 ubiquitin ligase adaptor involved in intermediate filament
processing in neural cells (Bomont et al., 2000). Over 40 different mutations in
GAN1 have been identified in patients with GAN (Houlden et al., 2007 and Koop
et al., 2007). They consist of in-frame deletion, insertion, missense, and nonsense
mutations, all of which disrupt Gan1 function. However, both human and murine
carriers of GAN1 mutations not only produce half the normal amount of
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endogenous GAN1, but are not affected by neuropathy or any other abnormalities
(Mussche et al., 2013). This suggests that enhancing the expression of GAN1 in
the nervous system may be of therapeutic benefit for patients with GAN. The
proof-of-concept of this gene therapy approach was described in Mussche et al.
Here, a GAN1 gene replacement therapy, consisting of GAN1 transgene delivered
by AAV, not only enhanced the expression of GAN1, but eliminated intermediate
filament aggregates within a series of patient fibroblasts harboring different
GAN1 mutations. Furthermore, virally-delivered GAN1 has been shown to reduce
neuronal intermediate filaments in the brain stem and spinal cord within Gan1
knockout mice (Mussche et al., 2013). In fact, therapeutic safety and efficacy of
scAAV9/jeT-GAN are currently being evaluated in clinical trials with the first
patient having been treated in 2015
(https://clinicaltrials.gov/ct2/show/NCT02362438).
Yet 90% of inherited peripheral neuropathies are dominantly-inherited,
requiring a gene therapy approach that reduces the expression of a toxic mutant
protein (Timmerman et al., 2014). In response, an ASO was developed for
autosomal dominant CMT type 1A, a demyelinating peripheral neuropathy
resulting from a 1.4 Mb duplication on chromosome 17 that contains the
peripheral myelin protein 22 (PMP22) gene (Lupski et al., 1992). This gene
encodes PMP22, a protein within Schwann cells that contributes to the lipid
organization and distribution in peripheral myelin (Garbay et al., 2000) While the
overexpression of PMP22 results in CMT type 1A, the deletion of this genomic
region and, thus, the loss of PMP22 results in a different neuropathy referred to as
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hereditary neuropathy with liability to pressure palsies (HNPP) (Lupski et al.,
1992). This indicates that genetic dosage of PMP22 is critical for myelin
homeostasis and, thus, peripheral nerve function, complicating the development
of a gene therapy, as the expression of PMP22 needs to be maintained to a certain
level. The ASO was designed to target the 3’UTR of PMP22, reducing
endogenous human PMP22 by ~50% in symptomatic C22 mice, a mouse model
of CMTA that harbors 7 copies of the human PMP22 gene, causing a severe
demyelinating neuropathy without exhibiting any overt adverse effects. Weekly,
subcutaneous injections of this ASO improved myelination of peripheral nerves,
leading to increases in muscle endurance and motor nerve conduction velocity.
Similar therapeutic effects were also seen when a post disease-onset rat model of
CMT1A, which harbors 3 copies of a cosmid containing Pmp22 in addition to its
2 biological copies, was treated with another ASO designed to exclusively target
rat Pmp22 (Zhao et al., 2018). Although these preclinical data clearly show the
efficacy of ASOs for the treatment of CMT1A, the long-term effects of this
treatment need to be evaluated. Even though a ~60% and 35% reduction of total
PMP22 were tolerated by C22 and wildtype mice, respectively, HNPP, the
neuropathy caused by the loss of PMP22 may develop with continuous treatment
of ASOs over time. Nonetheless, this study demonstrates the efficacy of the ASO
as a potential therapy for CMT1A and additional NMDs caused by copy number
variations, such as familial forms of Parkinson’s disease caused by duplications or
triplications of SNCA (synnuclein alpha) (Chartier-Harlin et al., 2004).
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Considering more than 1000 distinct mutations cause individual forms of
CMT, an allele-specific gene therapy that can specifically reduce a mutant allele
would be beneficial for many patients with a dominant form of CMT, regardless
of their disease-causing mutation. In response, Morelli et al recently developed
the first single-dose allele-specific gene therapy approach for dominant peripheral
neuropathies. This therapy, developed to treat CMT2D, an axonal neuropathy
caused by dominant mutations in GARS (glycl-tRNA-synthetase), consists of a
specific mutant Gars-targeting artificial microRNA expression cassette packaged
within self-complementary AAV serotype 9. Remarkably, this therapy both
prevented and treated symptoms of neuropathy in two independent mouse models
of CMT2D. These included a spontaneous mouse model harboring a mousespecific missense mutation (GarsP278KY/+), as well as the first humanized mouse
model of CMT that harbors an in-frame 12 base-pair deletion in Gars, a mutation
recently identified in a current patient with CMT2D (Gars∆ETAQ/+). These studies
demonstrate how precision animal modeling can be used to engineer improved
“humanized” preclinical models for testing personalized therapies for rare and
orphan diseases, and set an important precedent for the use of RNAi-based gene
therapy for this dominant NMD (Morelli et al., in preparation). This gene therapy
strategy has extremely broad implications, and could conceivably be applied to
other, related disorders, including other dominantly-inherited peripheral
neuropathies or motor neuron diseases.
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Considerations for Clinical Translation
All of the progressive translational research mentioned in this review
together represent the recent great advancements in therapeutic development for
NMDs. However, several caveats should be mentioned to further the clinical
translation of novel gene therapies and in order to deliver the most effective gene
therapies to patients. For example, many lessons have been learned from the
development and translation of several gene therapies developed for both SMA
and GAN. Both NMDs primarily affect either lower motor neurons, in the case of
SMA, or both lower motor and sensory neurons, in GAN. Thus, inquiry into the
route of delivery has been focused on methods that deliver each therapy directly
to the central nervous system and dorsal root ganglia. However, likely due to the
ubiquitous expression of SMN, some SMA1 patients also exhibit symptoms from
the periphery, arising from the autonomic and enteric nervous systems,
cardiovascular systems, and pancreas (Mendall et al., 2017). In fact, recent
clinical data have shown that the systemic infusion of SMN1 gene replacement
therapy has more efficacious outcomes compared to its intrathecal delivery
(Mendall et al., 2017). And although it is thought to be, primarily, a sensorimotor
peripheral neuropathy, symptoms arising from the autonomic nervous system
(ANS) have been reported by adolescent patients with GAN, including lactose
intolerance, constipation, obstipation, heat intolerance, and blood pressure
instability with orthostatic hypotension. Neuronal perikaryal inclusions within
neurons of the enteric ANS and in postganglionic neurons of the sympathetic and
parasympathetic ANS, in addition to peripheral motor and sensory neurons, have
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also been identified in GAN1 knockout mice (Armao et al., 2016). These data
suggest that a systemic delivery may be more efficacious, despite the current
intrathecal route of delivery for the Phase I GAN1 replacement therapy clinical
trial, wherein only neurons within the central nervous system and dorsal root
ganglia will be reached. Additional preclinical studies must be conducted to
establish the most effective and safest route of delivery, with administration
methods based on what is reported from the clinic.
A major hurdle in gene therapy development is ensuring that the therapy
targets each affected tissue as efficiently as possible without causing off-target
toxicities. For example, ASOs do not cross the blood brain barrier well, limiting
their ability to target both the central nervous system and the periphery upon
systemic delivery (Juliano et al., 2016). Also, when injected intravenously, ASOs
accumulate in liver, kidney, and lymph nodes, causing hybridization-independent
toxicities and limiting their administration to local injections (Frazier et al., 2015).
This strictly limits their therapeutic potential for a NMD caused by cellautonomous and non-cell-autonomous mechanisms, such as SMA or GAN. In
contrast, self-complementary AAVs (scAAVs) have an excellent safety profile
and have a broad tissue tropism, meaning they have a high transduction efficiency
with the ability to transduce many different cell types and tissues. In addition, in
contrast to ASOs, certain serotypes such as scAAV9 can cross the BBB.
However, while suitable for short artificial microRNA, scAAV vector delivery is
limited to transgenes that are 2.7 Kb in length or less. This severely restricts the
number of full-length genes that can be used for gene replacement therapies by
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scAAV (McCarty et al., 2008).
However, the delivery of abridged transgenes by scAAVs that express
truncated proteins may be effective at alleviating disease caused by null and/or
loss-of-function mutations. For example, although the full-length cDNA sequence
of DMD cannot be delivered by scAAVs, a truncated version can be. This
therapeutic strategy, similar in outcome to the exon skipping gene therapies for
Duchenne muscular dystrophy, may convert a severe dystrophy to a milder
Becker-like case, regardless of the patient’s specific mutation. Another
compensation for limited transgene capacity is the newly developed dual scAAV
vector system (McClements et al., 2017). This delivery system involves splitting a
large transgene expression cassette into two (one with a 5’ end and one with the
3’ end) with each half of the cassette packaged into a single scAAV vector. The
re-assembly of the full-length transgene occurs upon co-infection of the same cell
by both scAAV vectors harboring different halves of the transgene and
subsequent homologous recombination between the 5’ and 3’ genome. This
method can occur in vivo and has been tested in various animal models, although
its transduction efficiency is lower in comparison to canonical scAAV delivery
(McClements et al., 2017). However, this delivery system may still be efficacious
in cases where the delivery of a truncated transgene may not be effective at
mitigating disease.
Systemic injections also increase the probability of adverse off-target
effects of gene therapies. For example, CMTX is a peripheral neuropathy caused
by a loss-of-function mutation in connexin 32, a gap junction protein within the
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paranode of peripheral nerves that conducts ions necessary for the depolarization
of action potentials. The off-target expression of this protein may interfere with
the membrane potentials of other cell types, causing detrimental effects
(Sargiannidou et al., 2015). Incorporating cell-specific promotors within viral
delivery vehicles may help reduce the chances of such side effects (Sargiannidou
et al., 2015). Together, all are important considerations, as many NMD-causing
mutations are within ubiquitously or widely expressed genes. Many mutations
have even been reported in housekeeping genes whose function relative to
neuronal or muscle physiology remain enigmatic, and/or how they cause inherited
NMDs is unclear.
Many preclinical studies describing the effects of gene therapies for
NMDs assert that the earlier the therapeutic intervention, the better the outcome
for patients. One reason is that axon regeneration can only occur within a very
narrow time-period. This is due to the fact that many motor neuron disorders and
axonal neuropathies cause rapid distal-to-proximal axonal degeneration or “dyingback neuropathy,” with degenerating axons moving farther and farther away from
postsynaptic targets on muscle as disease progresses (Dadon-Nachum et al.,
2011).
Thus, even if pathology is ceased by gene therapy, in humans, axons need
to regrow over long distances, and the distal portions of peripheral nerves
progressively lose their ability to regenerate. This is largely due to the loss of
terminal Schwann cells and the Schwann cell basal lamina tube that occurs during
dying-back neuropathy, resulting in an extracellular environment that is inhibitory
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to nerve regeneration (Yaron et al., 2016 and Stoll et al., 2002). Furthermore,
damaged neuromuscular junctions progressively lose their ability to form a fully
functional synapse as disease progresses (Yaron et al., 2016). Thus, gene
therapies for these NMDs have a limited therapeutic window. This needs to be
taken into consideration when translating such gene therapies to the clinic.
Furthermore, many preclinical studies are being conducted with animal models
that do not fully recapitulate genetic mutations in human patients. For example, as
previously mentioned, the mdx mouse model used to study the effects of many
different gene therapies for Duchenne muscular dystrophy harbors a point
mutation in the dystrophin gene, while only a small fraction of patients have a
similar mutation. Also, many gene replacement therapies have been tested in
simple knockout mouse models and not within models that harbor disease-causing
mutations similar to those identified in patients. Thus, only a loss-of-function
disease mechanism is assumed, when, in reality, the mutation can contribute
pathology through multiple mechanisms, confounding preclinical testing of a gene
therapy approach. Using precision mouse models developed with efficient
genome-editing techniques, such as that used in Morelli et al to test a novel
therapy for CMT2D, may facilitate the successful transition from preclinical
testing to the clinical use of a gene therapy.
Conclusion
Here we review some of the major advancements for gene therapies for
many currently incurable NMDs. We also highlight the advent of direct genomeediting therapies and other innovative approaches that may improve existing gene
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therapy options and/or prevent NMDs from being inherited in future generations.
We also share the importance of enhancing the bioavailability and pharmokinetics
of gene therapy vectors as well as how to improve preclinical efficacy studies to
further advance the clinical translation of additional gene therapy approaches for
NMDs. Taken together though, it is amazing to think that a treatment may be just
around the corner for so many deserving families affected by these disorders.
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CHAPTER 5
ADDITIONAL CONTRIBUTIONS TO THE FIELD
Metabolite profiling for a mouse model of Charcot-Marie-Tooth type 2D:
implications for disease mechanisms and interventions. (2016) Biology Open
Bais P, Bebee K, Morelli KH, Norberg S, Currie M, Esokov A, Miers KE, Seburn
KL, Jordanova A, Bult CJ, Burgess RW.
How autosomal dominant mutations in GARS (glycyl tRNA synthetase)
cause Charcot-Marie-Tooth Disease Type 2D (CMT2D) remains controversial. In
effort to identify changes in metabolite abundance that may be indicative of the
pathophysiology underlying CMT2D, we compared metabolites isolated from the
spinal cord of Gars mutant mice and littermate controls. A profile of altered
metabolites that distinguish the affected and unaffected tissue was determined.
The metabolite with the largest systemic decrease in the mutant samples was
carnitine whereas glycine showed a modest increase. Thus, my role in this project
was to determine the ability of dietary supplementation with either metabolite to
alleviate symptoms of neuropathy in mouse models of CMT2D. Supplementation
with either glycine or acetyl-L-carnitine did not mitigate primary features of
neuropathy such as axonal atrophy or nerve conduction velocity. Carnitine
supplementation was modestly beneficial in gross motor performance as assayed
in the wire hang test. These data suggest that even though acetyl-L-carnitine
supplementation did not directly prevent or reverse symptoms of neuropathy, it
did improve muscle strength and endurance in mouse models of Gars-linked
neuropathy. Therefore, carnitine supplementation may be considered as a
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complimentary therapy used to enhance gross muscle strength in patients with
CMT2D.
Synaptic deficits at neuromuscular junctions in two mouse models of
Charcot-Marie-Tooth Type2D. Journal of Neuroscience. (2016) Spaulding EL,
Sleigh JN, Morelli KH, Pinter MJ, Burgess RW, Seburn KL
Mutations in GARS (glycyl tRNA synthetase) cause autosomal dominant
Charcot-Marie-Tooth type 2D (CMT2D), a currently incurable axonal neuropathy
that leads to progressive distal muscle weakness. Although, the mechanism(s)
through which mutant forms of GARS cause CMT2D remains controversial.
Based on reported clinical observations, and studies of mouse models of CMT2D,
we sought to determine whether weakened synaptic transmission at the
neuromuscular junction (NMJ) contributes to the pathophysiology underpinning
CMT2D. Indeed, electrophysiological studies including quantal analysis and
voltage-clamp of neuromuscular junctions within two mouse models of CMT2D
(GarsP278KY & GarsC201R) revealed synaptic deficits that caused reduced
presynaptic release of neurotransmitters at the NMJ. As a result, my primary role
in this study was to determine if drugs that modify either pre/post-synaptic
efficacy could improve muscle strength of GarsP278KY & GarsC201R mice. With the
use of the wire hang test, a behavioral test used to evaluate gross motor
performance, we determined that physostigmine treatment, a cholinesterase
inhibitor that enhances current duration at postsynaptic receptors, was able to
improve overall muscle strength in both mouse models of CMT2D. Overall, our
data suggests that synaptic deficits in NMJS contributes to the pathophysiology of
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CMT2D and that therapeutics that enhance synaptic strength may be a treatment
option for improving motor function in patients with this disorder.
Lack of neuropathy-related phenotypes in hint1 knockout mice. J
Neuropathol Exp Neuropathol. (2014) Seburn KL, Morelli KH, Jordanova A,
Burgess RW.
Mutations in HINT1, the gene encoding histidine triad nucleotide-binding
protein 1 (HINT1), cause a recessively inherited axonal neuropathy with
neuromyotonia prolonged nerve impulses from the peripheral nerves that result in
continuous muscle contraction. Affected individuals often experience progressive
muscle stiffness and cramping in distal muscles. Considering several lines of
evidence suggest that HINT1 mutations cause neuropathy and neuromyotonia
through a loss-of-function mechanism, we analyzed Hint1 knockout mice for their
relevance as a disease model to in turn investigate proposed mechanisms
underpinning this disorder. Hint1 knockout mice were examined for abnormal
neuromuscular behaviors; nerve, muscle, and neuromuscular junction anatomy;
and conduction nerve impulses. However, evidence of axon degeneration or
neuromyotonia could not be detected in any of the latter tests. Therefore, we
conclude that Hint1 knockout mice may be useful for studying the biochemical
activities of HINT1, but do not provide a disease model for investigating the
pathophysiology underlying HINT1-associated neuropathy and neuromyotonia.
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APPENDIX A: Chapter 2: Supplemental Data

Figure 12. Effects of Nrcam mutations on nodes of Ranvier A) In wild type
teased sciatic nerve axons, ankyrinG (ANKG) is found at nodes. Occasionally, a
slight offset between the labeling and the apparent center of the node based on the
Schwann cell morphology (arrowhead) is observed. This was not quantified
because it is observed in wild type mice and may be an artifact of either fixation
or sample preparation. An example of this is shown. B-D) examples of ANKG
labeling Nrcam-/- nodes show minor separation in the labeling (B), unequal
“splitting” of the labeling (C), or a normal node, but with some offset from the
Schwann cell center (D). Sodium channel (NaV1.6) density at nodes was assessed
by semiquantitative immunofluorescence using labeling of neurofilament light
chain as an internal control. The ratio of NaV1.6 to NEFL labeling intensity in
wild type and Nrcam-/- nerves is shown as box and whisker plots (E). No change
in NaV1.6 density was detected by this method (p=0.98, >20 nodes per genotype
from three animals were analyzed).
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F

Figure 13. Myelin structure in peripheral axons A-D) Electron micrographs of
femoral motor nerves collected at 50,000X magnification show the myelin
structure of control (A), Nrcam-/- (B), Sh3tc2-/- (C), and double mutant (D) axons.
E) The spacing of myelin wraps was evaluated by measuring the total myelin
thickness, counting the number of wraps, and dividing. Nrcam-/- myelin was more
tightly packed than control or Sh3tc2-/- myelin. Double mutant mice were not
worse than Nrcam-/- alone. F) The relationship between axon diameter and myelin
thickness is referred to as the g-ratio, calculated as the inner diameter of a nerve
fiber (the axonal diameter), divided by the outer diameter (the axon plus the
myelin thickness). The g-ratio was not changed in Nrcam-/- nerves, whereas Sh3tc/nerves had an increased g-ratio due to thinner myelin, as anticipated. Double
mutant mice were not different from Sh3tc2-/- alone. A-E are based on myelin
measurements from 9 control axons, 9 Nrcam-/- axons, 10 Sh3tc2-/- axons, and 8
double mutant axons. F is based on measurements from 8 control, 7 Nrcam-/-, 7
Sh3tc2-/-, and 8 double mutant mice. Scale bar in D represents 100 nm. * =
p<0.05, ***=p<0.001. Values are mean ± S.D.
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Figure 14. NMJ morphology in double mutant mice A, B) Additional examples
of NMJ dysmorphology in Nrcam-/- ;Sh3tc2-/- double mutant mice. C A control
neuromuscular junction labeled with anti-neurofilament/anti-SV2 to label nerve
(green), anti-S100 to label terminal Schwann cells (red), and Alexafluor647αBungartoxin to label acetylcholine receptors (purple). C’ shows the S100 only,
with terminal Schwann cells being restricted to the synaptic region. D) A double
mutant NMJ at 2.5 months of age shows normal morphology. D’) The S100
channel reveals terminal Schwann cell processes extending beyond the synaptic
region at this age. Scale bar in D’ represents 14µm in A, C-D and 19 µm in B.
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Figure 15. Two electrode voltage clamp data from NMJs of a double mutant
mouse Synaptic activity was recorded in ten muscle fibers from an Nrcam-/;Sh3tc2-/- double mutant mouse under two-electrode voltage-clamp conditions.
All fibers showed spontaneous activity (minis), but only 5 showed evoked
activity. A) The mini- amplitude was not different between the active (EPC) and
the silent (no EPC) fibers, and both were similar to previously reported control
values (~1.7 na). B) The frequency of spontaneous release was elevated in silent
fibers, consistent with previous studies (Snider and Harris, 1979). C, D) In fibers
that showed an evoked response, the amplitude (C), and quantal content (D), were
well within the normal range we have observed previously (quantal content
ranging from ~20 to ~80, with a median value of ~45). Thus, active synapses have
relatively normal synaptic transmission, but many synapses show a failure of
evoked release despite relatively normal spontaneous release. This is consistent
with a failure in action potentials to reach the nerve terminal following
stimulation of the distal nerve. Other explanations, such as a failure of presynaptic
Ca2+ channels are also possible, but such changes would have to occur rapidly
since active synapses show relatively normal function.
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Figure 16. Effects of Nrcam and Sh3tc2 mutations are recessive In all graphs, the
Nrcam genotype is abbreviated to Nr the Sh3tc2 genotype to Sh in the X-axis
labels. A) Nerve conduction velocity was examined in Nrcam heterozygotes,
Sh3tc2 heterozygotes, and double heterozygotes, and compared to control. Nerve
conduction velocity was chosen as the parameter because both Nrcam and Sh3tc2
homozygous mice had a significant reduction in this measure. No changes in
nerve conduction velocity were seen in any heterozygous combination. B) The
reduction in nerve conduction velocity seen in Sh3tc2-/- mice wild type for Nrcam
(+/+; -/-) was not made worse by heterozygosity for Nrcam (+/-; -/-) C) The
reduction in nerve conduction velocity seen in Nrcam-/- mice wild type for Sh3tc2
(-/-; +/+) was if anything improved by heterozygosity for Sh3tc2 (-/-; +/-);
however, this statistical difference is likely explained by the small sample number
(n=3) for the (-/-; +/-) animals Nonetheless, this change makes it clear that Sh3tc2
heterozygosity does not enhance the effects of Nrcam homozygosity. For (A), 10
wild type, 6 Nrcam+/- , 9 Sh3tc2+/-, and 7 double heterozygous mice were used.
For (B) 16 Nrcam+/- and 10 Nrcam+/+ mice were examined. For (C), 14
Sh3tc2+/+mice three Sh3tc2+/- were examined.
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APPENDIX B: Chapter 2: Materials & Methods
Mice: Mice were housed in PIV racks in the research animal facility at The
Jackson Laboratory and provided food and water ad libitum. All mouse husbandry
and experimental procedures were conducted according to the NIH Guide for
Care and Use of Laboratory Animals and were reviewed and approved by The
Animal Care and Use Committee of The Jackson Laboratory. Mice carrying
mutations in Gars have been previously described (Achilli et al., 2009; Seburn et
al., 2006), and their official strain designations are: CAST;B6-Gars
and C3.C(CBA)-Gars

Nmf249

/Rwb

C201R
/HRwb. The official strain designations of the newly

identified mutations in Sh3tc2 and Nrcam are: B6(129P2)-Sh3tc2

m1J

/GrsrRwb

m1J
and B6(129P2)-Nrcam
/GrsrRwb. For validation we also examined mice
tm2e.1(KOMP) Wtsi
carrying null alleles of each gene (B6N(Cg)-Nrcam
/J and
B6N(Cg)–Sh3tc2

tm1b(KOMP)Wtsi
/J) that were obtained from the NIH

repository for knockout mice (KOMP; https://www.komp.org/). The Scn8a mice
carry a C to A transversion, changing arginine at amino acid 914 to serine
(R914S). These mice are officially designated Scn8a

m10J

and are Jackson strain

23609 (https://www.jax.org/strain/023609). Unless otherwise noted, all
experimental cohorts used for direct comparisons consisted of littermate animals
to match strain and age to the greatest extent possible.
Mapping: The nm4302 mice were initially ascertained in a mixed B6.129 strain
background carrying a knockout allele of the cannabinoid receptor 2 (Jackson

154

strain 5786, Cnr2

tm1Dgen

). Two spontaneous mutations were identified in this

strain by a combination of genetic mapping and exome sequencing. The mutations
were mapped by out crossing an affected mouse to BALB/cByJ mice to generate
obligate heterozygous F1 offspring. These F1 mice were inter-crossed, and
produced affected offspring not at the expected 1:4, but closer to 1:16, consistent
with two recessive genes being required to produce the phenotype. Mapping with
129 SNPs spanning the entire genome in 11 affected mice compared to 16
unaffected littermates revealed two peaks of significant association on
chromosomes 12 and 18. Testing additional polymorphic markers in these regions
narrowed the intervals to between D12Mit222 (12:39503,868) and rs3724069
(12:79,259,640) on Chromosome 12, and between D18Mit124 (18:57,617,140)
and D18Mit183 18:64,987,826) on Chromosome 18 in mm9 NCBI Build 37.
Exome sequencing: Genomic DNA from an affected mouse was isolated and
fragmented. Pre-capture libraries were constructed using the methods described in
Hodges, E. et al. (Hodges et al., 2009), with 9 cycles of PCR done on the precapture library. The pre- capture library was hybridized to the alpha version of the
Roche NimbleGen Mouse Exome capture probe set (Roche NimbleGen, Madison,
WI, USA) according to the manufacturer’s instructions. The sequencing library
was quantified by QPCR and sequenced on a single lane of an Illumina HiSeq
GAIIX (Illumina, San Diego, CA, USA) using a 75 base single end sequencing
protocol. Sequences were aligned to the mouse reference genome (mm9, NCBI
Build 37) using Burrows-Wheeler transformation (BWA) version 0.5.8a, and
variants were identified using SAMtools version 1.0 (Li and Durbin, 2009; Li et
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al., 2009). A C>T conversion on Chr. 18 at 62,127,702 (18:61,968,048 in mm38)
creating a stop codon at G71X in Sh3tc2 was the best candidate variant and
aligned with mapping data. No candidate variants were identified in the Chr. 12
mapping interval; however, Nrcam was deemed a strong candidate based on a
previous characterization (Douglas et al., 2009). Analysis of Nrcam transcripts by
RT-PCR and Sanger sequencing revealed abnormal splicing events between
exons 25 and 26 and the presence of a B2 element insertion into exon 26. High
throughput sequencing reads confirming this event were subsequently identified,
but were initially filtered out of the analysis because the B2 element is an
endogenous sequence that does not map uniquely in the genome, and because the
insertion results in a 15 bp duplication of the flanking exon 26 sequence
(12:44,576,700-44,576,714 in mm38), allowing reads from upstream and
downstream of the insertion to align with apparently uninterrupted overlap.
Genotyping: Genomic DNA was prepared from tail-tip or toe-tip biopsy lysed
with proteinase K incubation. Primers NM4302Nrcam-F (5’AAATTCCTGCCAACAAGACC-3’) and NM4302Nrcam-R (5’TCCTCTGTGATCTGACTGCC-3’), which anneal to exon 26 and span the B2
insertion were used in a PCR reaction to identify the NM4302 Nrcam mutation.
The wildtype allele yields a PCR product of 115 bps and the mutant allele, 374
bps. NM4302Sh3tc2F (5’ GTG GAG GAC ACC AAT TCA GG 3’) and
NM4302Sh3tc2R (5’ CAC CCT CTG TCA GCC AGT TG 3’), with subsequent
Sanger sequencing with NM4302Sh3tc2F to detect the single base pair C to T
conversion in exon 3 of Sh3tc2. Mu-KOMPNrcam- F (5’-CGG TCG CTA CCA
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TTTA CCA GT-3’), Mu-KOMPNrcam-R (5’-TGC CAA TCA AGC GAA TTA
CT-3’), WT-KOMPNrcam-F (5’-CTA CTA TCA GCT AGC ATA ATG G-3’)
and WT-KOMPNrcam-R (5’-CTT GTA CTA TGC CAA TCA AGC G- 3’)
primer sets were used to detect the KOMP mutant and wildtype NrCAM allele,
respectively. Mu-KOMPSh3tc2-F (5’-GGG GGA AAA GAT ACT TCT GAGG3’), Mu- KOMPSh3tc2-R (5’-CGG TCG CTA CCA TTA CCA GT-3’), WTKOMPSh3tc2-F (5’- GTG CCA CAC TGG GCT TGA-3’), and WTKOMPSh3tc2-R (TTC CAA ACT GAA GGG AAT GTG-3’) primer sets were
used to identify the mutant and wildtype Sh3tc2 alleles, respectively.
Tissue lysate preparation: Whole brain samples were isolated from animals
immediately after they were euthanized by CO2 inhalation. The tissues were
frozen in liquid nitrogen and stored at -80 ̊C. Samples were homogenized using a
mortar and pestle followed by a Dounce homogenizer in 1% NP-40 in phosphate
buffered saline supplemented with Protease Inhibitor Cocktail Tablets (Roche,
Basal, Switzerland) then centrifuged at 14,000 g twice for 5 minutes at 4 ̊C.
Cleared homogenates were then sonicated at 4 ̊C and centrifuged again at 14,000
g for 5 minutes. Sciatic nerve lysates were prepared similarly, except they were
homogenized in 3% Triton X-100, 25 mM Tris, 1 mM EDTA, 5% glycerol, 150
mM NaCL, 1% NP-40 in phosphate buffered saline supplemented with Protease
Inhibitor Cocktail Tablets Protein concentrations were assessed using a Bradford
assay (BioRad, Hurcules, CA). 20 µg of protein for brain, and 10 µgs for sciatic
nerve were then analyzed by immunoblot.
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Western blot – Protein lysates were resolved on Mini-PROTEAN 4-15% TrisGlycine gels (BioRad, Hurcules, CA) and transferred to an Invitrolon &
Immobilon-P PVDF membrane for western blot analysis. Membranes were
blocked with 5% skim milk in TBST (1x Tris-buffered saline, 0.1% Tween-20),
and incubated overnight with anti- NRCAM (rabbit, Abcam, 1:1000 dilution) and
anti-GAPDH (mouse monoclonal, Cell Signaling, 1:1000) or anti-SCN8A (rabbit
polyclonal, Abcam), followed by Anti-Actin (rabbit polyclonal, Sigma) diluted in
blocking solution at 4 ̊C. Following three 10 minute washes in TBST, the blots
were incubated with the appropriate horseradish peroxidase- conjugated
secondary antibodies (PerkinElimer, Boston MA) diluted in blocking solution.
After three 10 minute washes in TBST, the blots were developed using Western
Lightening Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer,
Waltham, MA). Immunohistochemistry and histology – The entire triceps surae
(medial and lateral gastrocnemius, soleus, and plantaris) were dissected free from
both hind legs and weighed. Detailed methods for immunolabeling and histology
are available elsewhere (Burgess et al., 2010; Motley et al., 2011; Seburn et al.,
2006; Sleigh et al., 2014). For basic muscle morphology some muscles were fixed
in Bouin’s fixative, paraffin- embedded, and sectioned for standard histology with
hematoxylin and eosin stain. Neuromuscular junction staining and innervation
analysis. Muscles used for NMJ immunohistochemistry were fixed for 30 minutes
in ice-cold 4% paraformaldehyde diluted in phosphate buffered saline. NMJ
morphology was evaluated blind to genotype following labeling of the
acetylcholine receptors with Alexa-594 conjugated alpha- bungarotoxin
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(Invitrogen, Carlsbad, CA) and a cocktail of anti-neurofilament (2H3) and antiSV2 to label the motor axon and terminal (Developmental Studies Hybridoma
Bank, Iowa City, IA). Nerves were visualized with an Alexa-488 conjugated antimouse IgG1 antibody (Invitrogen). To quantify the innervation status NMJs
where the nerve completely overlapped the AChRs on the muscle were defined as
fully occupied, those with a portion of receptors clearly vacated by the
presynaptic nerve were defined as partially occupied, and those with AChR
plaques that had no associated nerve were defined as denervated.
Axon Histology: The femoral nerves, which include both a motor and sensory
branch (Scherer et al., 2005) were dissected free and fixed by immersion in 2%
paraformaldehyde, 2% glutaraldehyde in 0.1M cacodylate buffer for 12 hours.
Nerves were then plastic embedded, sectioned at 0.5 microns thickness, and
stained with Toluidine Blue. Images were collected at 40X magnification on a
Nikon Eclipse 600 microscope with DIC- Nomarski optics. Images were analyzed
for axon number using an automated method in Fiji/ImageJ that was manually
confirmed by visual inspection of images for mis- identified axons. Axon
diameter and myelin thickness were measured in Fiji/ImageJ with the Measure &
Label Plug-in.
Myelin analysis: Femoral nerves prepared above were thin sectioned (75nm) and
post- stained on grids for transmission electron microscopy. Grids were viewed on
a Jeol 1230 electron microscope and images were captured at 50,000X
magnification with a Hamamatsu digital camera system. Spacing of myelin wraps
was determined by measuring the total thickness of the myelin using Fiji (ImageJ)
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software, and counting the number of wraps in that total distance.
Nodes of Ranvier Analysis: Sciatic nerves were dissected free, fixed in cold,
buffered 4% paraformaldehyde for 30 minutes, and teased onto glass slides in a
drop of PBS. Samples were allowed to dry onto the slides overnight, and then
extracted in -20 ̊C acetone for 10 minutes. Samples were blocked and
permeabilized in PBS with 2.5% BSA and 0.5% Triton X-100. For determining
internodal distances, axons were then viewed under Nomarski DIC optics at 200X
magnification and fiber diameters and internodal distances were determined using
Fiji/ImageJ to analyze photomicrographs. For immunofluorescence, primary
antibodies were diluted in blocking buffer and applied overnight at 4 ̊C.
Following washes, secondary antibodies were also applied overnight at 4 ̊C.
Semi-quantitative analysis of NaV1.6 density at nodes was performed by
collecting confocal images of NaV1.6 and neurofilament labeling on teased
sciatic nerve axons under standardized imaging parameters. The labeling intensity
in a region of interest including the NaV1.6 signal was compared to the labeling
intensity of neurofilament in the adjacent axon in an equivalently sized region.
Background intensity in an equivalent area of neighboring blank space (no tissue)
was subtracted from both the neurofilament and NaV1.6 values. The following
primary antibodies were used: anti-Nrcam (rabbit, Abcam, 1:200 dilution), antiNaV1.6 (rabbit, Alamone, 1:200 dilution), anti-NaV1.6 (mouse monoclonal
IgG1, NeuroMab/Antibodies Inc., 1:5 dilution) anti-Kv1.2 (mouse monoclonal
IgG2bK, Millipore, Billerica, MA; 1:100 dilution), anti-AnkyrinG (rabbit, Santa
Cruz, 1:200) anti-neurofilament light chain (mouse IgG1 2H3, Developmental
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Studies Hybridoma Bank, 1:500). The following secondary antibodies
(Invitrogen) were used for visualization: anti-mouse IgG1 594, anti-mouse IgG1
Alexa 488, anti-mouse 488, anti-mouse IgG2bK Alexa IgG2bK 488, and antirabbit Alexa 594.
Nerve Conduction Analysis: Mice were anesthetized with 1.5-2.0% isoflurane
and placed on a thermostatically-regulated heating pad to maintain normal body
temperature. Compound muscle action potentials (CMAP) were evoked by
subcutaneous stimulation at the sciatic notch and at the ankle. For recording, the
active needle electrode was inserted in the center of the paw and a reference
electrode was placed in the skin between the first and second digits. Sciatic nerve
conduction velocity was determined by measuring CMAP latency and the
distance between points of stimulation. The presence of conduction block was
evaluated by integration measuring area under the CMAP (iCMAP) in response to
distal and proximal stimulation and expressing the difference between the
proximal and distal iCMAPs as a percentage ((proximal-distal)/distal)/100)).
Clinically, conduction block is considered present when there is a decrease in the
proximal amplitude of at least 20% relative to the distal, with less than a 20%
increase in temporal dispersion of the proximal CMAP waveform relative to distal
(Mallik and Weir, 2005).
Voltage-clamp: Detailed methods are available elsewhere (Rich et al., 2002;
Spaulding et al., 2016; Wang et al., 2004; Wang et al., 2005). Briefly, mice were
anesthetized and the levator auris longus (LAL) muscle (Angaut-Petit et al., 1987)
was removed and placed immediately in a recording chamber perfused
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continuously with Ringer’s solution (20–22°C) comprised of (in mmol/l): 118
NaCl, 3.5 KCl, 2 CaCl2, 0.7 MgSO4, 26.2 NaHCO3, 1.7 NaH2PO4, and 5.5
glucose, and equilibrated with 95%O2/5%CO2 to maintain a pH of 7.3–7.4. The
preparation was then placed under an upright epifluorescence microscope (Leica
DMLFSA). Synapses were located and fibers were impaled within 100 µm of the
terminal and voltage clamped to -50 mV. The muscle specific sodium channel
blocker (µ-Conotoxin GIIIB, Alomone, Israel )(Cruz et al., 1985; Robitaille and
Charlton, 1992) was introduced (~1 µM) to eliminate muscle action potentials.
Mini endplate currents (MEPC) were recorded continuously for 1 minute and
twenty evoked endplate currents (EPC) (when present) were recorded in response
to single stimuli delivered at 0.5 Hz.
Statistics: A one-way ANOVA followed by Tukey’s HSD posthoc comparison
(R- Team, 2008) was used for evaluating differences between genotypes for axon
counts, conduction velocity, body weight, and muscle-to-body-weight ratio
(MW:BW). Axon diameters and myelin thickness were compared using the nonparametric Kolmogorov- Smirnov two-sample test. NMJ innervation status
between genotypes and categories (fully innervated, partially innervated, and
denervated) was evaluated with a two-way ANOVA followed by Tukey’s HSD
and Roy posthoc comparisons (R-Team, 2008). Probability of p<0.05 was used as
a cutoff for declaring statistical significance in all comparisons.

162

APPENDIX C: Chapter 3: Supplemental Data
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35

Figure 17. The ∆ETAQ GARS mutation does not affect gene expression (A) RNA
and cDNA libraries were generated from patient fibroblasts. Subsequently, RTPCR products spanning the mutation were subjected to deep-sequencing analysis.
A cartoon representing the GARS exon7-exon8 junction is shown with the wildtype (blue) and mutant (red) PCR products indicated. Mapped sequence reads
were deemed informative if they spanned the nucleotides affected by the
mutation. Of the informative reads, 53.7% were from wild-type (WT) transcripts
and 46.3% were from ∆ETAQ GARS transcripts. (B) Western blot analyses were
performed with total protein lysates from fibroblast cell lines from affected
(Patient) and unaffected (Control) individuals using an anti-GARS or anti-actin
antibody, as indicated. Sample names are across the top and protein size markers
(kDa) are indicated on the left.
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Figure 18. The ∆ETAQ GARS mutation does cause aberrant binding to NRP1
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Figure 19. mRNA and protein levels in Gars∆ETAQ/huEx8 mice
RT-PCR using cDNA isolated from sciatic nerve confirmed expression of the
∆ETAQ mutation and/or the human-specific nucleotides in exon 8 of Gars as
indicated by the black arrows (n=3 mice per genotype). (A) Chromatograms from
Sanger sequencing analysis of RT-PCR products showing the first 34 bases of
GARS exon 8. Human-specific nucleotides expressed within Gars+/huEx8 and
Gars∆ETAQ/huEx8 are indicated by black arrows. The ∆ETAQ mutation (the 12 bps
deleted by the ∆ETAQ mutation are hilghlighted in red) is noted by the box in the
sequence above and is indicated by double sequence starting at base 13. (B)
Western blot analysis of GARS expression in the indicated mouse strains. The
blot was re-probed with an anti-NeuN antibody to control for variability in protein
loading.
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Figure 20. All miRNAs targeting ∆ETAQ disease allele tested in vitro (A) The
five miRNAs hairpins originally tested targeting the ∆ETAQ mutation in the
human GARS gene. The guide strand is indicated in blue, and the passenger strand
is in red. Grey and black arrowheads indicate the Drosha and Dicer cut sites
respectively. (B) The first set of miRNAs tested in a dual-luciferase assay.
HEK293 cells were cotransfected with a single miRNA and the dual luciferase
reporter containing either wild type or ∆ETAQ human GARS cloned as the 3’UTR
of Renilla luciferase. Gene silencing was determined by measuring the ratio of
Renilla to Firefly luciferase and triplicate data are presented as the average mean
ratio ± SEM. Based on the efficient knockdown of the human disease-allele and
preservation of the wild type allele, miEx8D12-1A was chosen as the lead
candidate. (C) The lead candidate miEx8D12-1A was tested in an additional dualluciferase assay against the mouse ∆ETAQ mutant gene. Despite effective
silencing of the human disease allele, it was unable to target the ∆ETAQ mouse
Gars mRNA. Triplicate data were averaged and presented as the mean ± SEM.
(D) The guide strand of the initial lead miRNA and its complementarity to the
target regions of both human and mouse ∆ETAQ Gars. Base pairing is indicated
by vertical lines with G-U bonds shown in red. (E) The hairpin structures of six
variants of miEx8D12-1A. Drosha and Dicer cut sites are indicated with grey and
black arrowheads. The guide strand is shown in blue, with the changes to the
original miR sequence indicated in red. G-U base pairing is shown with a red
vertical line. In vitro testing results for these miRNAs is shown in Figure 2. The
lead miRNA is marked with an asterisk and was renamed mi.∆ETAQ for all
further testing
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Figure 21. U6.miP278KY microRNAs can specifically knockdown P278KY
mouse Gars mRNA in vitro (A) Hairpin structures of all pre-miRNAs targeting
P278KY mouse Gars mRNA. The guide strand is shown in blue, while the
passenger strand is in red. Drosha and Dicer cut sites are indicated by grey and
black arrowheads, respectively. The best performing miRNA in vitro is marked
with an asterisk and the name was shortened to miP278KY for further testing. (B)
The sequence of the guide strand of the best performing miP278KY and it’s
complementarity to both wild type and mutant mouse Gars. The P278KY
mutation is shown in red. Vertical lines indicate the base paring between the
miRNA and the target genes, with weaker G-U bonds shown in red. Allelespecificity is achieved by effective base-pairing of the miRNA with the mutant
allele, while also having much lower complementarity to the wild type. (C)
miRNAs were tested in vitro by cotransfecting HEK293 cells with a single
miRNA and a dual-luciferase reporter containing either wild type or P278KY
mouse Gars cloned as the 3’UTR of Renilla luciferase. Target gene silencing was
determined by measuring the ratio of Renilla to Firefly luciferase. Triplicate data
were averaged and presented as the mean ratio ± SEM.
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Figure 22. Reduction in Mutant GARS Expression Also Alleviates Neuropathy
in Post-Disease Onset Gars(P278KY/+) Mice (A-B) mi-P278KY treatment yields
significant increases in grip strength as determined by the wire hang test starting
at 5 weeks post treatment in both early- (A) and late-symptomatic (B)
Gars(P278KY/+) mice. Treated P278KY mice also gain weight starting 3 weeks post
treatment with early-symptomatic mice (A) and 1 week post treatment with latesymptomatic mice (B). These data correlate with a significant an increase
MW:BW within scAAV9.mi.P278KY early- symptomatic Gars(P278KY/+) mice (C)
although scAAV9.miP278KY treatment was unable to improve NCV within this
cohort or MW:MW nor NCVs in the late-symptomatic P278KY mice (C-D).
However, scAAV9.miP278KY treatment significantly prevented further or
reversed NMJ breakdown in both early- and late- symptomatic Gars(P278KY/+)
mice. All statistics were completed with a One-Way Anova with Tukey Posthoc
comparisons. Star represents significance between MiLacZ and MiP278KYtreated GarsP278KY/+ mice (* = <0.05 ** = <0.005 *** =<0.001). A = significant
difference in fully innervated NMJs, B = significant difference in partially
innervated NMJs, and C = significant difference in denervated NMJs. Latesymptomatic Cohort: MiLacZ-treated Gars(+/+) n=6, scAAV9.miP278KY-treated
Gars(+/+) n=5-6, mi.LacZ-treated Gars(P278KY/+) n=6, and scAAV9.miP278YKtreated Gars(P278KY/+) n=7. Early-symptomatic Cohort: miLacZ –treated Gars(+/+)
n=3, scAAV9.miP278KY-treated Gars(+/+) n=3-4, mi.LacZ-treated Gars(P278KY)
n=6, and scAAV9.miP278KY-treated Gars(P278KY/+) n=7. Values are mean ± S.D.
All scale bars = 100 µm.
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Figure 23. Escalating doses of scAVV9.miP278KY delivered via ICV delivery
improves peripheral nerve function in Gars(P278KY/+) mice. (A-B) Significant
improvements in nerve conduction velocity correlate with reductions of mutant
Gars expression within dorsal root ganglia when scAAV9.miP278KY was
delivered by ICV compared to IV. (C) In contrast, these gains in peripheral nerve
function did not correlate with reductions in mutant Gars expression within liver.
N=5 for all experimental groups. IV = intravenous delivery of 1x1011 vg/mouse,
ICV = intracerebroventricular delivery, LD = low dose of 8.75x109 vg/mouse,
MD = median dose of 5.00 x1010 vg/mouse, and HD = 1x1011 vg/mouse. (A) Data
was analyzed by a One-Way ANOVA followed by Tukey’s posthoc comparisons.
a = significant from untreated, wildtype control; b = significant from untreated
P278KY control. (B-C) These data were analyzed with a Two-Way Anova with
Tukey Posthoc comparisons. Star represents significance between wildtype and
mutant Gars expression per experimental group (* = <0.05 ** = <0.005 ***
=<0.001). Values are mean ± S.D.
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Figure 24. Long term therapeutic effects of neonatal scAAV9.mi.P278KY
treatment. To access long term effects of scAAV9.mi.P278KY treatment, both
bodyweight and grip strength as determined by the wire hang test were recorded
from both Gars(P278KY/+) mice and littermate controls every 6 weeks after being
injected with scAAV9.mi.LacZ or scAAV9.mi.P278KY at P0 for 1 year post
injection. Remarkably, scAAV9.miP278KY-treated P278KY displayed
significant increases in body weight (A,) starting at 24 weeks post treatment and
grip strength (B) throughout the course of 1 year compared to vehicle controltreated P278KY mice. When evaluated for primary signs of neuropathy at 1 year
post-treatment treated-P278KY mice exhibited significantly greater MW:BW
ratios (C) and faster NCVs (D). Significance in (A-B) was determined by oneway ANOVA with Tukey’s HSD posthoc comparisons. Significance in (C-D) was
determined by two-way ANOVA with Tukey’s HSD posthoc comparisons.
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001 represents posthoc
significance between miLacZ-treated and scAAV9.miP278KY-treated
GarsP278KY/+ mice for all analyses. MiLacZ-treated Gars(+/+) n=3,
scAAV9.miP278KY-treated Gars(+/+) n=3, mi.LacZ-treated Gars(P278KY/+) n= 5,
and scAAV9.miP278YK-treated Gars(P278KY/+) n=7. Values are mean ± S.D.
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Figure 25. Improvements in phenotype negatively correlates with reductions in
mutant Gars expression in dorsal root ganglia (A-B) Scatter plot illustrating the
negative correlation between the percentage of the ∆ETAQ variant expression
within dorsal root ganglia and nerve conduction velocities quantified from
scAAV9.mi.∆ETAQ-treated Gars(∆ETAQ/huEx8) mice within late- (A) and early- (B)
symptomatic cohorts. (C-D) Scatter plot illustrating the relationship between the
percentage of the ∆ETAQ variant expression within liver and nerve conduction
velocities quantified from scAAV9.mi.∆ETAQ-treated Gars(∆ETAQ/huEx8) mice
within late- (C) and early- (D) symptomatic cohorts. (E-F) Scatter plot illustrating
the negative correlation between the percentage of the P278KY Gars variant
expression within dorsal root ganglia and nerve conduction velocities quantified
from scAAV9.mi.P278KY-treated Gars(P278KY/+) mice within late- (E) and early(F) symptomatic cohorts. (G-H) Scatter plot displaying the association between
the percentage of the P278KY Gars variant expression within liver and nerve
conduction velocities quantified from scAAV9.mi.P278KY-treated Gars(P278KY/+)
mice within late- (E) and early- (F) symptomatic cohorts.
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.
Varianta

kcat (s-1)

Km (µM)

kcat/Km (s-1 µM-1)

Ratio

Wild-type

0.049 ± 0.014

0.74 ± 0.30

0.066

1

P234KY

0.0012 ± 4.6 x 10-4

8.8 ± 3.3

1.3 x 10-4

1 / 500

∆ETAQ

8.7 x 10-6 ± 1.2 x 10-6

1.4 ± 0.085

6.2 x 10-6

1 / 11,000

a

Human amino-acid positions correspond to GenBank Accession number

NP_002038.2
Table 1. Kinetic analysis of mutant GARS proteins
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Age at Injection

Genotype

Treatment

Neonate (P0-P1)

(huEx8/huEx8)

Untreated

Average Ratio of
Mutant: Wildtype Gars
Expression ( ± SD)
14.0: 86.0 (± 3.28)

Neonate (P0-P1)

(huEx8/huEx8)

sc.AAV9.mi.LacZ

8.0: 92.0 (± 1.275)

Neonate (P0-P1)
Neonate (P0-P1)
Neonate (P0-P1)

(huEx8/huEx8)
(∆ETAQ/huEx8)
(∆ETAQ/huEx8)

sc.AAV9.mi.∆ETAQ
Untreated
sc.AAV9.mi.LacZ

9.6: 90.4 (± 2.07)
62.4: 37.6 (± 0.94)
62.5: 38.6 (± 0.96)

Neonate (P0-P1)
5 Weeks
5 Weeks
5 Weeks

(∆ETAQ/huEx8)
(huEx8/huEx8)
(huEx8/huEx8)
(∆ETAQ/huEx8)

sc.AAV9.mi.∆ETAQ
sc.AAV9.mi.LacZ
sc.AAV9.mi.∆ETAQ
sc.AAV9.mi.LacZ

46.9: 53.1 (±4.79)
9.6: 90.4 (± 2.53)
8.3:91.7 (± 2.92)
63.9: 36.1 (± 3.13)

5 Weeks
9 Weeks
9 Weeks
9 Weeks
9 Weeks

(∆ETAQ/huEx8)
(huEx8/huEx8)
(huEx8/huEx8)
(∆ETAQ/huEx8)
(∆ETAQ/huEx8)

sc.AAV9.mi.∆ETAQ
sc.AAV9.mi.LacZ
sc.AAV9.mi.∆ETAQ
sc.AAV9.mi.LacZ
sc.AAV9.mi.∆ETAQ

47.2: 52.8 (± 7.88)
10.3: 89.7 (± 3.04)
6.0: 94.0 (± 1.33)
59.3:40.7 (± 6.45)
45.3:54.74 (±6.02)

Table 2. Effects of scAAV9.mi.∆ETAQ on in vivo GARS expression in doral
root ganglia quantification of the percentage of ∆ETAQ Gars expression relative
to wildtype Gars expression (± standard deviation) as determined by
pyrosequencing per genotype, treatment, and experimental cohort as noted by the
age of injection. For the preonset study a total of 5 neonatal animals were used per
genotype and treatment groups. Late-symptomatic Cohort (injection at 9 weeks):
MiLacZ-treated Gars(huEx8/huEx8) n=5, scAAV9.mi∆ETAQ-treated Gars(huEx8/huEx8)
n=3, mi.LacZ-treated Gars(∆ETAQ/huEx8) n=6, and scAAV9.mi∆ETAQ-treated
Gars(∆ETAQ/huEx8) n=7. Early-symptomatic Cohort (injection at 5 weeks) :
Gars(huEx8/huEx8) n=6, scAAV9.mi∆ETAQ-treated Gars(huEx8/HuEx8) n=5, mi.LacZtreated Gars(∆ETAQ/huEx8) n=7, and scAAV9.mi∆ETAQ-treated Gars(∆ETAQ/huEx8)
n=8.
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Genotype

Treatment

Dose: Route of Delivery

(+/+)

Untreated

NA

Average Ratio of Mutant:Wildtype
Gars Expression ( ± SD)
1.2: 98.8 (± 0.43)

(+/+)

sc.AAV9.mi.LacZ

(+/+)

sc.AAV9.mi.P278KY
Untreated

1x1011 DRPS/animal: ICV
1x1011 DRPS/animal: ICV
NA
1x1011 DRPS/animal: ICV
1x1011 DRPS/animal: ICV
5x1010 DRPS/animal: ICV
8.75 x109 DRPS/animal: ICV
1x1011 DRPS/animal: IV

1.0: 99.0 (± 0.32)
0.2: 99.8 (± 0.22)
55.8: 44.2 (±9.93)
51.7: 48.3 (± 8.46)
22.2: 77.8 (±16.44)
33.3: 66.65 (± 9.1
38.5:62.15 (± 8.91)
9.8:90.2 (±8.22)

(P278KY/+)
(P278KY/+)
(P278KY/+)
(P278KY/+)
(P278KY/+)
(P278KY/+)

sc.AAV9.mi.LacZ
sc.AAV9.mi.P278KY
sc.AAV9.mi.P278KY
sc.AAV9.mi.P278KY
sc.AAV9.mi.P278KY

Table 3. Effects of scAAV9.miP278KY on allele-specific GARS expression in
dorsal root ganglia quantification of the percentage of P278KY Gars expression
relative to wildtype Gars expression (± standard deviation) as determined by
pyrosequencing per genotype, treatment, route of delivery and experimental
cohort as noted by the age of injection. For the preonset study a total of 5 neonatal
animals per experimental group. ICV = Intracerebroventricular delivery, IV=
Intravenous delivery, and NA = not available.
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Age at
Injection
5 Weeks

Genotype

Treatment

(+/+)

scAAV9.mi.LacZ

5 Weeks
5 Weeks
5 Weeks
9 Weeks
9 Weeks
9 Weeks

(+/+)
(P278KY/+)
(P278KY/+)
(+/+)
(+/+)
(P278KY/+)

sc.AAV9.mi.P278KY
sc.AAV9.mi.LacZ
sc.AAV9.mi.P278KY
sc.AAV9.mi.LacZ
sc.AAV9.mi.P278KY
sc.AAV9.mi.LacZ

Average Ratio of Wildtype:
Mutant Gars Expression ( ± SD)
1.6: 98.4(± 2.46)
0.7: 99.3 (± 0.55)
55.0: 45.0 (± 7.26)
36.2: 63.8 (± 14.74)
0.9: 99.1 (± 0.27)
0.0: 100.0 (± 0.00)
52.3:47.7 (± 4.64)

Table 4. Post onset effects of scAAV9.mi.P278KY on in vivo GARS expression
in doral root ganglia quantification of the percentage of P278KY Gars expression
relative to wildtype Gars expression (± standard deviation) as determined by
pyrosequencing per genotype, treatment, and experimental cohort as noted by the
age of injection. Late-symptomatic Cohort (injection at 9 weeks): MiLacZ-treated
Gars(+/+) n=5, scAAV9.miP278KY-treated Gars(+/+) n=3, mi.LacZ-treated
Gars(P278KY/+) n=6, and scAAV9.mi.P278KY-treated Gars(P278KY/+) n=7. Earlysymptomatic Cohort (injection at 5 weeks) : Gars(+/+) n=6, scAAV9.mi.P278KYtreated Gars(+/+) n=5, mi.LacZ-treated Gars(P278KY/+) n=7, and
scAAV9.mi.P278KY-treated Gars(P278KY/+) n=5.
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APPENDIX D: Chapter 3: Materials & Methods
Clinical Evaluation and Mutation Analysis: The proband was clinically
evaluated by P. Mancias and I.J. Butler at Texas Children’s Hospital (Houston,
TX) under Institutional Review Board approved protocols. Clinical data were
obtained after written informed consent from the proband’s parents. Diagnostic,
whole-exome sequencing (XomeDxPlus) was performed by GeneDx
(Gaithersburg, MD). For allele-specific Sanger sequencing we first isolated DNA
from patient-derived primary fibroblasts. Cells were treated with trypsin
according to the Wizard Genomic DNA Purification Kit (Promega) protocol. PCR
amplification was performed to obtain a 381 bp region including GARS exon 8
using PCR SuperMix (ThermoFisher Scientific). PCR products were cleaned
according to the QiaQuick PCR Purification Kit protocol and cloned into the
pCR4-TOPO vector using the TOPO TA Cloning Kit (ThermoFisher Scientific).
Vectors were then transformed into One Shot TOP10 Chemically Competent
E.coli cells (ThermoFisher Scientific) and plated on ampicillin-containing LB
agar plates. Plasmid DNA from six isolated colonies was purified and Sanger
sequenced using the PCR primers. Five colonies contained plasmids with the
amplicon of the wild-type allele and one colony contained plasmids with the
amplicon of the mutant allele. Primers used for the PCR reaction: forward
5’GCATTGCCAAAGTAGTACTGC 3’; and reverse 5’
CCTGACTCTGATCAGTCCAGATCG 3’.
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GARS Expression Studies: For RNA expression studies, RNA was isolated from
patient fibroblasts using the RNeasy Mini Kit (Qiagen) per the manufacturer’s
protocol. cDNA samples were generated from 1ug of RNA using the HighCapacity cDNA reverse transcription kit (Applied Biosystems) following the
manufacturer’s instructions. The resulting cDNA was used to amplify a 224 basepair product flanking the region bearing the ∆ETAQ mutation. The reaction was
column purified and the product was analyzed for quality via gel electrophoresis.
To prepare the sample for next-generation sequencing, the product was digested
and “tagmented” using Tn5 transposase. The library was amplified by PCR using
Kapa Hifi DNA polymerase and Illumina-compatible indexing primers. Final
library fragment size and purity was determined via gel electrophoresis, and
fragments were column purified and sequenced on the Illumina MiSeq with
paired 155 bp reads. All primer sequences are available upon request.
Overlapping reads were merged using PEAR (v0.9.6) and aligned using bwa mem
(v0.7.12) to custom references containing the wild-type exon 7-exon 8 junction or
the ∆ETAQ-containing equivalent. A custom python script (available upon
request) was used to count reads with higher-scoring alignment to each junction.
Uninformative reads (e.g., those not spanning the mutation) were disregarded.
For protein expression studies, cells were cultured and harvested under normal
conditions. Proteins were isolated in 1 mL cell lysis buffer [ 990 µL RIPA Lysis
Buffer (ThermoFisher Scientific) + 10 µL 100X Halt Protease Inhibitor
(ThermoFisher Scientific)]. Protein concentrations were quantified using the
Thermo Scientific PierceTM BCA Protein Assay Kit (ThermoFisher Scientific)
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and 10 µg of protein per sample was analyzed via western blot. Each protein
sample was prepared in 1X SDS-sample buffer (ThermoFisher Scientific) plus 5
µL 2-me beta-mercaptoethanol (β-ME) and boiled at 99°C for 10 minutes.
Samples were electrophoresed on pre-cast 4-20% tris-glycine gels (ThermoFisher
Scientific) at 150V for 1 hour. Proteins were transferred onto a polyvinylidene
difluoride (PVDF) membrane at 25V for 1.5 hours. The membrane was incubated
for 1 hour at room temperature with the respective primary antibody at the
following dilutions in blocking solution: anti-GARS 1:1000, anti-neuropilin-1
(Abcam) 1:1000, anti-Flag M2 (Sigma Aldrich) 1:10000, and anti-Sema3A
(Abcam) 1:1000. Membranes were then rinsed 3X in 1X TBST to remove
unbound antibody and incubated with the respective Hrp-conjugated secondary
antibody at 1:10,000. Membranes were rinsed in 1X TBST and exposed using
SuperSignal West Dura substrate and enhancer (ThermoFisher
Scientific).Expression Construct Development: All GARS expression
constructs were generated using Gateway cloning technology (Invitrogen). The
human GARS open-reading frame was amplified from human cDNA using
primers designed with Gateway sequences attB1 (forward) and attB2 (reverse;
primer sequences available on request). Entry clones were generated by
recombining PCR-purified amplicons into the pDONR221 vector using BP
clonase. After transformation into E. coli, DNA from individual entry clones was
isolated and subjected to sequencing analysis to confirm the presence of the
appropriate wild-type gene. Oligonucleotides containing sequences corresponding
to each GARS mutation studied were generated, and mutagenesis was performed
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using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene). After
transformation into E. coli, DNA from individual clones was purified and
sequenced to confirm the presence of each mutation and the absence of any errors.
Validated entry clones were purified and recombined into the appropriate
Gateway-compatible vector using LR clonase: pET-21a(+) for aminoacylation
assays and pTM3xFLAG for co-immunoprecipitation assays. DNA from the
resulting expression constructs was purified and digested with BsrGI (New
England Biosystems) to confirm the presence of the insert. For yeast
complementation assays, yeast GRS1 was expressed from pRS315 and human
GARS was expressed from the pYY1 expression construct containing
ΔMTSΔWHEP GARS; the pYY1 constructs were a gift from Chin-l Chien and
Chien-Chia Wang (National Central University, Taiwan).
Aminoacylation Assays: Wild-type and mutant GARS proteins were expressed
in E. coli with a C-terminal His tag and purified with nickel affinity resins
(Novagen). The T7 transcript of human tRNAGly/UCU (UCU, anticodon) was
prepared and purified as previously described (26), heat denatured at 85°C for 3
min, and annealed at 37°C for 20 min before use. Steady-state aminoacylation
assays were monitored at 37°C in 50 mM HEPES (pH 7.5), 20 mM KCl, 10 mM
MgCl2, 4 mM DTT, 2 mM ATP, and 50 mM 3H-glycine (Perkin Elmer) at a
specific activity of 16,500 dpm/pmole. The reaction was initiated by mixing
GARS enzyme (20–600 nM) with varying concentrations of tRNA (0.3–20 µM).
Aliquots of a reaction mixture were spotted on filter paper, quenched by 5%
trichloroacetic acid, washed, dried, and measured for radioactivity using a liquid
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scintillation counter (LS6000SC; Beckman Coulter Inc.). The amount of
radioactivity retained on filter pads was corrected for quenching effects to
determine the amount of synthesis of Gly-tRNAGly. Steady-state kinetics was
determined by fitting the initial rate of aminoacylation as a function of tRNA
concentration to the Michaelis-Menten equation (27).
Yeast Complementation Assays: Yeast complementation assays were carried
out using the haploid S. cerevisiae strain disrupted for the endogenous GRS1 and
maintained viable via pRS316 bearing the-wild type GRS1 locus previously
described (28-29). To assess the ability of wild-type and mutant GARS alleles to
support cellular growth, the haploid yeast strain was transformed with wild-type
or mutant constructs (see above), or a constructs bearing no GARS/GRS1 insert.
Transformed yeast cells were selected for the presence of both the maintenance
and experimental vectors by growth on solid media lacking leucine and uracil.
Colonies were grown to saturation in 2 mL liquid medium lacking leucine and
uracil at 30OC, 275 rpm for 48 hours. Undiluted cultures and dilutions of 1:10,
and 1:100 were spotted on 0.1% 5-FOA complete solid medium (Teknova,
Hollister CA) to select for cells that have spontaneously lost the maintenance
vector (20). Yeast viability was assessed after 4 days of incubation at 30OC. At
least two colonies per transformation were assayed and each transformation was
repeated at least twice.
MN1 Transfections for Immunoprecipitation: MN1 cells were grown at 37°C
in 5% CO2 and standard growth medium [Dulbecco’s modified eagle medium
(DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100
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U/ml penicillin, and 50 µg/ml of streptomycin (Invitrogen, Carlsbad, CA)]. Cells
were transfected using lipofectamine 2000 (Invitrogen) with 15 µg of a plasmid to
express wild-type or mutant GARS pTM3xFLAG, per T-175 flask. Cells
incubated for 48 hours at 37°C in 5% CO2. Cells were then harvested using 0.25%
trypsin (Invitrogen), centrifuged at 2,000 rpm for 2 minutes, and washed twice
with 1X PBS.
Co-immunoprecipitation Analyses: 25 µl of Dynabeads Protein G Magnetic
beads (Invitrogen) were used for each cell lysate from one T-175 flask. Beads
were washed twice in 1 mL of wash solution (0.5% bovine serum albumin and
0.1% Triton X-100 in PBS) and re-suspended in 1 mL of wash solution. Two µg
anti-Flag M2 antibody (Sigma) was added to the beads and incubated at 4˚C with
gentle shaking overnight. Harvested, transfected cells were re-suspended in 1.5
mL lysis buffer [20 mM Tris-HCl (pH7.5) 2.5mM MgCl2, 300mM KCl, 0.1%
NP-40, 1mM DTT, 0.2mM PMSF, 1x HaltTM Protease Inhibitor Cocktail (EDTA
free) (Thermo Scientific)] and incubated with gentle rocking at 4°C for 90
minutes. Cell lysates were centrifuged at 12,000 rpm for 5 min at 4°C. The
protein-containing supernatant was removed and utilized as the input for the
subsequent immunoprecipitation (IP) reaction in a clean tube. Protein was
quantified using the PierceTM BCA Protein Assay Kit (Thermo Scientific) and 1
mg of protein was used as input for each sample. Western blot analysis using the
anti-Flag M2 antibody (Sigma) (1:2,500 dilution) was used to confirm expression
of 3xFLAG tagged protein in input samples. Immediately before use, the αFlagconjugated magnetic beads were washed twice with 500 µl of lysis buffer using a
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magnetic rack, re-suspended in 25 µl lysis buffer and added directly to the protein
sample. The protein and beads were incubated at 4°C for 2 hours with gentle
shaking. Tubes were placed on a magnetic rack and the supernatant was removed
from the beads and discarded. The beads were washed 5 times with 1 mL of wash
buffer [20 mM Tris-HCl (pH7.5) 2.5mM MgCl2, 300mM KCl, 0.1% NP-40, 1mM
DTT] and re-suspended in 30 µl of wash buffer per 25 µl of starting beads
(Proteomics Core at the Fred Hutchinson Cancer Institute) or 50 µl of wash buffer
per 25 µl of starting beads (University of Michigan Proteomics Resource
Facility). 200 µg/ml of 3xFlag peptide was added to each sample and incubated at
4°C with gentle shaking for 3 hours to elute the bound flag-tagged protein. The
tubes were placed on a magnetic rack and the supernatant was saved and used for
subsequent analyses.
Mass Spectrometry and Bioinformatics: For mass spectrometry at the Fred
Hutchinson Cancer Institute, IP products were separated on a denaturing 4-20%
Tris-Glycine gel and silver stained using standard protocols. Destained gel slices
were reduced with 10 mM dithiothreitol (DTT) in 100 mM ammonium
bicarbonate at 56⁰C for 45 minutes. DTT was removed and alkylation performed
by adding 55 mM iodoacetamide in 100 mM ammonium bicarbonate to cover the
gel slices and incubating in the dark at room temperature for 30 minutes. Slices
were washed with 100 mM ammonium bicarbonate, dehydrated with 50%
acetonitrile, and then dried by vacuum centrifugation. Slices were then rehydrated in an ice-cold solution of 12.5 ng/uL trypsin in 50 mM ammonium
bicarbonate and incubated on ice for 1 hour. The trypsin solution was removed
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and replaced with 50 mM ammonium bicarbonate and digestion was carried out
overnight at 37⁰C. The digestion solution was removed and saved, and peptides
were extracted from the slices by the addition of 0.1% trifluoroacetic acid (TFA)
and lightly vortexing for 30 minutes followed by the addition of an equal volume
of 100% acetonitrile and lightly vortexing for an additional 30 minutes. The
TFA/acetonitrile wash solution was combined with the original digestion solution
and the resulting extraction solution was brought to dryness by vacuum
centrifugation. The extracted peptide material was desalted with a Millipore C18
Zip-Tip using the manufacturer’s recommended procedure and brought to dryness
again by vacuum centrifugation. Desalted peptides samples were brought up in 10
µL of 2% acetonitrile in 0.1% formic acid and 8 µL was analyzed by LC/ESI
MS/MS using a Thermo Scientific Easy-nLC 1000 (Thermo Scientific) HPLC
system coupled to a hybrid Orbitrap Elite (Thermo Scientific) mass spectrometer
using an instrument configuration as described (22). The LC system consisted of a
reversed-phase trap column (100 µm × 20 mm) packed with Magic C18AQ (5
µm, 200 Å resin; Michrom Bioresources) followed by peptide separations on a
reversed-phase column (75 µm × 250 mm) packed with Magic C18AQ (5 µm,
100Å resin; Michrom Bioresources) directly mounted on the electrospray ion
source. A 90-minute gradient from 7% to 35% acetonitrile in 0.1% formic acid at
a flow rate of 400 nL/minute was used for chromatographic separations. The
heated capillary temperature was set to 310⁰C and a spray voltage of 2300 V was
applied to the electrospray tip. The Orbitrap Elite instrument was operated in the
data-dependent mode, switching automatically between MS survey scans in the
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Orbitrap (AGC target value 1,000,000, resolution 120,000, and injection time 200
milliseconds) with MS/MS spectra acquisition in the linear ion trap (AGC target
value of 10,000, and injection time 100 milliseconds). The 15 most intense ions
from the Fourier-transform (FT) full scan were selected for fragmentation in the
linear trap by collision-induced dissociation with normalized collision energy of
35%. Selected ions were dynamically excluded for 30 seconds with a list size of
500 and exclusion mass width of +/- 10 ppm.
For mass spectrometry at the University of Michigan, IP products were
concentrated using a TCA precipitation protocol. 2 µl of 2% sodium deoxycholate
was added to 200 µl of IP product and incubated on ice for 30 min. 20 µl of 100%
(w/v) TCA was added (bringing TCA to ~10%) and incubated on ice for 1 hour.
The IP product was then centrifuged at maximum speed at 4˚C for 10 min. The
supernatant was discarded and the remaining pellet was washed in 500 µl of
acetone, and incubated on ice for 10 min. The acetone solution was centrifuged at
max speed at 4˚C for 10 min. The resulting pellet was re-suspended in 30 µl of a
solution containing 20 mM HEPES and 8M Urea (pH=8.0). Three independently
generated IP products for each wild-type, ∆ETAQ, and an untagged wild-type
GARS control sample were sent for analysis. Tandem mass spectrometry was
performed using the Orbitrap Fusion Mass Spectrometer (Thermo Scientific) at
the University of Michigan Proteomics Resource Facility.
For all mass spectrometry data analyses, the open source proteomics search
engine X!Tandem (The Global Proteome Machine Organization), was used to
match tandem mass spectrometry data with peptide spectra. Peptide Prophet was
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used to validate peptide assignments (30) and Protein Prophet was employed to
group peptides into proteins (31). ABACUS extracted spectral counts for the data
for quantitative analysis (32). Finally, interactions were scored to remove
background and comparisons of interacting proteins was performed to calculate
the relative fold changes for protein interactions between wild-type and ∆ETAQ
GARS.
Targeted Assessment of NRP1 GARS Interactions: The NSC-34 cell line was
purchased from ATCC and cultured under standard conditions. Cells were grown
to 70% confluency before transfection. A human wild-type, P234KY, or ∆ETAQ
GARS cDNA was cloned into the pcDNA6 plasmid to express GARS in-frame
with a V5 tag. Transfections were performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instruction. For cell lysate
preparations, NSC-34 cells (36 hours after transfection) were washed twice in
phosphate-buffered saline (PBS), scraped into PBS, pelleted, and resuspended in
Pierce IP Lysis Buffer (Thermo Scientific) for 30 min and centrifuged for 7 min at
12,000×g; the insoluble fraction was discarded. Protein G beads (Invitrogen) were
pre-incubated with anti-NRP1 antibody (Abcam) or rabbit IgG (Cell signaling) for
30 min before mixed with the cell lysates for overnight. Beads were then washed
3X with buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 0.1% Triton X-100, 5%
glycerol). The immunoprecipitates were fractionated by 4-12% Bis-Tris-Plus
SDS-PAGE gels (Invitrogen) and transferred to PVDF membranes using the iBlot
Dry Blotting System (Invitrogen). Membranes were blocked for 1 hour with Tris
Buffered Saline with Tween 20 (TBST) containing 5% nonfat dry milk. Wild-type
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and mutant GARS proteins were detected using mouse monoclonal V5 antibody
purchased from Invitrogen. NRP1 was detected by utilizing the same antibody for
co-immunoprecipitation. After incubated with primary antibodies, membranes
were washed and incubated with HRP-conjugated anti-mouse or anti-rabbit
secondary antibodies (Cell Signaling) and followed by detection using ECL
western blotting substrate (Thermo Scientific) and exposed using the FluorChem
M imager (ProteinSimple).
Cloning of Allele-Specific, Mutant GARS-targeted miRNAs: All design rules
for artificial microRNAs, including: 22 nt mature miRNA length, perfect
antisense complementarity to the target mRNA (Gars; GARS), <60% GC content
of the mature duplex, and guide-strand biasing, such that the last 4 nucleotides of
the antisense 5′ end were A:U rich, and the last 4 nucleotides of the antisense 3′
end were G:C rich are previously described in (33). All mutant Gars-targeting
microRNA constructs were designed and engineered in the Harper lab adhering as
closely as possible to these design rules but with the seed match region focused on
the differing nucleotides present in the mutant P278KY or ∆ETAQ alleles, with
intentional mismatches between the mature miRNA guide strand the wild-type
GARS/Gars. All miRNAs were cloned into a U6T6 expression vector as
previously described (25). After in vitro testing was completed, lead candidate
U6.miRNAs were cloned into a self-complementary proviral AAV plasmid that
also contained a CMV promoter-driven eGFP reporter gene. scAAV9 viruses
were generated and titered by the Viral Vector Core at The Research Institute at
Nationwide Children’s Hospital.
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Luciferase Assays: The dual luciferase plasmids were created using the
Psicheck2 vector (Promega), with a Firefly luciferase cassette serving as a
transfection control, and the various Gars gene target regions cloned downstream
of the Renilla luciferase stop codon, thereby serving as a 3’ UTR. HEK293 cells
were co-transfected (Lipofectamine-2000, Invitrogen) with the appropriate dual
luciferase reporter and an individual U6.miRNA expression plasmid in a 1:5
molar ratio. GARS silencing was determined by measuring Firefly and Renilla
activity 24 hours post transfection, using the Dual-Luciferase Reporter Assay
System (Promega). Triplicate data were averaged and knockdown significance
was analyzed using two-way ANOVA. Results are presented as the mean ratio of
Renilla to firefly ± SEM.
Mice: Mice were housed in pressurized individually ventilated (PIV) racks in the
research animal facility at The Jackson Laboratory and provided food and water
ad libitum. All mouse husbandry and experimental procedures were conducted
according to the NIH Guide for Care and Use of Laboratory Animals and were
reviewed and approved by The Animal Care and Use Committee of The Jackson
Laboratory. Gars (CAST;B6-GarsNmf249/Rwb (referred to as GarsP278KY/+ ) are
previously described in (1). The official strain designations of the newly
engineered mouse models are B6;FVB-Gars<em1Rwb>/Rwb (referred to as
GarshuEx8) and B6;FVB-Gars<em2Rwb>/Rwb (referred to as Gars(∆ETAQ/+)).
Unless otherwise noted, all experimental cohorts used for direct comparisons
consisted of littermate animals to match strain and age to the greatest extent
possible. Both males and females mice were used for each experiment. P0-P1
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mice were isolated and injected with a gene therapy vector to determine if allelespecific knockdown of mutant Gars expression prevents the onset of disease
while both 5-week (early-symptomatic) and 9 week-old symptomatic (late
symptomatic) mice were used to determine post-disease onset therapeutic effects
of each gene therapy vector. Each mouse model displays full phenotypic
penetrance therefore the criteria for each animal to enter an experimental cohort
only included genotype and age. Randomization was based rolling administration
with genotype. Each mouse within each cohort was randomly assigned to a
treatment. Each litter contained mice treated with control or experimental gene
therapy vectors to eliminate possible litter effects.
Generation of Gars(∆ETAQ/+) & Gars(+/huEx8) Models With CRISPR/Cas9
Genome-Editing Technology: Donor Constructs: For GarshuEx8/+, the mouse
exon 8 sequence was replaced with a double-stranded donor vector containing the
human exon 8 sequence. The donor vector was synthesized by recombineering a
10 kb sequence containing the mouse exon 8 sequence flanked by a 2.8kb long 5’
arm of homology and a 7 kb 3’ arm of homology isolated from a C57BL/6J BAC
library into a retrieval vector containing short arms of homology for this
fragment. The mouse exon 8 sequence was then removed from the vector and
replaced with the human exon 8 sequence via restriction digest and subsequent
ligation with T4 ligase. As for Gars∆ETAQ/+, the donor construct consisted of a ssoligonucleotide sequence spanning the first 52 bases of mouse exon 8 with short
arms of homology (see below for sequence) containing a 12-base deletion (bases
12-23 of exon 8) referred to as ∆ETAQ.
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Microinjection: Preparation and microinjection of Crispr/Cas9 reagents was
performed as described in (34). All components including Cas9 mRNA (100
ng/µl, either TriLink or synthesized by in vitro transcription), sgRNA, guides 144
and 1340 (50 ng/µl; guide sequence below), and each donor vector (20 ng/µl
plasmid DNA or 100 ng/ul ssODN) were injected into the male pronucleus and
cytoplasm of ~300 zygotes at the pronuclei stage. All zygotes were isolated from
a superovulated FVB/NJ (JAX stock #001600) females mated with C57BL/6NJ
(JAX stock #005304) males. After, groups of 15-25 blastocysts were transferred
into the uterus of pseudopregnant females.
ssODN donor:
AGTTTACTTGTAACAGGCTTTGTTTTATTGGAAGCACATTGTCTTACTT
GTAATAGACTGGTTTATTTAATTTTATAGATACTTGAGACCGGGGATTT
TCtTGAATTTCAAACGACTTTTGGAATTCAAC
sgRNA 144: AAAATTCCCTGTGCAGTTTC
sgRNA 1340: TCAGAAATGAGATCTCACCT
Genotyping: Transgenic mice were genotyped based on the presence of either the
humanized exon 8 or ∆ETAQ constructs. Genomic DNA was prepared from tail
biopsy lysed with proteinase K incubation (20:1 buffer to enzyme concentration)
overnight at 55˚ C and then boiled for 15 minutes to inactivate proteinase K.
Amplification condition was performed in a 20 ul reaction volume consisting of 4
µl of 5x Phusion GC buffer, 0.4 µl 10 mM dNTPs, 1 µl each of forward and
reverse primers (sequences listed below) diluted to 10µM, 1 ul of genomic DNA,
0.6 µl of DMSO, 0.2 µl of Phusion DNA Polymerase (BioLabs, M0530) and 11.8
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µls of nuclease-free water. PCR reaction was amplified by PCR machine (Biorad)
with the thermal cycle programmed for 30 seconds at 98˚C as initial denaturation,
followed by 35 cycles of 10 seconds at 98 C˚ for denaturation, 62 C˚ for 30
seconds for annealing, 20 seconds for 72˚ C for extension, with a final extension
at 72˚ C for 5 minutes. PCR products were purified and sequenced by JAX
sequencing core.
Primers HuEx8F0_F:CATAACATCACGCGTGGTTCC and
HuEx8R0_R:CAAGTGTGGCGGTTTCCATC that span the 2.8 kb 5’ arm of
homology to the 3’ end of Gars exon 8 and subsequent Sanger sequencing with
HuEx8R0_R was used to identify human single nucleotide polymorphisms in
exon 8 of Gars within GarshuEx8 founders and subsequent generations. Primers
delETAQF0_F: GGCCATAAGCATAATTTTACTGTG and
∆ETAGF0_R:TACAACAGAAACAAACTGTGGTCA with subsequent Sanger
sequencing with ∆ETAGF0_R to detect the 12 base-pair deletion in bases 13-24
in Gars(∆ETAQ/+) founders and subsequent generations.
Reverse Transcription-PCR: Primers Gars2F_
CTCCCACCACTGGCAATGAC and Gars2R_ CTCACTCAGCAGCAGCTCC
were used to amplify a portion of the Gars open reading frame spanning Gars
exon 8 from first-strand cDNA generated from sciatic nerve RNA isolated from
Gars(+/huEx8) and Gars(∆ETAQ/huEx8) mice. Humanized exon 8 and ∆ETAQ transcript
sequences were identified with Sanger sequencing and primer Gars2F.
Tissue Lysate Preparation: Whole brain samples were isolated from animals
immediately after they were euthanized by CO2 inhalation. The tissues were
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frozen in liquid nitrogen and stored at -80 ̊C. Samples were homogenized using a
mortar and pestle followed by a Dounce homogenizer in 1% NP-40 in phosphate
buffered saline supplemented with Protease Inhibitor Cocktail Tablets (Roche,
Basal, Switzerland) then centrifuged at 14,000 g twice for 5 minutes at 4 ̊C.
Cleared homogenates were then sonicated at 4 ̊C and centrifuged again at 14,000
g for 5 minutes. Protein concentrations were assessed using a Bradford assay
(BioRad, Hurcules, CA). 20 µg of protein was then analyzed by immunoblot.
Western Blot Analysis: Protein lysates were resolved on Mini-PROTEAN 415% Tris-Glycine gels (BioRad, Hurcules, CA) and transferred to an Invitrolon &
Immobilon-P PVDF membrane for western blot analysis. Membranes were
blocked with 5% skim milk in TBST (1x Tris-buffered saline, 0.1% Tween-20),
and incubated overnight with anti- GARS (rabbit, Abcam, 1:1000 dilution) and
anti-NeuN (mouse monoclonal, Clone A60, Cell Signaling, 1:1000) diluted in
blocking solution at 4 ̊C. Following three 10 minute washes in TBST, the blots
were incubated with the appropriate horseradish peroxidase- conjugated
secondary antibodies (Anti-Mouse IgG (Goat), HRP-Labeled & Anti-Rabbit IgG
(Goat, HRP-Labeled) Perkin Elmer, Boston MA) diluted in blocking solution.
After three 10 minute washes in TBST, the blots were developed using Western
Lightening Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer,
Waltham, MA).
Assessment of Axonal Neuropathy in All Mouse Models: Grip strength was
evaluated by wire hang test (19) to evaluate gross muscle strength and endurance.
Nerve conduction studies, motor nerve histology and analysis, neuromuscular
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junction immunofluorescence and analysis, and body weight evaluation were
completed as previously described in Chapter 2 Supplementary materials (pg.
123-125).
Neonatal Delivery of scAAV9.mi.P278KY & scAAV9.mi.∆ETAQ: Prior to all
injections of mice at P0-P1, all pups were anesthetized via cryoanesthesia as
previously described in (35). Once properly anesthetized, all
intracerebroventricular injections were performed using a Hamilton syringe (cat
no. 65460_03) with a 32-gauge needle and escalating doses of
scAAV9.miP278KY as stated in Table S1 or 2.6 x 1011 DRPS/mouse of miETAQ
(~2-10 uls) diluted in sterile phosphate buffer saline. All gene therapy vectors
were injected in to the lateral ventricles by position the needle directly lateral to
the sagittal suture and rostral to the neonatal coronal suture. For intravenous
injections, all cyroanesthetized mice were injected with 1x1011 DRPS/mouse
directly into the superficial temporal vein in a caudal orientation with a use of a
Hamilton syringe (cat no. 7655-01) with a 32-gauge needle.
Intrathecal Delivery of Gene Therapy Constructs to Post-Onset Mice: With
the use of a Hamilton syringe (cat no. 7655-01) with a 32 gauge needle, all adult
post-onset mice were injected with ~1x1011 DRPS/mouse of scAAV9.mi.P278KY
or scAAV9.mi.∆ETAQ diluted into sterile phosphate buffer saline (~ 10 uls) with
an intrathecal injection by lumbar puncture. Here, all mice were anesthetized with
isoflurane and received an injection of the proper vector into the L6 spinous
process with the use of a Hamilton syringe with a 32-gauge needle. Each vector
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was slowly injected and the needle left in place for 5-10 seconds prior to
withdrawal.
Quantification of Allele-Specific Expression: Whole liver and lumbar dorsal
root ganglian samples were isolated from animals immediately after they were
euthanized by cervical dislocation. The tissues were frozen in liquid nitrogen and
stored at -80 ̊C. Samples were homogenized using a mortar and pestle followed by
a Dounce homogenizer and RNA was isolated from liver using Trizol Reagent
(ThermoFishercat no. 15596018) and dorsal root ganglia using either a
RNeasyMini Kit (Qiagen, cat nos. 74104 and 74106) or mirVanaTM miRNA
Isolation Kit (ThermFisher Scientific, cat no. AM1560). All RNA samples were
reversed transcribed using SuperScript™ III First-Strand Synthesis System
(cat no. 18080051). To quantify allele-specific expression of wildtype and
mutant GARS, EpigenDx (http://epigendx.com/d/ ) performed pyrosequencing on
the PSQ96 HS System (Qiagen) following the manufacturer’s instructions, using
custom assays.
Statistical Analysis: Statistical tests were performed using GraphPad’s Prism 7
software. A two-tailed t test, one-way or two-way ANOVA followed Tukey’s
HSD posthoc comparisons test (as indicated in Figure legend) was used to
determine significant differences between treatment and/or genotypes for axon
counts, conduction velocity, grip strength, and body weight. Axon diameters were
compared using non-parametric Kolmogorov- Smirnov two-sample and ShapiroWilk normality tests. NMJ innervation status between genotypes and categories
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(fully innervated, partially innervated, and denervated) was evaluated with a twoway ANOVA followed by Tukey’s HSD posthoc comparisons test.
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